tokens,ner_tags,id,nct_id,text,ner_manual_ct_target
"['Virtual', 'Reality', 'Augmented', 'Gait', 'Adaptation', 'in', 'Stroke', 'Survivors', '|', 'The', 'major', 'problem', 'in', 'stroke', 'survivors', 'that', 'is', 'being', 'addressed', 'in', 'this', 'research', 'project', 'is', 'walking', 'asymmetry', ',', 'i.e.', ',', 'difference', 'between', 'the', 'legs', 'during', 'walking', '(', 'e.g.', 'steps', 'on', 'the', 'more', 'affected', 'side', 'are', 'longer', 'than', 'the', 'other', ')', '.', 'A', 'potential', 'solution', 'to', 'this', 'problem', 'is', 'using', 'new', 'technology', 'like', 'virtual', 'reality', 'during', 'walking', 'training', 'to', 'make', 'stroke', 'survivors', 'have', 'a', 'better', 'sense', 'of', 'their', 'asymmetry', '.', 'A', 'second', 'problem', 'that', 'we', 'aim', 'to', 'address', 'in', 'this', 'study', 'is', 'whether', 'asymmetry', 'is', 'accurately', 'felt', 'by', 'the', 'stroke', 'survivors', 'and', 'how', 'we', 'can', 'address', 'it', '.', 'Our', 'ongoing', 'work', 'on', 'the', 'effects', 'of', 'virtual', 'reality', 'on', 'learning', 'new', 'walking', 'tasks', 'in', 'stroke', 'survivors', 'indicates', 'that', 'virtual', 'reality', 'maybe', 'particularly', 'important', 'for', 'those', 'with', 'walking', 'asymmetry', '.', 'In', 'this', 'study', ',', 'we', 'plan', 'to', 'recruit', 'stroke', 'survivors', 'who', 'have', 'such', 'asymmetries', 'during', 'walking', 'and', 'have', 'them', 'learn', 'a', 'new', 'walking', 'task', 'in', 'virtual', 'reality', '.', 'We', 'will', 'also', 'test', 'the', 'stroke', 'survivors', 'to', 'determine', 'if', 'there', 'is', 'a', 'relationship', 'between', 'how', 'well', 'they', 'learn', 'the', 'new', 'task', 'with', 'their', 'ability', 'to', 'feel', 'asymmetry', 'accurately', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03787693,NCT03787693,"Virtual Reality Augmented Gait Adaptation in Stroke Survivors | The major problem in stroke survivors that is being addressed in this research project is walking asymmetry, i.e., difference between the legs during walking (e.g. steps on the more affected side are longer than the other). A potential solution to this problem is using new technology like virtual reality during walking training to make stroke survivors have a better sense of their asymmetry. A second problem that we aim to address in this study is whether asymmetry is accurately felt by the stroke survivors and how we can address it. Our ongoing work on the effects of virtual reality on learning new walking tasks in stroke survivors indicates that virtual reality maybe particularly important for those with walking asymmetry. In this study, we plan to recruit stroke survivors who have such asymmetries during walking and have them learn a new walking task in virtual reality. We will also test the stroke survivors to determine if there is a relationship between how well they learn the new task with their ability to feel asymmetry accurately.","[(0, 41, 'OTHER', 'Virtual Reality Augmented Gait Adaptation'), (45, 51, 'CONDITION', 'Stroke'), (85, 91, 'CONDITION', 'stroke'), (154, 171, 'CONDITION', 'walking asymmetry'), (354, 369, 'OTHER', 'virtual reality'), (377, 393, 'PHYSICAL', 'walking training'), (402, 408, 'CONDITION', 'stroke'), (560, 566, 'CONDITION', 'stroke'), (639, 654, 'OTHER', 'virtual reality'), (688, 694, 'CONDITION', 'stroke'), (720, 735, 'OTHER', 'virtual reality'), (833, 839, 'CONDITION', 'stroke'), (864, 890, 'CONDITION', 'asymmetries during walking'), (933, 948, 'OTHER', 'virtual reality'), (972, 978, 'CONDITION', 'stroke')]"
"['Clevidipine', 'for', 'Vasospasm', 'After', 'Subarachnoid', 'Hemorrhage', '|', 'Vasospasm', 'occurs', 'frequently', 'after', 'aneurysmal', 'subarachnoid', 'hemorrhage', 'and', 'can', 'lead', 'to', 'strokes', '.', 'The', 'investigators', 'will', 'investigate', 'if', 'infusion', 'of', 'a', 'novel', 'drug', ',', 'clevidipine', ',', 'will', 'decrease', 'vasospasm', 'during', 'the', 'infusion', 'and', 'post', 'infusion', 'period', 'using', 'transcranial', 'doppler', 'monitoring', 'of', 'patients', 'with', 'subarachnoid', 'hemorrhage', 'and', 'moderate', 'severity', 'vasospasm']","['B-DRUG', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT02011321,NCT02011321,"Clevidipine for Vasospasm After Subarachnoid Hemorrhage | Vasospasm occurs frequently after aneurysmal subarachnoid hemorrhage and can lead to strokes. The investigators will investigate if infusion of a novel drug, clevidipine, will decrease vasospasm during the infusion and post infusion period using transcranial doppler monitoring of patients with subarachnoid hemorrhage and moderate severity vasospasm","[(0, 11, 'DRUG', 'Clevidipine'), (16, 25, 'CONDITION', 'Vasospasm'), (32, 55, 'CONDITION', 'Subarachnoid Hemorrhage'), (58, 67, 'CONDITION', 'Vasospasm'), (92, 126, 'CONDITION', 'aneurysmal subarachnoid hemorrhage'), (216, 227, 'DRUG', 'clevidipine'), (243, 252, 'CONDITION', 'vasospasm'), (353, 376, 'CONDITION', 'subarachnoid hemorrhage'), (381, 408, 'CONDITION', 'moderate severity vasospasm')]"
"['Utilizing', 'Gaming', 'Mechanics', 'to', 'Optimize', 'Telerehabilitation', 'Adherence', 'in', 'Persons', 'With', 'Stroke', '|', 'This', 'trial', 'studies', 'the', 'impact', 'of', 'motivational', 'strategies', 'designed', 'by', 'the', 'gaming', 'industry', 'on', 'adherence', 'to', 'a', 'home', 'tele', '-', 'rehabilitation', 'program', 'designed', 'to', 'improve', 'hand', 'function', 'in', 'persons', 'with', 'stroke', '.', 'A', 'growing', 'literature', 'suggests', 'that', 'the', 'extended', 'practice', 'of', 'challenging', 'hand', 'tasks', 'can', 'produce', 'measurable', 'changes', 'in', 'hand', 'function', 'in', 'persons', 'with', 'stroke', '.', 'Current', 'health', 'care', 'delivery', 'systems', 'do', 'not', 'support', 'this', 'volume', 'of', 'directly', 'supervised', 'rehabilitation', ',', 'making', 'it', 'necessary', 'for', 'patients', 'to', 'perform', 'a', 'substantial', 'amount', 'of', 'activity', 'at', 'home', ',', 'unsupervised', '.', 'Unfortunately', ',', 'adherence', 'to', 'unsupervised', 'home', 'exercise', 'regimens', 'is', 'quite', 'poor', 'in', 'this', 'population', '.', 'The', 'investigator', ""'s"", 'goal', 'is', 'to', 'assess', 'the', 'impact', 'of', 'several', 'well', '-', 'established', 'game', 'design', 'strategies', ':', '1', ')', 'Scaffolded', 'increases', 'in', 'game', 'difficulty', '2', ')', 'In', '-', 'game', 'rewards', '3', ')', 'Quests', 'with', 'enhanced', 'narrative', '.', 'The', 'investigator', ""'s"", 'will', 'utilize', 'these', 'enhancements', 'to', 'study', 'their', 'impact', 'on', 'motivation', 'to', 'perform', 'a', 'tele', '-', 'rehabilitation-', 'based', 'home', 'exercise', 'program', ',', 'adherence', 'to', 'the', 'program', 'and', 'changes', 'in', 'hand', 'function', '.', 'The', 'proposed', 'study', 'will', 'utilize', 'a', 'system', 'of', 'novel', 'rehabilitation', 'technologies', 'designed', 'to', 'facilitate', 'home', 'exercise', 'performance', '.', 'Subjects', 'will', 'perform', '3', 'simulated', 'rehabilitation', 'activities', 'supported', 'by', 'a', 'passive', 'exoskeleton', ',', 'an', 'infrared', 'camera', 'and', 'software', 'that', 'will', 'allow', 'subjects', 'to', 'exercise', 'at', 'home', '.', 'The', 'investigator', ""'s"", 'will', 'investigate', ':', '1', ')', 'Differences', 'in', 'measures', 'of', 'motivation', 'elicited', 'by', 'motivationally', 'enhanced', 'simulations', 'and', 'un', '-', 'enhanced', 'control', 'versions.2', ')', 'The', 'impact', 'of', 'motivational', 'enhancements', 'on', 'actual', 'adherence', 'to', 'a', 'tele', '-', 'rehabilitation', 'program', 'in', 'persons', 'with', 'stroke', 'and', '3', ')', 'The', 'impact', 'of', 'motivational', 'enhancement', 'on', 'improvements', 'in', 'hand', 'function', 'achieved', 'by', 'these', 'subjects', '.', 'This', 'proposal', 'will', 'address', 'a', 'critical', 'gap', 'in', 'modern', 'rehabilitation', '-', 'adherence', 'to', 'autonomous', 'rehabilitation', 'programs', '.', 'Patient', 'participation', 'in', 'unsupervised', 'rehabilitation', 'is', 'one', 'of', 'the', 'assumptions', 'underpinning', 'our', 'health', 'care', 'system', '.', 'This', 'said', ',', 'no', 'data', 'collected', 'to', 'date', 'supports', 'that', 'adherence', 'is', 'acceptable', '.', 'The', 'technology', 'and', 'methodology', 'in', 'this', 'proposal', 'are', 'an', 'important', 'step', 'towards', 'leveraging', 'extensive', 'research', 'and', 'development', 'done', 'by', 'the', 'computer', 'gaming', 'industry', 'into', 'improved', 'rehabilitation', 'practice', '.']","['O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03985761,NCT03985761,"Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke | This trial studies the impact of motivational strategies designed by the gaming industry on adherence to a home tele-rehabilitation program designed to improve hand function in persons with stroke. A growing literature suggests that the extended practice of challenging hand tasks can produce measurable changes in hand function in persons with stroke. Current health care delivery systems do not support this volume of directly supervised rehabilitation, making it necessary for patients to perform a substantial amount of activity at home, unsupervised. Unfortunately, adherence to unsupervised home exercise regimens is quite poor in this population. The investigator's goal is to assess the impact of several well-established game design strategies: 1) Scaffolded increases in game difficulty 2) In-game rewards 3) Quests with enhanced narrative. The investigator's will utilize these enhancements to study their impact on motivation to perform a tele-rehabilitation- based home exercise program, adherence to the program and changes in hand function. The proposed study will utilize a system of novel rehabilitation technologies designed to facilitate home exercise performance. Subjects will perform 3 simulated rehabilitation activities supported by a passive exoskeleton, an infrared camera and software that will allow subjects to exercise at home. The investigator's will investigate: 1) Differences in measures of motivation elicited by motivationally enhanced simulations and un-enhanced control versions.2) The impact of motivational enhancements on actual adherence to a tele-rehabilitation program in persons with stroke and 3) The impact of motivational enhancement on improvements in hand function achieved by these subjects. This proposal will address a critical gap in modern rehabilitation - adherence to autonomous rehabilitation programs. Patient participation in unsupervised rehabilitation is one of the assumptions underpinning our health care system. This said, no data collected to date supports that adherence is acceptable. The technology and methodology in this proposal are an important step towards leveraging extensive research and development done by the computer gaming industry into improved rehabilitation practice.","[(10, 26, 'OTHER', 'Gaming Mechanics'), (39, 57, 'PHYSICAL', 'Telerehabilitation'), (84, 90, 'CONDITION', 'Stroke'), (126, 149, 'BEHAVIOURAL', 'motivational strategies'), (200, 232, 'PHYSICAL', 'home tele-rehabilitation program'), (283, 289, 'CONDITION', 'stroke'), (438, 444, 'CONDITION', 'stroke'), (1044, 1092, 'PHYSICAL', 'tele-rehabilitation- based home exercise program'), (1250, 1263, 'PHYSICAL', 'home exercise'), (1301, 1336, 'PHYSICAL', 'simulated rehabilitation activities'), (1352, 1371, 'PHYSICAL', 'passive exoskeleton'), (1433, 1449, 'PHYSICAL', 'exercise at home'), (1541, 1576, 'BEHAVIOURAL', 'motivationally enhanced simulations'), (1581, 1600, 'CONTROL', 'un-enhanced control'), (1627, 1652, 'BEHAVIOURAL', 'motivational enhancements'), (1678, 1705, 'PHYSICAL', 'tele-rehabilitation program'), (1722, 1728, 'CONDITION', 'stroke'), (1750, 1774, 'BEHAVIOURAL', 'motivational enhancement'), (1918, 1952, 'PHYSICAL', 'autonomous rehabilitation programs')]"
"['Improving', 'Obstructive', 'Sleep', 'Apnea', 'Management', 'Via', 'Wireless', 'Telemonitoring', '|', 'Obstructive', 'sleep', 'apnea', '(', 'OSA', ')', 'is', 'a', 'major', 'chronic', 'condition', 'affecting', 'the', 'quality', 'of', 'life', 'of', 'up', 'to', 'one', '-', 'fifth', 'of', 'all', 'Veterans', '.', 'Because', 'of', 'disappointingly', 'low', 'adherence', 'to', 'the', 'gold', '-', 'standard', 'treatment', '(', 'continuous', 'positive', 'airway', 'pressure', 'therapy', '-', 'CPAP', ')', ',', 'the', 'Institute', 'of', 'Medicine', 'has', 'stated', 'that', 'new', 'adherence', 'strategies', 'are', 'needed', 'that', 'improve', 'the', 'quality', 'of', 'care', ',', 'reduce', 'social', 'and', 'economic', 'costs', ',', 'and', 'help', 'OSA', 'patients', 'live', 'happier', ',', 'healthier', ',', 'and', 'more', 'productive', 'lives', 'through', 'improved', 'clinical', 'management', '.', 'The', 'combination', 'of', 'a', 'self', '-', 'management', 'approach', 'along', 'with', 'emerging', 'wireless', 'technologies', 'has', 'strong', 'potential', 'to', 'increase', 'treatment', 'adherence', 'and', 'improve', 'outcomes', '.']","['O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00682838,NCT00682838,"Improving Obstructive Sleep Apnea Management Via Wireless Telemonitoring | Obstructive sleep apnea (OSA) is a major chronic condition affecting the quality of life of up to one-fifth of all Veterans. Because of disappointingly low adherence to the gold-standard treatment (continuous positive airway pressure therapy - CPAP), the Institute of Medicine has stated that new adherence strategies are needed that improve the quality of care, reduce social and economic costs, and help OSA patients live happier, healthier, and more productive lives through improved clinical management. The combination of a self-management approach along with emerging wireless technologies has strong potential to increase treatment adherence and improve outcomes.","[(10, 33, 'CONDITION', 'Obstructive Sleep Apnea'), (49, 72, 'OTHER', 'Wireless Telemonitoring'), (75, 98, 'CONDITION', 'Obstructive sleep apnea'), (100, 103, 'CONDITION', 'OSA'), (481, 484, 'CONDITION', 'OSA'), (604, 628, 'BEHAVIOURAL', 'self-management approach'), (649, 670, 'OTHER', 'wireless technologies')]"
"['CONFIDENCE', ':', 'A', 'Multinational', ',', 'Multicenter', ',', 'Randomized', ',', 'Parallel', 'Group', ',', 'Open', '-', 'Label', 'Study', 'to', 'Assess', 'Medication', 'Satisfaction', 'in', 'Patients', 'With', 'Relapsing', 'Remitting', 'Multiple', 'Sclerosis', '(', 'RRMS', ')', 'Treated', 'With', 'Subcutaneous', 'Injections', 'of', 'Copaxone(R', ')', '(', 'Glatiramer', 'Acetate', ')', '40', 'mg', '/', 'mL', 'Three', 'Times', 'a', 'Week', 'Compared', 'to', '20', 'mg', '/', 'mL', 'Daily', '|', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'compare', 'patient', 'medication', 'satisfaction', 'as', 'measured', 'by', 'the', 'Medication', 'Satisfaction', 'Questionnaire', '(', 'MSQ', ')', 'scores', 'between', 'the', 'Copaxone', '40', 'mg', '/', 'mL', 'three', 'time', 'a', 'week', '(', 'TIW', ')', 'group', 'and', 'the', 'Copaxone', '20', 'mg', '/', 'mL', 'once', 'daily', '(', 'QD', ')', 'group', 'over', '6', 'months', 'of', 'treatment', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02499900,NCT02499900,"CONFIDENCE: A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone(R) (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily | The primary objective of this study is to compare patient medication satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) scores between the Copaxone 40 mg/mL three time a week (TIW) group and the Copaxone 20 mg/mL once daily (QD) group over 6 months of treatment.","[(138, 176, 'CONDITION', 'Relapsing Remitting Multiple Sclerosis'), (178, 182, 'CONDITION', 'RRMS'), (224, 235, 'DRUG', 'Copaxone(R)'), (237, 255, 'DRUG', 'Glatiramer Acetate'), (478, 486, 'DRUG', 'Copaxone'), (534, 542, 'DRUG', 'Copaxone')]"
"['The', 'Ontario', 'Prehospital', 'Advanced', 'Life', 'Support', '(', 'OPALS', ')', 'Study', 'for', 'Critically', 'Ill', 'and', 'Injured', 'Pediatric', 'Patients', '|', 'The', 'OPALS', 'Pediatric', 'Study', 'will', 'examine', 'the', 'incremental', 'impact', 'of', 'introducing', 'a', 'prehospital', 'full', 'advanced', 'life', 'support', 'in', 'pediatric', 'patients', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O']",NCT00298532,NCT00298532,The Ontario Prehospital Advanced Life Support (OPALS) Study for Critically Ill and Injured Pediatric Patients | The OPALS Pediatric Study will examine the incremental impact of introducing a prehospital full advanced life support in pediatric patients.,"[(64, 78, 'CONDITION', 'Critically Ill'), (191, 229, 'OTHER', 'prehospital full advanced life support')]"
"['The', 'Effect', 'of', 'Kinesiotaping', 'on', 'Glenohumeral', 'Shoulder', 'Subluxation', 'in', 'Post', '-', 'stroke', 'Patients', '|', 'To', 'evaluate', 'the', 'effectiveness', 'of', 'the', 'kinesiotaping', 'on', 'pain', ',', 'recovery', 'of', 'movement', 'and', 'daily', 'life', 'activities', 'in', 'Turkish', 'hemiplegic', 'patients', '.']","['O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT04468750,NCT04468750,"The Effect of Kinesiotaping on Glenohumeral Shoulder Subluxation in Post-stroke Patients | To evaluate the effectiveness of the kinesiotaping on pain, recovery of movement and daily life activities in Turkish hemiplegic patients.","[(14, 27, 'OTHER', 'Kinesiotaping'), (31, 64, 'CONDITION', 'Glenohumeral Shoulder Subluxation'), (73, 79, 'CONDITION', 'stroke'), (128, 141, 'OTHER', 'kinesiotaping'), (145, 149, 'CONDITION', 'pain'), (209, 219, 'CONDITION', 'hemiplegic')]"
"['Multi', '-', 'Center', 'Project', ':', 'Supported', 'Speed', 'Treadmill', 'Training', 'Exercise', 'Program', '(', 'SSTTEP', ')', 'for', 'Marginally', 'Ambulatory', 'Children', 'With', 'Cerebral', 'Palsy', '|', 'The', 'investigators', 'are', 'studying', 'the', 'effects', 'of', 'a', '12', '-', 'week', 'exercise', 'program', ',', 'consisting', 'of', 'either', ':', '\n\n', 'Walking', 'on', 'a', 'treadmill', 'with', 'partial', 'body', 'weight', '\n', 'Functional', 'exercise', 'program', '\n\n', 'The', 'investigators', 'would', 'like', 'to', 'know', 'the', 'effects', 'these', 'two', 'exercise', 'programs', 'have', 'on', 'the', 'quality', 'of', 'life', ',', 'muscle', 'strength', 'and', 'control', ',', 'coordination', ',', 'walking', ',', 'and', 'functional', 'movement', 'of', 'children', 'with', 'cerebral', 'palsy', 'who', 'are', 'marginal', 'ambulators', '.', 'This', 'is', 'a', 'randomized', 'control', 'trial', 'with', 'subjects', 'randomly', 'assigned', 'to', 'one', 'of', 'the', '2', 'groups', '.', 'Subjects', 'in', 'both', 'groups', 'will', 'be', 'seen', 'twice', 'a', 'day', 'for', 'two', 'weeks', 'at', 'our', 'hospital', 'for', 'intervention', 'and', 'parent', 'training', ',', 'and', 'then', 'participate', 'in', 'a', '10', 'week', 'home', '-', 'based', 'program', '.', 'During', 'each', 'subject', ""'s"", 'two', '-', 'week', 'clinic', '-', 'based', 'training', ',', 'a', 'parent', 'or', 'caregiver', 'is', 'trained', 'in', 'all', 'home', 'program', 'exercises', 'and/or', 'equipment', 'usage', '.', 'This', 'person', 'must', 'be', 'able', 'to', 'safely', 'perform', 'the', 'exercise', 'program', 'with', 'the', 'child', '.', 'Each', 'subject', 'will', 'also', 'need', 'to', 'participate', 'in', 'three', 'separate', '5', '-', 'hour', 'long', 'data', 'collection', 'sessions', 'scheduled', 'over', 'the', '4', 'month', 'study', 'period', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00467415,NCT00467415,"Multi-Center Project: Supported Speed Treadmill Training Exercise Program (SSTTEP) for Marginally Ambulatory Children With Cerebral Palsy | The investigators are studying the effects of a 12-week exercise program, consisting of either:

Walking on a treadmill with partial body weight
Functional exercise program

The investigators would like to know the effects these two exercise programs have on the quality of life, muscle strength and control, coordination, walking, and functional movement of children with cerebral palsy who are marginal ambulators. This is a randomized control trial with subjects randomly assigned to one of the 2 groups.Subjects in both groups will be seen twice a day for two weeks at our hospital for intervention and parent training, and then participate in a 10 week home-based program. During each subject's two-week clinic-based training, a parent or caregiver is trained in all home program exercises and/or equipment usage. This person must be able to safely perform the exercise program with the child. Each subject will also need to participate in three separate 5-hour long data collection sessions scheduled over the 4 month study period.","[(22, 73, 'PHYSICAL', 'Supported Speed Treadmill Training Exercise Program'), (75, 81, 'PHYSICAL', 'SSTTEP'), (123, 137, 'CONDITION', 'Cerebral Palsy'), (196, 212, 'PHYSICAL', 'exercise program'), (237, 284, 'PHYSICAL', 'Walking on a treadmill with partial body weight'), (285, 312, 'PHYSICAL', 'Functional exercise program'), (373, 390, 'PHYSICAL', 'exercise programs'), (513, 527, 'CONDITION', 'cerebral palsy'), (798, 816, 'PHYSICAL', 'home-based program'), (912, 934, 'PHYSICAL', 'home program exercises'), (1006, 1014, 'PHYSICAL', 'exercise')]"
"['REACT', '-', 'Recovery', 'Enhancement', 'From', 'TBI', 'Using', 'ACT', '.', 'A', 'Pilot', 'Study', '.', '|', 'Is', 'Acceptance', 'and', 'Commitment', 'Therapy', '(', 'ACT', ')', 'feasible', 'and', 'acceptable', 'for', 'adults', 'with', 'severe', 'Traumatic', 'Brain', 'Injury', '(', 'sTBI', ')', 'in', 'inpatient', 'services', '?', 'sTBI', 'is', 'associated', 'with', 'depression', ',', 'anxiety', 'and', 'low', 'self', 'awareness', '.', 'A', 'key', 'factor', 'in', 'recovery', 'is', 'adjustment', 'to', 'the', 'effects', 'of', 'injury', '.', 'Psychological', 'intervention', 'may', 'facilitate', 'this', 'change;', 'however', 'what', 'works', 'is', 'unclear', '.', 'ACT', 'seeks', 'to', 'improve', 'psychological', 'flexibility;', 'the', 'ability', 'to', 'be', 'present', 'with', 'difficult', 'thoughts', 'and', 'emotions', ',', 'rather', 'than', 'fighting', 'them', ',', 'and', 'to', 'accept', 'ourselves', 'as', 'we', 'are', ',', 'not', 'what', 'we', 'believe', 'we', 'should', 'be', '.', 'Current', 'research', 'is', 'limited', ',', 'but', 'what', 'is', 'published', 'suggests', 'it', 'may', 'be', 'useful', 'for', 'this', 'group', '.', '\n\n', 'Due', 'to', 'the', 'limited', 'research', 'this', 'pilot', 'study', 'aims', 'to', 'conduct', 'preliminary', 'analysis', 'on', 'the', 'acceptability', 'and', 'feasibility', 'of', 'ACT', 'for', 'people', 'with', 'sTBI', 'whilst', 'also', 'examining', 'the', 'suitability', 'of', 'the', 'study', 'protocol', 'in', 'order', 'to', 'make', 'recommendations', 'for', 'future', 'studies', '.', 'Clients', 'and', 'staff', 'from', 'three', 'Brain', 'Injury', 'Rehabilitation', 'Trust', '(', 'BIRT', ')', 'centres', 'will', 'be', 'recruited', ',', 'one', 'of', 'which', 'will', 'serve', 'as', 'the', 'intervention', 'centre', '.', '\n\n', 'Clients', 'in', 'the', 'intervention', 'group', 'will', 'be', 'asked', 'to', 'complete', 'questionnaires', 'a', 'week', 'before', 'and', 'after', 'participation', 'in', 'the', '6', 'week', 'ACT', 'programme', '.', 'Clients', 'in', 'the', 'comparison', 'group', 'will', 'be', 'asked', 'to', 'complete', 'questionnaires', 'a', 'week', 'before', 'and', 'after', 'receiving', '6', 'weeks', 'of', 'treatment', 'as', 'usual', '(', 'TAU', ')', '.', 'The', 'treatment', 'group', 'will', 'also', 'receive', 'TAU', '.', 'All', 'participants', 'will', 'be', 'invited', 'to', 'participate', 'in', 'a', 'focus', 'group', 'at', 'the', 'end', 'of', 'this', '8', 'week', 'period', 'to', 'discuss', 'their', 'involvement', 'in', 'the', 'study', '.', '\n\n', 'Staff', 'will', 'be', 'asked', 'to', 'complete', 'a', 'parallel', 'version', 'of', 'one', 'of', 'the', 'client', 'questionnaires', 'within', 'a', 'similar', 'timeframe', '.', 'In', 'addition', 'staff', 'at', 'the', 'intervention', 'centre', 'will', 'be', 'invited', 'to', 'attend', 'a', 'focus', 'group', 'and', 'complete', 'an', 'additional', 'questionnaire', 'after', 'the', 'eight', 'week', 'period', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02337114,NCT02337114,"REACT - Recovery Enhancement From TBI Using ACT. A Pilot Study. | Is Acceptance and Commitment Therapy (ACT) feasible and acceptable for adults with severe Traumatic Brain Injury (sTBI) in inpatient services? sTBI is associated with depression, anxiety and low self awareness. A key factor in recovery is adjustment to the effects of injury. Psychological intervention may facilitate this change; however what works is unclear. ACT seeks to improve psychological flexibility; the ability to be present with difficult thoughts and emotions, rather than fighting them, and to accept ourselves as we are, not what we believe we should be. Current research is limited, but what is published suggests it may be useful for this group.

Due to the limited research this pilot study aims to conduct preliminary analysis on the acceptability and feasibility of ACT for people with sTBI whilst also examining the suitability of the study protocol in order to make recommendations for future studies. Clients and staff from three Brain Injury Rehabilitation Trust (BIRT) centres will be recruited, one of which will serve as the intervention centre.

Clients in the intervention group will be asked to complete questionnaires a week before and after participation in the 6 week ACT programme. Clients in the comparison group will be asked to complete questionnaires a week before and after receiving 6 weeks of treatment as usual (TAU). The treatment group will also receive TAU. All participants will be invited to participate in a focus group at the end of this 8 week period to discuss their involvement in the study.

Staff will be asked to complete a parallel version of one of the client questionnaires within a similar timeframe. In addition staff at the intervention centre will be invited to attend a focus group and complete an additional questionnaire after the eight week period.","[(34, 37, 'CONDITION', 'TBI'), (44, 47, 'BEHAVIOURAL', 'ACT'), (69, 102, 'BEHAVIOURAL', 'Acceptance and Commitment Therapy'), (104, 107, 'BEHAVIOURAL', 'ACT'), (149, 178, 'CONDITION', 'severe Traumatic Brain Injury'), (180, 184, 'CONDITION', 'sTBI'), (209, 213, 'CONDITION', 'sTBI'), (233, 243, 'CONDITION', 'depression'), (245, 252, 'CONDITION', 'anxiety'), (428, 431, 'BEHAVIOURAL', 'ACT'), (852, 855, 'BEHAVIOURAL', 'ACT'), (872, 876, 'CONDITION', 'sTBI'), (1267, 1270, 'BEHAVIOURAL', 'ACT'), (1400, 1418, 'CONTROL', 'treatment as usual'), (1420, 1423, 'CONTROL', 'TAU'), (1464, 1467, 'CONTROL', 'TAU')]"
"['Pathogenesis', 'of', 'Rett', 'Syndrome', ':', 'Natural', 'History', 'and', 'Treatment', '|', 'Rett', 'syndrome', '(', 'RTT', ')', 'is', 'a', 'disorder', 'in', 'which', 'the', 'nervous', 'system', 'does', 'not', 'develop', 'properly', '.', 'RTT', 'generally', 'affects', 'girls', ',', 'but', 'there', 'are', 'some', 'boys', 'who', 'have', 'been', 'diagnosed', 'with', 'RTT', '.', 'Symptoms', 'of', 'RTT', 'include', 'small', 'brain', 'size', ',', 'poor', 'language', 'skills', ',', 'repetitive', 'hand', 'movements', ',', 'and', 'seizures', '.', 'This', 'study', 'will', 'evaluate', 'the', 'effectiveness', 'of', 'two', 'drugs', 'in', 'treating', 'the', 'symptoms', 'of', 'RTT', '.']","['O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT00069550,NCT00069550,"Pathogenesis of Rett Syndrome: Natural History and Treatment | Rett syndrome (RTT) is a disorder in which the nervous system does not develop properly. RTT generally affects girls, but there are some boys who have been diagnosed with RTT. Symptoms of RTT include small brain size, poor language skills, repetitive hand movements, and seizures. This study will evaluate the effectiveness of two drugs in treating the symptoms of RTT.","[(16, 29, 'CONDITION', 'Rett Syndrome'), (63, 76, 'CONDITION', 'Rett syndrome'), (78, 81, 'CONDITION', 'RTT'), (152, 155, 'CONDITION', 'RTT'), (234, 237, 'CONDITION', 'RTT'), (251, 254, 'CONDITION', 'RTT'), (428, 431, 'CONDITION', 'RTT')]"
"['Diffusion', 'Weighted', 'Magnetic', 'Resonance', 'Imaging', 'and', 'the', 'Optic', 'Nerve', 'Neuropathy', '.', '|', 'The', 'aim', 'of', 'the', 'project', 'is', 'to', 'create', 'a', 'new', ',', 'non', '-', 'invasive', 'and', 'safe', 'protocol', 'for', 'the', 'early', 'diagnosis', 'of', 'various', 'types', 'of', 'optic', 'neuropathies', 'with', 'the', 'use', 'of', 'diffusion', 'magnetic', 'resonance', 'imaging']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05353413,NCT05353413,"Diffusion Weighted Magnetic Resonance Imaging and the Optic Nerve Neuropathy. | The aim of the project is to create a new, non-invasive and safe protocol for the early diagnosis of various types of optic neuropathies with the use of diffusion magnetic resonance imaging","[(54, 76, 'CONDITION', 'Optic Nerve Neuropathy'), (198, 216, 'CONDITION', 'optic neuropathies')]"
"['Central', 'Mechanisms', 'of', 'Calmare', ':', 'an', 'fMRI', 'Trial', '|', 'Pilot', 'one', '-', 'treatment', 'and', 'extended', '10', '-', 'treatment', 'studies', 'are', 'carried', 'out', 'on', 'participants', 'with', 'peripheral', 'neuropathy', 'comparing', 'traditional', 'TENS', 'and', 'Calmare', 'stimulation', 'protocols', 'using', 'a', 'double', '-', 'blind', 'apparatus', '.', 'Resting', 'fMRI', 'scans', 'are', 'obtained', 'before', 'and', 'after', 'the', 'treatment', ',', 'as', 'well', 'as', 'after', 'most', 'of', 'the', 'pain', 'has', 'returned', '.']","['O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-CTRL', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O']",NCT04242797,NCT04242797,"Central Mechanisms of Calmare: an fMRI Trial | Pilot one-treatment and extended 10-treatment studies are carried out on participants with peripheral neuropathy comparing traditional TENS and Calmare stimulation protocols using a double-blind apparatus. Resting fMRI scans are obtained before and after the treatment, as well as after most of the pain has returned.","[(22, 29, 'OTHER', 'Calmare'), (138, 159, 'CONDITION', 'peripheral neuropathy'), (182, 186, 'CONTROL', 'TENS'), (191, 198, 'OTHER', 'Calmare'), (346, 350, 'CONDITION', 'pain')]"
"['Assessing', 'Outcomes', 'of', 'Enhanced', 'Chronic', 'Disease', 'Care', 'Through', 'Patient', 'Education', 'and', 'a', 'Value', '-', 'based', 'Formulary', 'Study', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'effect', 'of', 'two', 'novel', 'interventions', ';', '(', '1', ')', 'a', 'value', '-', 'based', 'formulary', 'which', 'eliminates', 'copayment', 'for', 'selected', 'high', '-', 'value', 'medications', '(', 'proven', 'to', 'prevent', 'heart', 'attacks', ',', 'stroke', ',', 'and', 'hospitalizations', ')', ';', 'and', '(', '2', ')', 'a', 'comprehensive', 'patient', 'education', 'program', 'aimed', 'at', 'lifestyle', 'modification', 'and', 'optimal', 'drug', 'use', ',', 'combined', 'with', 'relay', 'of', 'information', 'on', 'medication', 'use', ',', 'on', 'the', 'risk', 'of', 'adverse', 'clinical', 'outcomes', '(', 'mortality', ',', 'heart', 'attack', ',', 'stroke', ',', 'need', 'for', 'coronary', 'revascularization', ',', 'and', 'chronic', 'disease', 'related', 'hospitalizations', ')', 'in', 'low', '-', 'income', 'seniors', 'with', 'chronic', 'conditions', 'over', 'three', 'years', 'of', 'follow', '-', 'up', 'or', 'until', 'March', '31', ',', '2021', '(', 'whichever', 'comes', 'first', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02579655,NCT02579655,"Assessing Outcomes of Enhanced Chronic Disease Care Through Patient Education and a Value-based Formulary Study | The purpose of this study is to determine the effect of two novel interventions; (1) a value-based formulary which eliminates copayment for selected high-value medications (proven to prevent heart attacks, stroke, and hospitalizations); and (2) a comprehensive patient education program aimed at lifestyle modification and optimal drug use, combined with relay of information on medication use, on the risk of adverse clinical outcomes (mortality, heart attack, stroke, need for coronary revascularization, and chronic disease related hospitalizations) in low-income seniors with chronic conditions over three years of follow-up or until March 31, 2021 (whichever comes first).","[(60, 77, 'BEHAVIOURAL', 'Patient Education'), (84, 105, 'OTHER', 'Value-based Formulary'), (201, 222, 'OTHER', 'value-based formulary'), (375, 392, 'BEHAVIOURAL', 'patient education'), (562, 574, 'CONDITION', 'heart attack'), (576, 582, 'CONDITION', 'stroke')]"
"['Glutamate', 'Concentrations', 'in', 'the', 'Brain', 'Over', 'the', 'Course', 'of', 'a', 'Migraine', '-', 'like', 'Attack', '|', 'To', 'investigate', 'the', 'glutaminergic', 'system', 'in', 'the', 'onset', 'of', 'migraine', '-', 'like', 'attacks', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04220606,NCT04220606,Glutamate Concentrations in the Brain Over the Course of a Migraine-like Attack | To investigate the glutaminergic system in the onset of migraine-like attacks.,"[(59, 79, 'CONDITION', 'Migraine-like Attack'), (138, 159, 'CONDITION', 'migraine-like attacks')]"
"['A', 'Multisite', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', 'Trial', 'Evaluating', 'Pitolisant', '(', 'BF2.649', ')', 'For', 'Alcohol', 'Use', 'Disorder', 'Treatment', '|', 'The', 'study', 'primary', 'end', 'point', 'is', 'the', 'decrease', 'in', 'the', 'number', 'of', 'monthly', 'heavy', 'drinking', 'days', '(', 'HDD', ')', '(', '≥', '60', 'g', '/', 'day', 'in', 'men', 'and', '≥', '40', 'g', '/', 'd', 'in', 'women', ')', 'from', 'baseline', 'to', 'the', 'end', 'of', 'the', 'double', 'blind', 'Randomized', 'Treatment', '(', 'RT', ')', '.', '\n\n', 'The', 'Secondary', 'end', 'points', 'will', 'be', 'designed', 'to', 'assess', 'safety', 'and', 'tolerability', 'and', 'to', 'further', 'investigate', 'the', 'effect', 'of', 'pitolisant', 'on', 'other', 'alcohol', 'use', 'criteria', '(', 'e.g.', 'total', 'alcohol', 'consumption', ',', 'number', 'of', 'abstinence', 'days', ')', ',', 'craving', 'as', 'well', 'as', 'the', 'improvement', 'in', 'mental', 'health', '(', 'depression', ',', 'sleep', ')', 'and', 'quality', 'of', 'life', '.', '\n\n', 'Total', 'alcohol', 'consumption', '(', 'TAC', ')', 'from', 'baseline', 'to', 'end', 'of', 'treatment', '.', 'TAC', 'was', 'defined', 'as', 'mean', 'daily', 'alcohol', 'consumption', 'in', 'g', '/', 'day', 'over', 'a', 'month', '(', '28', 'days', ')', '.', '\n', 'Percent', 'of', 'patients', 'without', 'HDDs', 'during', 'the', '24', 'weeks', 'RT', 'phase', 'of', 'the', 'study', '.', '(', 'Continuous', 'Controlled', 'Drinking', '=', 'CCD', ')', '\n', 'Percent', 'of', 'Abstinent', 'Days', 'during', 'RT', 'phase', '(', 'PAD', ')', '\n', 'Continuous', 'Abstinence', 'Duration', 'from', 'baseline', 'during', '24', 'weeks', 'RT', 'phase', '(', 'CAD', ')', '\n', '4', '-', 'week', 'point', 'prevalence', 'abstinence', 'at', 'end', 'of', 'treatment', '\n', 'Improvement', 'in', 'alcohol', 'biomarkers', '(', 'e.g.', 'ALAT', ',', 'ASAT', ',', '%', 'CDT', ')', 'during', '24', 'week', 'RT', 'phase', '\n', 'Craving', '(', 'Obsessive', 'Compulsive', 'Drinking', 'Scale', ')', 'during', '24', 'week', 'RT', 'phase', '\n', 'Beck', 'Depression', 'Inventory', '(', 'BDI', ')', 'during', '24', 'week', 'RT', 'phase', '\n', 'Quality', 'of', 'sleep', '(', 'Pittsburgh', 'Sleep', 'Quality', 'Index', ')', 'during', 'RT', 'phase', '.', '\n', 'Treatment', 'retention', 'during', '24', 'week', 'RT', '\n', 'Quality', 'of', 'life', '(', 'SF-12', ')', 'during', 'RT', 'phase', '\n', 'Percent', 'patients', 'without', 'HDDs', 'during', 'the', 'OL', 'follow', 'up', 'period', '\n', 'Quality', 'of', 'life', '(', 'SF-12', ')', 'during', 'OL', 'phase', '\n', 'Quality', 'of', 'sleep', '(', 'Pittsburgh', 'Sleep', 'Quality', 'Index', ')', 'during', 'OL', 'phase', '\n', 'Treatment', 'retention', 'OL', 'phase', 'Safety', 'will', 'be', 'assessed', 'by', 'evaluation', 'of', 'treatment', 'emergent', 'adverse', 'events', '(', 'TEAE', ')', ',', 'physical', 'examinations', ',', 'clinical', 'laboratory', 'tests', '(', 'blood', 'chemistry', ',', 'hematology', ',', 'and', 'urinalysis', ')', ',', 'subsequent', 'end', 'of', 'treatment', 'potential', 'withdrawal', ',', 'evaluation', 'scales', 'and', 'physical', 'examination', ',', 'measurement', 'of', 'heart', 'rate', ',', 'blood', 'pressure', ',', 'and', 'body', 'weight', 'at', 'each', 'study', 'visit', ')', 'V0', '-', 'FU5', ')', '.', 'If', 'at', 'ECG', 'Fridericia', ""'s"", 'corrected', 'QT', 'interval', '≥', '500', 'ms', 'or', 'if', 'difference', 'to', 'baseline', 'is', '≥', '60', 'ms', 'it', 'will', 'be', 'required', 'to', 'check', 'ECG', 'by', 'second', 'measurement', 'after', 'lying', 'down', '10', 'minutes', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02800083,NCT02800083,"A Multisite Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Pitolisant (BF2.649) For Alcohol Use Disorder Treatment | The study primary end point is the decrease in the number of monthly heavy drinking days (HDD) (≥ 60 g/day in men and ≥ 40 g/d in women) from baseline to the end of the double blind Randomized Treatment (RT).

The Secondary end points will be designed to assess safety and tolerability and to further investigate the effect of pitolisant on other alcohol use criteria (e.g. total alcohol consumption, number of abstinence days), craving as well as the improvement in mental health (depression, sleep) and quality of life.

Total alcohol consumption (TAC) from baseline to end of treatment. TAC was defined as mean daily alcohol consumption in g/day over a month (28 days).
Percent of patients without HDDs during the 24 weeks RT phase of the study. (Continuous Controlled Drinking=CCD)
Percent of Abstinent Days during RT phase (PAD)
Continuous Abstinence Duration from baseline during 24 weeks RT phase (CAD)
4-week point prevalence abstinence at end of treatment
Improvement in alcohol biomarkers (e.g. ALAT, ASAT, % CDT) during 24 week RT phase
Craving (Obsessive Compulsive Drinking Scale) during 24 week RT phase
Beck Depression Inventory (BDI) during 24 week RT phase
Quality of sleep (Pittsburgh Sleep Quality Index) during RT phase.
Treatment retention during 24 week RT
Quality of life (SF-12) during RT phase
Percent patients without HDDs during the OL follow up period
Quality of life (SF-12) during OL phase
Quality of sleep (Pittsburgh Sleep Quality Index) during OL phase
Treatment retention OL phase Safety will be assessed by evaluation of treatment emergent adverse events (TEAE), physical examinations, clinical laboratory tests (blood chemistry, hematology, and urinalysis), subsequent end of treatment potential withdrawal, evaluation scales and physical examination, measurement of heart rate, blood pressure, and body weight at each study visit )V0-FU5). If at ECG Fridericia's corrected QT interval ≥ 500 ms or if difference to baseline is ≥ 60 ms it will be required to check ECG by second measurement after lying down 10 minutes.","[(38, 45, 'CONTROL', 'Placebo'), (74, 84, 'DRUG', 'Pitolisant'), (86, 93, 'DRUG', 'BF2.649'), (99, 119, 'CONDITION', 'Alcohol Use Disorder'), (459, 469, 'DRUG', 'pitolisant')]"
"['The', 'Norwegian', 'Study', 'of', 'Chronic', 'Fatigue', 'Syndrome', 'in', 'Adolescents', ':', 'Pathophysiology', 'and', 'Intervention', 'Trial', '|', 'The', 'purpose', 'of', 'this', 'study', 'IS', 'to', '\n\n', 'explore', 'the', 'underlying', 'pathophysiology', 'of', 'chronic', 'fatigue', 'syndrome', '(', 'CFS', ')', 'in', 'adolescents', ',', 'particularly', 'focusing', 'on', 'genetics', ',', 'infections', '/', 'immunology', ',', 'endocrinology', ',', 'autonomic', 'control', 'and', 'cognitions', '\n', 'to', 'assess', 'the', 'effect', 'of', 'clonidine', '(', 'a', 'drug', 'that', 'attenuates', 'sympathetic', 'nervous', 'activity', ')', 'in', 'adolescent', 'CFS', '.']","['O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT01040429,NCT01040429,"The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial | The purpose of this study IS to

explore the underlying pathophysiology of chronic fatigue syndrome (CFS) in adolescents, particularly focusing on genetics, infections/immunology, endocrinology, autonomic control and cognitions
to assess the effect of clonidine (a drug that attenuates sympathetic nervous activity) in adolescent CFS.","[(23, 47, 'CONDITION', 'Chronic Fatigue Syndrome'), (180, 204, 'CONDITION', 'chronic fatigue syndrome'), (206, 209, 'CONDITION', 'CFS'), (357, 366, 'DRUG', 'clonidine'), (435, 438, 'CONDITION', 'CFS')]"
"['The', 'underlying', 'goal', 'of', 'this', 'study', 'is', 'to', 'assess', '[', '18F', ']', 'PBR06', 'PET', 'imaging', 'as', 'a', 'tool', 'to', 'detect', 'microglial', 'activation', 'in', 'the', 'brain', 'of', 'Alzheimer', 'Disease', '(', 'AD', ')', ',', 'Parkinson', 'Disease', '(', 'PD', ')', 'and', 'Multiple', 'Sclerosis', '(', 'MS', ')', 'research', 'participants', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT01028209,NCT01028209,"The underlying goal of this study is to assess [18F] PBR06 PET imaging as a tool to detect microglial activation in the brain of Alzheimer Disease (AD), Parkinson Disease (PD) and Multiple Sclerosis (MS) research participants.","[(129, 146, 'CONDITION', 'Alzheimer Disease'), (148, 150, 'CONDITION', 'AD'), (153, 170, 'CONDITION', 'Parkinson Disease'), (172, 174, 'CONDITION', 'PD'), (180, 198, 'CONDITION', 'Multiple Sclerosis'), (200, 202, 'CONDITION', 'MS')]"
"['Comparison', 'of', 'Aquatic', 'and', 'Land', '-', 'based', 'Group', 'Exercise', 'for', 'Individuals', 'With', 'Parkinson', 'Disease', '|', 'This', 'study', 'will', 'investigate', 'the', 'impact', 'of', 'land', 'based', 'or', 'aquatic', 'based', 'group', 'exercise', 'on', 'the', 'balance', ',', 'walking', ',', 'balance', 'confidence', ',', 'and', 'quality', 'of', 'life', 'of', 'people', 'with', 'idiopathic', 'Parkinson', 'disease', '.', 'Participants', 'will', 'be', 'randomized', 'to', 'participate', 'in', 'a', 'land', 'based', 'or', 'aquatic', 'based', 'group', 'exercise', 'program', '2', 'times', 'per', 'week', 'for', '12', 'weeks', '.', 'Prior', 'to', 'and', 'after', 'participation', ',', 'balance', ',', 'walking', ',', 'quality', 'of', 'life', ',', 'and', 'balance', 'confidence', 'will', 'be', 'measured', 'by', 'a', 'blinded', 'examiner', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04291027,NCT04291027,"Comparison of Aquatic and Land-based Group Exercise for Individuals With Parkinson Disease | This study will investigate the impact of land based or aquatic based group exercise on the balance, walking, balance confidence, and quality of life of people with idiopathic Parkinson disease. Participants will be randomized to participate in a land based or aquatic based group exercise program 2 times per week for 12 weeks. Prior to and after participation, balance, walking, quality of life, and balance confidence will be measured by a blinded examiner.","[(14, 51, 'PHYSICAL', 'Aquatic and Land-based Group Exercise'), (73, 90, 'CONDITION', 'Parkinson Disease'), (135, 177, 'PHYSICAL', 'land based or aquatic based group exercise'), (258, 286, 'CONDITION', 'idiopathic Parkinson disease'), (340, 390, 'PHYSICAL', 'land based or aquatic based group exercise program')]"
"['Comparison', 'of', 'Two', 'Analgesic', 'Strategies', 'After', 'Scheduled', 'Caesarean', ':', 'Block', 'of', 'the', 'Lumbar', 'Region', 'With', 'Ropivacaine', 'Versus', 'Intrathecal', 'Morphine', '|', 'To', 'demonstrate', 'the', 'superiority', 'of', 'square', 'lumbar', 'block', 'to', 'ropivacaine', 'compared', 'to', 'intrathecal', 'morphine', 'in', 'the', 'efficacy', 'of', 'postoperative', 'analgesia', 'following', 'scheduled', 'caesarean', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04755712,NCT04755712,Comparison of Two Analgesic Strategies After Scheduled Caesarean : Block of the Lumbar Region With Ropivacaine Versus Intrathecal Morphine | To demonstrate the superiority of square lumbar block to ropivacaine compared to intrathecal morphine in the efficacy of postoperative analgesia following scheduled caesarean.,"[(55, 64, 'CONDITION', 'Caesarean'), (99, 110, 'DRUG', 'Ropivacaine'), (130, 138, 'DRUG', 'Morphine'), (198, 209, 'DRUG', 'ropivacaine'), (234, 242, 'DRUG', 'morphine'), (306, 315, 'CONDITION', 'caesarean')]"
"['Investigation', 'of', 'the', 'NMDA', 'Receptor', 'System', 'in', 'Man', 'as', 'a', 'Potential', 'Surrogate', 'Marker', 'for', 'Deficit', 'Syndrome', 'in', 'Schizophrenia', ':', 'a', '[', '123]I', '-', 'CNS', '1261', 'Single', 'Photon', 'Emission', 'Tomography', '(', 'SPET', ')', 'Study', '|', 'This', 'study', 'was', 'designed', 'to', 'compare', 'the', '[', '123]I', '-', 'CNS', '1261', 'binding', 'to', 'NMDA', 'receptor', 'between', 'healthy', 'volunteers', 'and', 'different', 'subgroups', 'of', 'schizophrenic', 'patients', '.', 'Investigation', 'of', 'the', 'potential', 'influence', 'of', 'antipsychotic', 'and', 'concomitant', 'medication', 'on', '[', '123I', ']', 'CNS', '1261', 'binding', 'is', 'also', 'relevant', '.', 'Fifteen', 'healthy', 'subjects', '(', 'male', 'and', 'female', 'of', 'non', '-', 'child', 'bearing', 'potential', ')', 'will', 'be', 'recruited', 'and', '40', 'schizophrenic', 'patients', 'divided', 'in', '3', 'subgroups', 'as', 'indicated', 'before', ':', 'Subgroup', 'a', ')', 'treatment', '-', 'naive', ',', '(', 'n=10', ')', ';', 'Subgroup', 'b', ')', 'on', 'stable', 'treatment', 'with', 'risperidone', '(', 'without', 'criteria', 'of', 'deficit', 'syndrome', 'on', 'the', 'SDS', 'scale', ',', '(', 'n=15);Subgroup', 'c', ')', 'on', 'stable', 'treatment', 'with', 'risperidone', 'fitting', 'criteria', 'of', 'deficit', 'syndrome', 'on', 'the', 'SDS', 'scale', ',', '(', 'n=15', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00364429,NCT00364429,"Investigation of the NMDA Receptor System in Man as a Potential Surrogate Marker for Deficit Syndrome in Schizophrenia: a [123]I-CNS 1261 Single Photon Emission Tomography (SPET) Study | This study was designed to compare the [123]I-CNS 1261 binding to NMDA receptor between healthy volunteers and different subgroups of schizophrenic patients. Investigation of the potential influence of antipsychotic and concomitant medication on [123I] CNS 1261 binding is also relevant.Fifteen healthy subjects (male and female of non-child bearing potential) will be recruited and 40 schizophrenic patients divided in 3 subgroups as indicated before: Subgroup a) treatment-naive, (n=10); Subgroup b) on stable treatment with risperidone (without criteria of deficit syndrome on the SDS scale, (n=15);Subgroup c) on stable treatment with risperidone fitting criteria of deficit syndrome on the SDS scale, (n=15).","[(85, 101, 'CONDITION', 'Deficit Syndrome'), (105, 118, 'CONDITION', 'Schizophrenia'), (321, 334, 'CONDITION', 'schizophrenic'), (389, 402, 'DRUG', 'antipsychotic'), (573, 586, 'CONDITION', 'schizophrenic'), (714, 725, 'DRUG', 'risperidone'), (747, 763, 'CONDITION', 'deficit syndrome'), (826, 837, 'DRUG', 'risperidone'), (858, 874, 'CONDITION', 'deficit syndrome')]"
"['A', 'Phase', 'IIa', ',', 'Randomized', ',', 'Multicenter', ',', 'Double', '-', 'Blind', ',', 'Active', 'Comparator-', 'and', 'Placebo', '-', 'Controlled', ',', 'Clinical', 'Trial', 'to', 'Study', 'the', 'Safety', 'and', 'Efficacy', 'of', 'MK8998', 'in', 'Acutely', 'Psychotic', 'Patients', 'With', 'Schizophrenia', '|', 'A', 'study', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'treatment', 'with', 'MK-8998', 'as', 'compared', 'to', 'placebo', 'and', 'olanzapine', 'for', 'acutely', 'psychotic', 'patients', 'with', 'schizophrenia', '.', 'The', 'primary', 'hypothesis', 'is', 'that', 'in', 'participants', 'undergoing', 'an', 'acute', 'psychotic', 'episode', 'of', 'schizophrenia', ',', 'MK-8998', '6', 'to', '8', 'mg', 'twice', 'daily', 'is', 'superior', 'to', 'placebo', 'in', 'the', 'treatment', 'of', 'symptoms', 'of', 'schizophrenia', 'as', 'measured', 'by', 'the', 'mean', 'change', 'from', 'baseline', 'in', 'the', 'Positive', 'and', 'Negative', 'Syndrome', 'Scale', '(', 'PANSS', ')', 'total', 'score', 'at', 'Week', '4', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00827918,NCT00827918,"A Phase IIa, Randomized, Multicenter, Double-Blind, Active Comparator- and Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of MK8998 in Acutely Psychotic Patients With Schizophrenia | A study to evaluate the safety and efficacy of treatment with MK-8998 as compared to placebo and olanzapine for acutely psychotic patients with schizophrenia. The primary hypothesis is that in participants undergoing an acute psychotic episode of schizophrenia, MK-8998 6 to 8 mg twice daily is superior to placebo in the treatment of symptoms of schizophrenia as measured by the mean change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score at Week 4.","[(75, 82, 'CONTROL', 'Placebo'), (146, 152, 'DRUG', 'MK8998'), (156, 173, 'CONDITION', 'Acutely Psychotic'), (188, 201, 'CONDITION', 'Schizophrenia'), (266, 273, 'DRUG', 'MK-8998'), (289, 296, 'CONTROL', 'placebo'), (301, 311, 'DRUG', 'olanzapine'), (316, 333, 'CONDITION', 'acutely psychotic'), (348, 361, 'CONDITION', 'schizophrenia'), (424, 439, 'CONDITION', 'acute psychotic'), (451, 464, 'CONDITION', 'schizophrenia'), (466, 473, 'DRUG', 'MK-8998'), (511, 518, 'CONTROL', 'placebo'), (551, 564, 'CONDITION', 'schizophrenia')]"
"['A', 'Phase', 'IB', ',', 'Open', '-', 'Label', ',', 'Safety', 'Study', 'of', 'the', 'Combination', 'of', 'Sunitinib', 'and', 'Radiation', 'for', 'the', 'Treatment', 'of', 'Patients', 'With', 'Cancer', '|', 'This', 'study', 'is', 'using', 'the', 'combination', 'of', 'radiation', 'and', 'antiangiogenic', 'agents', '(', 'agents', 'that', 'destroy', 'existing', 'blood', 'vessels', ')', 'seems', 'to', 'be', 'an', 'approach', 'to', 'tumor', 'cure', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT00437372,NCT00437372,"A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer | This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.","[(59, 68, 'DRUG', 'Sunitinib'), (73, 82, 'RADIOTHERAPY', 'Radiation'), (118, 124, 'CONDITION', 'Cancer'), (166, 175, 'RADIOTHERAPY', 'radiation'), (274, 279, 'CONDITION', 'tumor')]"
"['A', 'Phase', '2', 'Extension', 'Study', 'to', 'Evaluate', 'the', 'Long', '-', 'Term', 'Safety', ',', 'Tolerability', ',', 'Efficacy', ',', 'Pharmacokinetics', ',', 'and', 'Pharmacodynamics', 'of', 'AOC', '1001', 'Administered', 'Intravenously', 'to', 'Adult', 'Myotonic', 'Dystrophy', 'Type', '1', '(', 'DM1', ')', 'Patients', '|', 'AOC', '1001', '-', 'CS2', '(', 'MARINA', '-', 'OLE', ')', 'is', 'a', 'Phase', '2', 'extension', 'of', 'the', 'AOC', '1001', '-', 'CS1', '(', 'MARINA', ')', 'study', 'to', 'evaluate', 'the', 'safety', ',', 'tolerability', ',', 'efficacy', ',', 'pharmacokinetics', 'and', 'pharmacodynamics', 'of', 'multiple', '-', 'doses', 'of', 'AOC', '1001', 'Administered', 'Intravenously', 'to', 'Adult', 'Myotonic', 'Dystrophy', 'Type', '1', '(', 'DM1', ')', 'patients']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT05479981,NCT05479981,"A Phase 2 Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients | AOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients","[(126, 134, 'DRUG', 'AOC 1001'), (171, 196, 'CONDITION', 'Myotonic Dystrophy Type 1'), (198, 201, 'CONDITION', 'DM1'), (405, 413, 'DRUG', 'AOC 1001'), (450, 475, 'CONDITION', 'Myotonic Dystrophy Type 1'), (477, 480, 'CONDITION', 'DM1')]"
"['Investigation', 'the', 'Effect', 'of', 'Cervical', 'Mobilization', 'on', 'Balance', 'and', 'Plantar', 'Pressure', 'Distribution', 'in', 'Multiple', 'Sclerosis', 'Patients', ':', 'A', 'Randomized', 'Crossover', 'Controlled', 'Study', '|', 'MS', 'patients', 'were', 'randomly', 'divided', 'into', 'traditional', 'therapy', 'and', 'traditional', 'therapy', '+', 'cervical', 'mobilization', 'groups', '.', 'While', 'muscle', 'strengthening', ',', 'stretching', ',', 'balance', 'and', 'coordination', 'exercises', 'were', 'given', 'to', 'the', 'traditional', 'group', ',', 'cervical', 'mobilization', 'was', 'applied', 'in', 'addition', 'to', 'these', 'in', 'cervical', 'group', '.', 'Patients', 'received', 'treatments', 'twice', 'a', 'week', 'for', '4', 'weeks', '.', 'The', 'effect', 'of', 'the', 'applied', 'treatment', 'on', 'the', 'tonus', 'and', 'plantar', 'pressure', 'distribution', 'was', 'analyzed', '.', 'Treatments', 'were', 'interrupted', 'for', '4', 'weeks', 'and', 'the', 'groups', 'continued', 'with', 'the', 'treatment', 'they', 'did', 'not', 'receive', '(', 'crossover', 'design', ')', '.', 'The', 'group', 'that', 'received', 'traditional', 'treatment', 'in', 'the', 'first', 'period', 'completed', 'traditional', '+', 'cervical', 'mobilization', ',', 'and', 'the', 'other', 'group', 'with', 'traditional', '+', 'cervical', 'mobilization', 'traditionally', 'completed', 'the', 'treatment', '.']","['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O']",NCT04543448,NCT04543448,"Investigation the Effect of Cervical Mobilization on Balance and Plantar Pressure Distribution in Multiple Sclerosis Patients: A Randomized Crossover Controlled Study | MS patients were randomly divided into traditional therapy and traditional therapy + cervical mobilization groups. While muscle strengthening, stretching, balance and coordination exercises were given to the traditional group, cervical mobilization was applied in addition to these in cervical group. Patients received treatments twice a week for 4 weeks. The effect of the applied treatment on the tonus and plantar pressure distribution was analyzed. Treatments were interrupted for 4 weeks and the groups continued with the treatment they did not receive (crossover design). The group that received traditional treatment in the first period completed traditional + cervical mobilization, and the other group with traditional + cervical mobilization traditionally completed the treatment.","[(28, 49, 'PHYSICAL', 'Cervical Mobilization'), (98, 116, 'CONDITION', 'Multiple Sclerosis'), (169, 171, 'CONDITION', 'MS'), (208, 227, 'CONTROL', 'traditional therapy'), (232, 251, 'CONTROL', 'traditional therapy'), (254, 275, 'PHYSICAL', 'cervical mobilization'), (290, 310, 'CONTROL', 'muscle strengthening'), (312, 322, 'CONTROL', 'stretching'), (324, 358, 'CONTROL', 'balance and coordination exercises'), (396, 417, 'PHYSICAL', 'cervical mobilization'), (771, 792, 'CONTROL', 'traditional treatment'), (823, 858, 'PHYSICAL', 'traditional + cervical mobilization'), (885, 920, 'PHYSICAL', 'traditional + cervical mobilization')]"
"['Effect', 'of', 'Atypical', 'Antipsychotics', 'on', 'Gene', 'Expression', 'in', 'Soft', 'Tissues', 'of', 'Healthy', 'Subjects', '-', 'A', 'Placebo', 'Controlled', 'Randomised', 'Pilot', 'Study', '|', 'Schizophrenia', 'is', 'a', 'severe', 'chronic', 'and', 'disabling', 'mental', 'disorder', 'and', 'is', 'associated', 'with', 'a', 'significant', 'reduction', 'in', 'life', 'expectancy', '.', 'Atypical', 'antipsychotic', 'treatment', 'compliance', 'may', 'be', 'jeopardized', 'because', 'of', 'drug', 'induced', 'weight', 'gain', 'and', 'abnormalities', 'in', 'carbohydrate', 'and', 'lipid', 'metabolism', '.', '\n\n', 'Aim', ':', 'to', 'gain', 'data', 'on', 'drug', 'related', 'effects', 'on', 'gene', 'expression', 'and', 'regulation', 'with', 'special', 'regard', 'to', 'glucose', 'metabolism', '.']","['O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01185743,NCT01185743,"Effect of Atypical Antipsychotics on Gene Expression in Soft Tissues of Healthy Subjects - A Placebo Controlled Randomised Pilot Study | Schizophrenia is a severe chronic and disabling mental disorder and is associated with a significant reduction in life expectancy. Atypical antipsychotic treatment compliance may be jeopardized because of drug induced weight gain and abnormalities in carbohydrate and lipid metabolism.

Aim: to gain data on drug related effects on gene expression and regulation with special regard to glucose metabolism.","[(10, 33, 'DRUG', 'Atypical Antipsychotics'), (93, 100, 'CONTROL', 'Placebo'), (137, 150, 'CONDITION', 'Schizophrenia'), (268, 290, 'DRUG', 'Atypical antipsychotic')]"
"['A', '12', '-', 'week', ',', 'Double', 'Blind', ',', 'Placebo', '-', 'controlled', ',', 'Randomized', ',', 'Parallel', 'Group', ',', 'Multicenter', ',', 'Fixed', 'Dose', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'a', '20', 'mg', '/', 'd', 'Oral', 'Dose', 'of', 'KW-6002', '(', 'Istradefylline', ')', 'as', 'Treatment', 'for', 'Parkinson', ""'s"", 'Disease', 'in', 'Patients', 'With', 'Motor', 'Response', 'Complications', 'on', 'Levodopa', '/', 'Carbidopa', 'Therapy', '.', '|', 'To', 'establish', 'the', 'efficacy', 'of', 'a', '20', 'mg', '/', 'day', 'dose', 'of', 'istradefylline', 'for', 'reducing', 'the', 'percentage', 'of', 'OFF', 'time', 'in', 'patients', 'with', 'advanced', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'treated', 'with', 'levodopa', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O']",NCT00199407,NCT00199407,"A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy. | To establish the efficacy of a 20 mg/day dose of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.","[(25, 32, 'CONTROL', 'Placebo'), (165, 172, 'DRUG', 'KW-6002'), (174, 188, 'DRUG', 'Istradefylline'), (207, 226, 'CONDITION', ""Parkinson's Disease""), (244, 272, 'CONDITION', 'Motor Response Complications'), (276, 284, 'DRUG', 'Levodopa'), (285, 294, 'DRUG', 'Carbidopa'), (355, 369, 'DRUG', 'istradefylline'), (427, 455, 'CONDITION', ""advanced Parkinson's disease""), (457, 459, 'CONDITION', 'PD'), (474, 482, 'DRUG', 'levodopa')]"
"['The', 'Identification', 'and', 'Prevention', 'of', 'Sarcopenia', 'in', 'Older', 'Patients', 'in', 'the', 'Acute', 'Hospital', 'Setting', '|', 'This', 'study', 'will', 'assess', 'whether', 'the', 'use', 'of', 'technology', 'using', 'the', 'Virtual', 'Gate', 'Device', '(', 'VGD', ')', 'will', 'prevent', 'or', 'minimize', 'the', 'development', 'of', 'hospital', 'acquired', 'Sarcopenia', 'resulting', 'from', 'Immobilization', '.']","['O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O']",NCT04092790,NCT04092790,The Identification and Prevention of Sarcopenia in Older Patients in the Acute Hospital Setting | This study will assess whether the use of technology using the Virtual Gate Device (VGD) will prevent or minimize the development of hospital acquired Sarcopenia resulting from Immobilization.,"[(37, 47, 'CONDITION', 'Sarcopenia'), (161, 180, 'OTHER', 'Virtual Gate Device'), (182, 185, 'OTHER', 'VGD'), (249, 259, 'CONDITION', 'Sarcopenia')]"
"['Weight', 'Management', 'in', 'Spinal', 'Cord', 'Injury', '-', 'Intervention', 'and', 'Monitoring', 'Via', 'Tele', '-', 'Nutrition', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'provide', 'tele', '-', 'nutrition', 'counseling', 'after', 'a', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'During', 'the', 'three', 'months', 'of', 'participation', ',', 'subjects', 'will', 'be', 'given', 'an', 'iPad', 'and', 'the', 'iPad', 'will', 'be', 'used', 'to', 'record', 'meals', 'using', 'a', 'photo', 'journal', 'application', ',', 'YouAte', '.', 'In', 'addition', ',', 'subjects', 'will', 'receive', 'dietary', 'advice', 'two', 'times', 'a', 'month', 'with', 'a', 'registered', 'dietitian', '(', 'RD', ')', '.', 'The', 'dietitian', 'role', 'in', 'the', 'study', 'will', 'be', 'to', 'educate', 'healthy', 'weight', 'management', 'and', 'accommodate', 'any', 'cultural', 'and', 'behavioral', 'habits', '.', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'show', 'that', 'the', 'proposed', 'tele', '-', 'nutrition', 'program', 'will', 'be', 'effective', 'with', 'weight', 'management', 'through', '3', '-', 'month', 'tele', '-', 'nutrition', 'counseling', 'via', 'iPad', 'FaceTime', '.', 'The', 'hypotheses', 'are', '1', ')', 'that', 'weight', 'and', 'waist', 'circumference', 'will', 'not', 'increase', 'after', '3', 'months', 'of', 'tele', '-', 'nutrition', 'program', ',', '2', ')', 'quality', 'of', 'life', 'will', 'improve', ',', 'and', '3', ')', 'quality', 'of', 'diet', 'will', 'improve', '.']","['B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03714217,NCT03714217,"Weight Management in Spinal Cord Injury - Intervention and Monitoring Via Tele-Nutrition | The purpose of the study is to provide tele-nutrition counseling after a spinal cord injury (SCI). During the three months of participation, subjects will be given an iPad and the iPad will be used to record meals using a photo journal application, YouAte. In addition, subjects will receive dietary advice two times a month with a registered dietitian (RD). The dietitian role in the study will be to educate healthy weight management and accommodate any cultural and behavioral habits. The objective of this study is to show that the proposed tele-nutrition program will be effective with weight management through 3-month tele-nutrition counseling via iPad FaceTime. The hypotheses are 1) that weight and waist circumference will not increase after 3 months of tele-nutrition program, 2) quality of life will improve, and 3) quality of diet will improve.","[(0, 17, 'BEHAVIOURAL', 'Weight Management'), (21, 39, 'CONDITION', 'Spinal Cord Injury'), (74, 88, 'BEHAVIOURAL', 'Tele-Nutrition'), (130, 155, 'BEHAVIOURAL', 'tele-nutrition counseling'), (164, 182, 'CONDITION', 'spinal cord injury'), (184, 187, 'CONDITION', 'SCI'), (340, 346, 'BEHAVIOURAL', 'YouAte'), (383, 397, 'BEHAVIOURAL', 'dietary advice'), (509, 526, 'BEHAVIOURAL', 'weight management'), (636, 658, 'BEHAVIOURAL', 'tele-nutrition program')]"
"['Effectiveness', 'of', 'Dry', 'Needling', 'and', 'Intramuscular', 'Electrostimulation', 'in', 'the', 'Treatment', 'of', 'Myofascial', 'Trigger', 'Points', 'in', 'Patients', 'With', 'Neck', 'Pain', '|', 'Hypothesis', 'The', 'application', 'of', 'intramuscular', 'electrostimulation', 'will', 'be', 'more', 'effectiveness', 'than', 'the', 'dry', 'needling', 'in', 'myofascial', 'trigger', 'points', 'treatment', '.', '\n\n', 'Objetives', ':', '\n\n', 'To', 'determine', 'the', 'effectiveness', 'of', 'intramuscular', 'electrostimulation', 'in', 'the', 'treatment', 'of', 'trigger', 'points', 'of', 'the', 'levator', 'scapula', 'muscle', 'for', 'the', 'improvement', 'of', 'pain', 'in', 'mechanical', 'cervicalgia', '.', '\n\n', 'Participants', ':', 'Subjects', 'with', 'diagnosed', 'of', 'myofascial', 'pain', 'syndrome', 'in', 'cervical', 'region', 'and', 'active', 'trigger', 'points', 'in', 'levator', 'scapulae', 'muscle', ',', 'randomly', 'assigned', 'to', 'experimental', 'or', 'control', 'group', '.', '\n\n', 'Intervention', ':', 'Control', 'group', ':', 'one', 'session', 'of', 'dry', 'needling', 'in', 'active', 'trigger', 'points', ';', 'experimental', 'group', ':', 'one', 'session', 'of', 'intramuscular', 'stimulation', 'in', 'active', 'trigger', 'points', '.', '\n\n', 'Main', 'Outcomes', 'Measures', ':', 'Pain', ',', 'pressure', 'pain', 'threshold', '(', 'PPT', ')', ',', 'active', 'cervical', 'range', 'of', 'motion', 'and', 'strength', 'muscle', '.', 'The', 'measures', 'will', 'be', 'taken', 'before', ',', 'after', 'and', 'one', 'week', 'after', 'the', 'interventions', '.']","['O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03025230,NCT03025230,"Effectiveness of Dry Needling and Intramuscular Electrostimulation in the Treatment of Myofascial Trigger Points in Patients With Neck Pain | Hypothesis The application of intramuscular electrostimulation will be more effectiveness than the dry needling in myofascial trigger points treatment.

Objetives:

To determine the effectiveness of intramuscular electrostimulation in the treatment of trigger points of the levator scapula muscle for the improvement of pain in mechanical cervicalgia.

Participants: Subjects with diagnosed of myofascial pain syndrome in cervical region and active trigger points in levator scapulae muscle, randomly assigned to experimental or control group.

Intervention: Control group: one session of dry needling in active trigger points; experimental group: one session of intramuscular stimulation in active trigger points.

Main Outcomes Measures: Pain, pressure pain threshold (PPT), active cervical range of motion and strength muscle . The measures will be taken before, after and one week after the interventions.","[(17, 29, 'CONTROL', 'Dry Needling'), (34, 66, 'OTHER', 'Intramuscular Electrostimulation'), (87, 112, 'CONDITION', 'Myofascial Trigger Points'), (130, 139, 'CONDITION', 'Neck Pain'), (172, 204, 'OTHER', 'intramuscular electrostimulation'), (241, 253, 'CONTROL', 'dry needling'), (257, 282, 'CONDITION', 'myofascial trigger points'), (394, 438, 'CONDITION', 'trigger points of the levator scapula muscle'), (462, 466, 'CONDITION', 'pain'), (470, 492, 'CONDITION', 'mechanical cervicalgia'), (536, 560, 'CONDITION', 'myofascial pain syndrome'), (591, 632, 'CONDITION', 'trigger points in levator scapulae muscle'), (731, 743, 'CONTROL', 'dry needling'), (805, 830, 'OTHER', 'intramuscular stimulation')]"
"['The', 'Relationship', 'Between', 'Post', 'Dural', 'Puncture', 'Headache', 'and', 'Joint', 'Laxity', '|', 'Post', '-', 'spinal', 'headache', 'is', 'divided', 'into', '3', 'according', 'to', 'the', 'severity', 'scale', '.', 'It', 'is', 'divided', 'into', '3', 'groups', 'as', 'mild', ',', 'moderate', 'and', 'severe', 'according', 'to', 'the', 'presence', 'of', 'symptoms', 'such', 'as', 'nausea', ',', 'vomiting', ',', 'and', 'dizziness', 'that', 'prevent', 'daily', 'activity', '.', '\n\n', 'It', 'has', 'been', 'reported', 'that', 'CSF', 'leakage', 'may', 'be', 'higher', 'due', 'to', 'the', 'weakness', 'of', 'the', 'regional', 'dural', 'sac', 'in', 'primary', 'connective', 'tissue', 'diseases', 'with', 'joint', 'laxity', 'and', 'isolated', 'joint', 'hypermobility', '.', 'Joint', 'laxity', 'is', 'scored', 'according', 'to', 'the', 'level', 'of', 'motion', 'in', '5', 'different', 'joints', 'and', 'a', 'maximum', 'of', '9', 'points', 'is', 'obtained', '.', '\n\n', 'In', 'this', 'study', ',', 'it', 'was', 'aimed', 'to', 'investigate', 'whether', 'joint', 'laxity', 'contributes', 'to', 'the', 'development', 'of', 'post', '-', 'spinal', 'headache', 'by', 'questioning', 'the', 'correlation', 'between', 'joint', 'laxity', 'examination', 'score', 'and', 'postspinal', 'headache', 'in', 'patients', 'with', 'post', '-', 'spinal', 'headache', '.']","['O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT05212194,NCT05212194,"The Relationship Between Post Dural Puncture Headache and Joint Laxity | Post-spinal headache is divided into 3 according to the severity scale. It is divided into 3 groups as mild, moderate and severe according to the presence of symptoms such as nausea, vomiting, and dizziness that prevent daily activity.

It has been reported that CSF leakage may be higher due to the weakness of the regional dural sac in primary connective tissue diseases with joint laxity and isolated joint hypermobility. Joint laxity is scored according to the level of motion in 5 different joints and a maximum of 9 points is obtained.

In this study, it was aimed to investigate whether joint laxity contributes to the development of post-spinal headache by questioning the correlation between joint laxity examination score and postspinal headache in patients with post-spinal headache.","[(25, 53, 'CONDITION', 'Post Dural Puncture Headache'), (58, 70, 'CONDITION', 'Joint Laxity'), (73, 93, 'CONDITION', 'Post-spinal headache'), (451, 463, 'CONDITION', 'joint laxity'), (477, 496, 'CONDITION', 'joint hypermobility'), (498, 510, 'CONDITION', 'Joint laxity'), (667, 679, 'CONDITION', 'joint laxity'), (714, 734, 'CONDITION', 'post-spinal headache'), (774, 786, 'CONDITION', 'joint laxity'), (809, 828, 'CONDITION', 'postspinal headache'), (846, 866, 'CONDITION', 'post-spinal headache')]"
"['Carotid', 'Occlusion', 'Surgery', 'Study', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'extracranial', '-', 'intracranial', 'bypass', 'surgery', 'when', 'added', 'to', 'best', 'medical', 'therapy', 'can', 'reduce', 'the', 'subsequent', 'risk', 'of', 'ipsilateral', 'stroke', 'in', 'high', '-', 'risk', 'patients', 'with', 'recently', 'symptomatic', 'carotid', 'occlusion', 'and', 'increased', 'cerebral', 'oxygen', 'extraction', 'fraction', 'measured', 'by', 'positron', 'emission', 'tomography', '(', 'PET', ')', '.']","['B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00029146,NCT00029146,Carotid Occlusion Surgery Study | The purpose of this study is to determine if extracranial-intracranial bypass surgery when added to best medical therapy can reduce the subsequent risk of ipsilateral stroke in high-risk patients with recently symptomatic carotid occlusion and increased cerebral oxygen extraction fraction measured by positron emission tomography (PET).,"[(0, 25, 'SURGICAL', 'Carotid Occlusion Surgery'), (79, 119, 'SURGICAL', 'extracranial-intracranial bypass surgery'), (189, 207, 'CONDITION', 'ipsilateral stroke'), (244, 273, 'CONDITION', 'symptomatic carotid occlusion')]"
"['Investigating', 'the', 'Effects', 'of', 'Combining', 'rTMS', 'With', 'Visual', 'Feedback', 'Training', 'to', 'Improve', 'Movements', 'in', 'the', 'Paretic', 'Lower', 'Limb', 'and', 'Gait', 'Performance', '|', 'After', 'stroke', ',', 'patients', 'often', 'experience', 'motor', 'deficits', 'that', 'interrupt', 'normal', 'lower', 'extremity', 'movement', 'and', 'gait', 'function', '.', 'Recent', 'developments', 'in', 'neuroimaging', 'have', 'focus', 'on', 'the', 'reasons', 'why', 'some', 'patients', 'recover', 'well', 'while', 'some', 'do', 'poorly', '.', 'However', ',', 'there', 'is', 'still', 'no', 'consensus', 'on', 'the', 'exact', 'mechanisms', 'involved', 'in', 'regaining', 'the', 'functions', 'after', 'rehabilitation', '.', 'Application', 'of', 'repetitive', 'transcranial', 'magnetic', 'stimulation', '(', 'rTMS', ')', 'to', 'facilitate', 'neural', 'plasticity', 'during', 'stroke', 'treatment', 'has', 'recently', 'gained', 'considerable', 'attention', '.', 'The', 'possible', 'mechanism', 'through', 'which', 'rTMS', 'acts', 'is', 'based', 'on', 'the', 'interhemispheric', 'competition', '(', 'IHC', ')', 'model', ',', 'which', 'explains', 'that', 'patients', 'with', 'stroke', 'experience', 'alterations', 'in', 'cortical', 'excitability', 'and', 'exhibit', 'abnormally', 'high', 'interhemispheric', 'inhibition', 'from', 'the', 'unaffected', 'hemisphere', 'to', 'the', 'affected', 'hemisphere', '.', 'The', 'visual', 'feedback', 'training', 'can', 'improve', 'postural', 'control', 'and', 'enhance', 'motor', 'performance', '.', 'Several', 'rTMS', 'studies', 'have', 'evaluated', 'the', 'lower', 'extremity', 'dysfunction', 'following', 'stroke', ',', 'but', 'few', 'studies', 'have', 'explored', 'the', 'efficacy', 'of', 'applying', 'rTMS', 'on', 'the', 'lower', 'extremities', '.', 'We', 'expect', 'the', 'study', 'can', 'help', 'us', 'to', 'further', 'exploration', 'of', 'the', 'change', 'of', 'clinical', 'function', 'and', 'cortical', 'excitability', 'following', 'rTMS', 'and', 'visual', 'feedback', 'training', 'in', 'subjects', 'with', 'stroke', '.', 'In', 'addition', ',', 'the', 'results', 'of', 'this', 'project', 'will', 'be', 'provided', 'for', 'further', 'rehabilitation', 'programs', 'in', 'people', 'with', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03689491,NCT03689491,"Investigating the Effects of Combining rTMS With Visual Feedback Training to Improve Movements in the Paretic Lower Limb and Gait Performance | After stroke, patients often experience motor deficits that interrupt normal lower extremity movement and gait function. Recent developments in neuroimaging have focus on the reasons why some patients recover well while some do poorly. However, there is still no consensus on the exact mechanisms involved in regaining the functions after rehabilitation. Application of repetitive transcranial magnetic stimulation (rTMS) to facilitate neural plasticity during stroke treatment has recently gained considerable attention. The possible mechanism through which rTMS acts is based on the interhemispheric competition (IHC) model, which explains that patients with stroke experience alterations in cortical excitability and exhibit abnormally high interhemispheric inhibition from the unaffected hemisphere to the affected hemisphere. The visual feedback training can improve postural control and enhance motor performance. Several rTMS studies have evaluated the lower extremity dysfunction following stroke, but few studies have explored the efficacy of applying rTMS on the lower extremities. We expect the study can help us to further exploration of the change of clinical function and cortical excitability following rTMS and visual feedback training in subjects with stroke. In addition, the results of this project will be provided for further rehabilitation programs in people with stroke.","[(39, 43, 'OTHER', 'rTMS'), (49, 73, 'OTHER', 'Visual Feedback Training'), (150, 156, 'CONDITION', 'stroke'), (514, 558, 'OTHER', 'repetitive transcranial magnetic stimulation'), (560, 564, 'OTHER', 'rTMS'), (605, 611, 'CONDITION', 'stroke'), (703, 707, 'OTHER', 'rTMS'), (805, 811, 'CONDITION', 'stroke'), (979, 1003, 'OTHER', 'visual feedback training'), (1072, 1076, 'OTHER', 'rTMS'), (1142, 1148, 'CONDITION', 'stroke'), (1205, 1209, 'OTHER', 'rTMS'), (1362, 1366, 'OTHER', 'rTMS'), (1371, 1395, 'OTHER', 'visual feedback training'), (1413, 1419, 'CONDITION', 'stroke'), (1530, 1536, 'CONDITION', 'stroke')]"
"['A', 'Randomized', 'Controlled', 'Trial', 'of', 'Adjunctive', 'D', '-', 'Cycloserine', 'to', 'Intermittent', 'Theta', '-', 'burst', 'Stimulation', 'Transcranial', 'Magnetic', 'Stimulation', 'in', 'Fibromyalgia', '|', 'Background', '&', 'Rationale', ':', 'Fibromyalgia', 'is', 'characterized', 'by', 'widespread', 'pain', ',', 'fatigue', ',', 'mood', 'and', 'anxiety', 'as', 'well', 'as', 'cognitive', 'complaints', '.', 'For', 'an', 'unacceptable', 'proportion', 'of', 'patients', ',', 'depressive', 'symptoms', 'remain', 'impairing', 'despite', 'multiple', 'treatments', '.', '\n\n', 'For', 'such', 'patients', ',', 'novel', 'treatments', 'include', 'non', '-', 'invasive', 'brain', 'stimulation', '.', 'Transcranial', 'Magnetic', 'Stimulation', '(', 'TMS', ')', 'targeting', 'the', 'dorsolateral', 'prefrontal', 'cortex', '(', 'DLPFC', ')', 'or', 'the', 'primary', 'motor', 'cortex', '(', 'M1', ')', 'is', 'the', 'non', '-', 'invasive', 'neurostimulation', 'method', 'with', 'the', 'largest', 'evidence', 'base', 'in', 'fibromyalgia', '.', 'It', 'involves', 'generating', 'magnetic', 'fields', 'outside', 'of', 'the', 'body', 'to', 'change', 'the', 'firing', 'of', 'neurons', 'in', 'the', 'brain', ',', 'and', 'has', 'a', 'very', 'favorable', 'tolerability', 'profile', '.', 'Recent', 'meta', '-', 'analyses', 'indicate', 'that', 'both', 'the', 'DLPFC', 'and', 'M1', 'targets', 'are', 'associated', 'with', 'improvements', 'in', 'pain', ',', 'mood', 'and', 'anxiety', ',', 'however', 'the', 'benefits', 'are', 'more', 'persistent', 'when', 'the', 'DLPFC', 'is', 'targeted', '(', 'Su', 'et', 'al', ',', '2021', '-', 'J', 'Clin', 'Med', ')', '.', 'The', 'DLPFC', 'is', 'important', 'in', 'fibromyalgia', 'through', 'its', 'implication', 'in', 'several', 'symptoms', 'domains', 'in', 'fibromyalgia', ',', 'as', 'well', 'as', 'pain', 'catastrophization', '.', '\n\n', 'The', 'researchers', 'neurophysiological', 'data', 'and', 'clinical', 'data', 'in', 'depression', 'suggests', 'that', 'the', 'researchers', 'can', 'enhance', 'the', 'effects', 'of', 'TMS', 'by', 'using', 'an', 'adjunctive', 'medication', 'called', 'D', '-', 'Cycloserine', '(', 'DCS', ',', '100', 'mg', ')', 'in', 'conjunction', 'with', 'a', 'protocol', 'called', 'intermittent', 'theta', '-', 'burst', 'stimulation', '(', 'iTBS', ')', '.', 'Specifically', ',', 'this', 'data', 'indicated', 'that', 'several', 'converging', 'features', 'of', 'fibromyalgia', 'improve', 'with', 'augmented', 'iTBS', ',', 'specifically', 'depressive', 'symptoms', ',', 'anxiety', 'symptoms', ',', 'fatigue', ',', 'and', 'cognitive', 'function', '.', 'The', 'researchers', 'therefore', 'hypothesize', 'that', 'the', 'combination', 'of', 'D', '-', 'cycloserine', 'and', 'TMS', 'will', 'lead', 'to', 'greater', 'improvements', 'in', 'fibromyalgia', 'symptoms', 'than', 'TMS', 'alone', '.', '\n\n', 'Although', 'iTBS', 'has', 'not', 'yet', 'been', 'studied', 'in', 'fibromyalgia', ',', 'it', 'has', 'a', 'well', 'characterized', 'neurophysiological', 'effect', 'and', 'been', 'shown', 'to', 'be', 'non', '-', 'inferior', 'to', 'conventional', 'TMS', 'protocols', 'in', 'conditions', 'such', 'as', 'depression', '.', 'More', 'importantly', ',', 'its', 'physiological', 'basis', 'can', 'be', 'manipulated', 'with', 'D', '-', 'Cycloserine', 'whereas', 'this', 'has', 'not', 'been', 'convincingly', 'demonstrated', 'with', 'rTMS', '(', 'see', 'Brown', 'et', 'al', ',', '2019', ',', '2021', 'Brain', 'Stim', ')', '.', '\n\n', 'Research', 'Question', 'and', 'Objectives', ':', 'To', 'conduct', 'a', 'randomized', 'placebo', '-', 'controlled', 'trial', 'of', 'DCS', 'in', 'adjunct', 'with', 'rTMS', 'in', 'Fibromyalgia', '.', 'Participants', 'will', 'be', 'randomized', 'to', 'receive', '100', 'mg', 'of', 'DCS', 'or', 'placebo', 'together', 'with', 'TMS', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O']",NCT05395494,NCT05395494,"A Randomized Controlled Trial of Adjunctive D-Cycloserine to Intermittent Theta-burst Stimulation Transcranial Magnetic Stimulation in Fibromyalgia | Background & Rationale: Fibromyalgia is characterized by widespread pain, fatigue, mood and anxiety as well as cognitive complaints. For an unacceptable proportion of patients, depressive symptoms remain impairing despite multiple treatments.

For such patients, novel treatments include non-invasive brain stimulation. Transcranial Magnetic Stimulation (TMS) targeting the dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex (M1) is the non-invasive neurostimulation method with the largest evidence base in fibromyalgia. It involves generating magnetic fields outside of the body to change the firing of neurons in the brain, and has a very favorable tolerability profile. Recent meta-analyses indicate that both the DLPFC and M1 targets are associated with improvements in pain, mood and anxiety, however the benefits are more persistent when the DLPFC is targeted (Su et al, 2021 - J Clin Med). The DLPFC is important in fibromyalgia through its implication in several symptoms domains in fibromyalgia, as well as pain catastrophization.

The researchers neurophysiological data and clinical data in depression suggests that the researchers can enhance the effects of TMS by using an adjunctive medication called D-Cycloserine (DCS, 100mg) in conjunction with a protocol called intermittent theta-burst stimulation (iTBS). Specifically, this data indicated that several converging features of fibromyalgia improve with augmented iTBS, specifically depressive symptoms, anxiety symptoms, fatigue, and cognitive function. The researchers therefore hypothesize that the combination of D-cycloserine and TMS will lead to greater improvements in fibromyalgia symptoms than TMS alone.

Although iTBS has not yet been studied in fibromyalgia, it has a well characterized neurophysiological effect and been shown to be non-inferior to conventional TMS protocols in conditions such as depression. More importantly, its physiological basis can be manipulated with D-Cycloserine whereas this has not been convincingly demonstrated with rTMS (see Brown et al, 2019, 2021 Brain Stim).

Research Question and Objectives: To conduct a randomized placebo-controlled trial of DCS in adjunct with rTMS in Fibromyalgia. Participants will be randomized to receive 100mg of DCS or placebo together with TMS.","[(44, 57, 'DRUG', 'D-Cycloserine'), (61, 131, 'OTHER', 'Intermittent Theta-burst Stimulation Transcranial Magnetic Stimulation'), (135, 147, 'CONDITION', 'Fibromyalgia'), (174, 186, 'CONDITION', 'Fibromyalgia'), (218, 222, 'CONDITION', 'pain'), (224, 231, 'CONDITION', 'fatigue'), (242, 249, 'CONDITION', 'anxiety'), (327, 337, 'CONDITION', 'depressive'), (438, 468, 'OTHER', 'non-invasive brain stimulation'), (470, 595, 'OTHER', 'Transcranial Magnetic Stimulation (TMS) targeting the dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex (M1)'), (674, 686, 'CONDITION', 'fibromyalgia'), (884, 889, 'OTHER', 'DLPFC'), (894, 896, 'OTHER', 'M1'), (941, 945, 'CONDITION', 'pain'), (956, 963, 'CONDITION', 'anxiety'), (1015, 1020, 'OTHER', 'DLPFC'), (1068, 1073, 'OTHER', 'DLPFC'), (1090, 1102, 'CONDITION', 'fibromyalgia'), (1158, 1170, 'CONDITION', 'fibromyalgia'), (1183, 1205, 'CONDITION', 'pain catastrophization'), (1269, 1279, 'CONDITION', 'depression'), (1337, 1340, 'OTHER', 'TMS'), (1382, 1395, 'DRUG', 'D-Cycloserine'), (1397, 1400, 'DRUG', 'DCS'), (1447, 1483, 'OTHER', 'intermittent theta-burst stimulation'), (1485, 1489, 'OTHER', 'iTBS'), (1562, 1574, 'CONDITION', 'fibromyalgia'), (1598, 1602, 'OTHER', 'iTBS'), (1617, 1627, 'CONDITION', 'depressive'), (1638, 1645, 'CONDITION', 'anxiety'), (1656, 1663, 'CONDITION', 'fatigue'), (1751, 1764, 'DRUG', 'D-cycloserine'), (1769, 1772, 'OTHER', 'TMS'), (1810, 1822, 'CONDITION', 'fibromyalgia'), (1837, 1840, 'OTHER', 'TMS'), (1858, 1862, 'OTHER', 'iTBS'), (1891, 1903, 'CONDITION', 'fibromyalgia'), (2009, 2012, 'OTHER', 'TMS'), (2045, 2055, 'CONDITION', 'depression'), (2123, 2136, 'DRUG', 'D-Cycloserine'), (2194, 2198, 'OTHER', 'rTMS'), (2300, 2307, 'CONTROL', 'placebo'), (2328, 2331, 'DRUG', 'DCS'), (2348, 2352, 'OTHER', 'rTMS'), (2356, 2368, 'CONDITION', 'Fibromyalgia'), (2422, 2425, 'DRUG', 'DCS'), (2429, 2454, 'CONTROL', 'placebo together with TMS')]"
"['The', 'Effect', 'of', 'Intraoperative', 'Variations', 'in', 'Positive', '-', 'End', 'Expiratory', 'Pressure', 'on', 'Subdural', 'Pressure', ',', 'Optic', 'Nerve', 'Sheath', 'Diameter', ',', 'Lung', 'Compliance', 'and', 'Brain', 'Perfusion', 'Pressure', 'in', 'Supratentorial', 'Tumor', 'Surgery', '|', 'We', 'aim', 'to', 'determine', 'the', 'level', 'of', 'intraoperative', 'PEEP', 'that', 'optimizes', 'lung', 'compliance', 'without', 'causing', 'a', 'rise', 'in', 'subdural', 'pressure', 'and', 'if', 'we', 'can', 'utilize', 'optic', 'nerve', 'sheath', 'diameter', 'measurement', 'as', 'an', 'indicator', 'for', 'ICP', 'while', 'optimizing', 'lung', 'compliance', 'during', 'supratentorial', 'tumor', 'surgeries', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04316208,NCT04316208,"The Effect of Intraoperative Variations in Positive-End Expiratory Pressure on Subdural Pressure, Optic Nerve Sheath Diameter, Lung Compliance and Brain Perfusion Pressure in Supratentorial Tumor Surgery | We aim to determine the level of intraoperative PEEP that optimizes lung compliance without causing a rise in subdural pressure and if we can utilize optic nerve sheath diameter measurement as an indicator for ICP while optimizing lung compliance during supratentorial tumor surgeries.","[(14, 75, 'OTHER', 'Intraoperative Variations in Positive-End Expiratory Pressure'), (175, 203, 'CONDITION', 'Supratentorial Tumor Surgery'), (239, 258, 'OTHER', 'intraoperative PEEP'), (460, 490, 'CONDITION', 'supratentorial tumor surgeries')]"
"['Effectiveness', 'of', 'Balance', 'Training', 'With', 'Kinesthetic', 'Ability', 'Trainer', '-', 'KAT2000', 'in', 'Patients', 'With', 'Peripheral', 'Neuropathic', 'Pain', ':', 'a', 'Randomized', 'Controlled', 'Study', '|', 'Objective', ':', 'To', 'determine', 'the', 'effectiveness', 'of', 'balance', 'training', 'with', 'Kinesthetic', 'Ability', 'Trainer', '2000', '(', 'KAT', '2000', ')', 'in', 'patients', 'with', 'peripheral', 'neuropathic', 'pain', 'related', 'balance', 'disorder', '.', '\n\n', 'Methods', ':', 'A', 'total', 'of', '60', 'patients', 'who', 'developed', 'peripheral', 'neuropathic', 'pain', '-', 'related', 'balance', 'impairment', 'in', 'the', 'chronic', 'phase', 'due', 'to', 'lumber', 'disc', 'herniation', ',', 'lumber', 'spondylosis', 'and', 'gonarthrosis', 'were', 'included', 'into', 'this', 'randomized', 'controlled', 'prospective', 'study', 'and', 'randomized', 'into', 'either', 'balance', 'exercises', 'groups', 'or', 'KAT', '2000', 'exercises', 'groups', '.', 'Balance', 'exercises', 'were', 'given', 'all', 'patients', 'in', 'Group', '1', '(', 'n=30', ')', '.', 'In', 'addition', 'to', 'balance', 'exercises', ',', 'KAT', '2000', 'balance', 'exercises', 'were', 'given', 'all', 'patients', 'in', 'group', '2', '(', 'n=30', ')', '.', 'All', 'patients', 'received', '45', '-', 'min', 'individualized', 'training', 'session', 'for', 'three', 'times', 'a', 'week', 'for', '4', 'weeks', '.', 'Patients', 'were', 'evaluated', 'according', 'to', 'pain', ',', 'static', 'and', 'dynamic', 'balance', 'and', 'quality', 'of', 'life', '(', 'QoL', ')', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03359772,NCT03359772,"Effectiveness of Balance Training With Kinesthetic Ability Trainer-KAT2000 in Patients With Peripheral Neuropathic Pain: a Randomized Controlled Study | Objective: To determine the effectiveness of balance training with Kinesthetic Ability Trainer 2000 (KAT 2000) in patients with peripheral neuropathic pain related balance disorder.

Methods: A total of 60 patients who developed peripheral neuropathic pain-related balance impairment in the chronic phase due to lumber disc herniation, lumber spondylosis and gonarthrosis were included into this randomized controlled prospective study and randomized into either balance exercises groups or KAT 2000 exercises groups. Balance exercises were given all patients in Group 1 (n=30). In addition to balance exercises, KAT 2000 balance exercises were given all patients in group 2 (n=30). All patients received 45-min individualized training session for three times a week for 4 weeks. Patients were evaluated according to pain, static and dynamic balance and quality of life (QoL).","[(39, 74, 'PHYSICAL', 'Kinesthetic Ability Trainer-KAT2000'), (92, 119, 'CONDITION', 'Peripheral Neuropathic Pain'), (220, 252, 'PHYSICAL', 'Kinesthetic Ability Trainer 2000'), (254, 262, 'PHYSICAL', 'KAT 2000'), (281, 308, 'CONDITION', 'peripheral neuropathic pain'), (317, 333, 'CONDITION', 'balance disorder'), (382, 409, 'CONDITION', 'peripheral neuropathic pain'), (418, 425, 'CONDITION', 'balance'), (465, 487, 'CONDITION', 'lumber disc herniation'), (489, 507, 'CONDITION', 'lumber spondylosis'), (512, 524, 'CONDITION', 'gonarthrosis'), (616, 633, 'CONTROL', 'balance exercises'), (644, 662, 'PHYSICAL', 'KAT 2000 exercises'), (671, 688, 'CONTROL', 'Balance exercises'), (747, 764, 'CONTROL', 'balance exercises'), (766, 792, 'PHYSICAL', 'KAT 2000 balance exercises')]"
"['The', 'Effect', 'of', 'Whole', 'Body', 'Vibration', 'on', 'Spasticity', 'in', 'Spinal', 'Cord', 'Injury', 'Patients', '|', 'Extended', 'periods', 'of', 'tilt', 'table', 'standing', 'have', 'been', 'observed', 'to', 'improve', 'spasticity', 'in', 'individuals', 'with', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'effect', 'of', 'three', 'sessions', 'of', 'whole', 'body', 'vibration', 'while', 'tilt', 'table', 'standing', 'on', 'spasticity', 'in', 'individuals', 'with', 'a', 'complete', 'or', 'incomplete', 'SCI', 'above', 'the', 'neurological', 'level', 'of', 'T10', '.', 'Participants', 'in', 'this', 'study', 'will', 'undergo', 'whole', 'body', 'vibration', 'while', 'standing', 'on', 'a', 'tilt', 'table', 'for', 'a', 'total', 'of', 'approximately', '14', 'minutes', 'for', 'a', 'total', 'of', '3', 'sessions', 'on', '3', 'separate', 'days', '.', 'Spasticity', 'monitoring', 'will', 'be', 'evaluated', 'prior', 'to', 'and', 'after', 'the', 'intervention', 'with', 'the', 'Modified', 'Penn', 'Spasm', 'Frequency', 'Scale', ',', 'an', 'interview', 'to', 'obtain', 'the', 'individual', ""'s"", 'perception', 'and', 'impression', 'of', 'the', 'effect', 'of', 'whole', 'body', 'vibration', 'on', 'the', 'performance', 'of', 'activities', 'of', 'daily', 'living', ',', 'quality', 'of', 'life', ',', 'pain', 'scale', ',', 'and', 'global', 'impression', 'of', 'change', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02127606,NCT02127606,"The Effect of Whole Body Vibration on Spasticity in Spinal Cord Injury Patients | Extended periods of tilt table standing have been observed to improve spasticity in individuals with spinal cord injury (SCI). The purpose of this study is to determine the effect of three sessions of whole body vibration while tilt table standing on spasticity in individuals with a complete or incomplete SCI above the neurological level of T10. Participants in this study will undergo whole body vibration while standing on a tilt table for a total of approximately 14 minutes for a total of 3 sessions on 3 separate days. Spasticity monitoring will be evaluated prior to and after the intervention with the Modified Penn Spasm Frequency Scale, an interview to obtain the individual's perception and impression of the effect of whole body vibration on the performance of activities of daily living, quality of life, pain scale, and global impression of change.","[(14, 34, 'OTHER', 'Whole Body Vibration'), (38, 48, 'CONDITION', 'Spasticity'), (52, 70, 'CONDITION', 'Spinal Cord Injury'), (183, 201, 'CONDITION', 'spinal cord injury'), (203, 206, 'CONDITION', 'SCI'), (283, 303, 'OTHER', 'whole body vibration'), (333, 343, 'CONDITION', 'spasticity'), (366, 392, 'CONDITION', 'complete or incomplete SCI'), (470, 490, 'OTHER', 'whole body vibration'), (608, 618, 'CONDITION', 'Spasticity'), (813, 833, 'OTHER', 'whole body vibration')]"
"['Molecular', 'Profile', 'of', 'the', 'Evolution', 'of', 'Inclusion', 'Body', 'Myositis', '|', 'This', 'study', 'aims', 'at', 'assessing', 'the', 'gene', 'expression', 'in', 'the', 'muscles', 'of', 'patients', 'suffering', 'from', 'sporadic', 'Inclusion', 'Body', 'Myositis', '(', 'sIBM', ')', 'at', 'various', 'stages', 'of', 'the', 'disease', ',', 'by', 'comparison', 'with', 'muscles', 'of', 'control', 'subject', '.', 'The', 'investigators', 'use', 'the', 'RNA', '-', 'seq', 'technique', 'to', 'analyze', 'the', 'gene', 'expression', 'levels', 'and', 'potential', 'alternate', 'transcripts', ',', 'including', 'long', 'non', '-', 'coding', 'RNAs', '(', 'lncRNAs', ')', ',', 'in', 'muscle', 'tissue', 'samples', '.', 'The', 'gene', 'expression', 'profiles', 'will', 'point', 'to', 'the', 'genes', 'of', 'interest', 'that', 'can', 'then', 'become', 'the', 'object', 'of', 'future', 'studies', ',', 'in', 'which', 'epigenetic', 'changes', 'of', 'these', 'genes', 'will', 'be', 'explored', 'further', '.', 'The', 'value', 'of', 'those', 'possible', 'biomarkers', 'will', 'be', 'assessed', '.', 'The', 'investigators', 'will', 'also', 'evaluate', 'the', 'correlation', 'between', 'the', 'gene', 'expression', 'profile', ',', 'the', 'degree', 'of', 'functional', 'impairment', ',', 'the', 'histological', 'picture', 'and', 'the', 'presence', 'or', 'absence', 'of', 'autoantibodies', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03299335,NCT03299335,"Molecular Profile of the Evolution of Inclusion Body Myositis | This study aims at assessing the gene expression in the muscles of patients suffering from sporadic Inclusion Body Myositis (sIBM) at various stages of the disease, by comparison with muscles of control subject. The investigators use the RNA-seq technique to analyze the gene expression levels and potential alternate transcripts, including long non-coding RNAs (lncRNAs), in muscle tissue samples. The gene expression profiles will point to the genes of interest that can then become the object of future studies, in which epigenetic changes of these genes will be explored further. The value of those possible biomarkers will be assessed. The investigators will also evaluate the correlation between the gene expression profile, the degree of functional impairment, the histological picture and the presence or absence of autoantibodies.","[(38, 61, 'CONDITION', 'Inclusion Body Myositis'), (155, 187, 'CONDITION', 'sporadic Inclusion Body Myositis'), (189, 193, 'CONDITION', 'sIBM')]"
"['Study', 'of', 'Clinical', 'Types', 'and', 'Surgical', 'Out', 'Come', 'of', 'Pediatic', 'Exotropia', '|', 'study', 'aiming', 'to', 'evaluate', 'all', 'children', 'presented', 'to', 'strabismus', 'clinic', 'in', 'ophthalmology', 'department', 'at', 'sohag', 'university', 'hospital', 'with', 'divergent', 'squint', '(', 'exotropia', ')', 'and', 'to', 'record', 'surgical', 'outcome', 'of', 'those', 'who', 'underwent', 'strabismus', 'surgery', 'in', 'our', 'hospital']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'O', 'O', 'O']",NCT05089422,NCT05089422,Study of Clinical Types and Surgical Out Come of Pediatic Exotropia | study aiming to evaluate all children presented to strabismus clinic in ophthalmology department at sohag university hospital with divergent squint (exotropia) and to record surgical outcome of those who underwent strabismus surgery in our hospital,"[(58, 67, 'CONDITION', 'Exotropia'), (201, 217, 'CONDITION', 'divergent squint'), (219, 228, 'CONDITION', 'exotropia'), (284, 302, 'SURGICAL', 'strabismus surgery')]"
"['Can', 'Dance', 'Therapy', 'Improve', 'Motor', 'Learning', 'in', 'Parkinson', ""'s"", 'Disease', '?', '|', 'In', 'order', 'to', 'find', 'the', 'most', 'effective', 'rehabilitative', 'therapies', 'for', 'Parkinsonian', 'patients', ',', 'the', 'present', 'study', 'is', 'aimed', 'to', 'evaluate', 'whether', ',', 'in', 'a', 'multidisciplinary', 'intensive', 'rehabilitation', 'treatment', ',', 'the', 'dance', 'therapy', ',', 'applied', 'to', 'the', 'motor', 'learning', ',', 'promote', 'additional', 'benefits', '.']","['O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03549793,NCT03549793,"Can Dance Therapy Improve Motor Learning in Parkinson's Disease? | In order to find the most effective rehabilitative therapies for Parkinsonian patients, the present study is aimed to evaluate whether, in a multidisciplinary intensive rehabilitation treatment, the dance therapy, applied to the motor learning, promote additional benefits.","[(4, 17, 'PHYSICAL', 'Dance Therapy'), (44, 63, 'CONDITION', ""Parkinson's Disease""), (132, 144, 'CONDITION', 'Parkinsonian'), (266, 279, 'PHYSICAL', 'dance therapy')]"
"['Follow', '-', 'up', 'of', 'Patients', ""'"", 'Physical', 'Activity', 'in', 'Post', '-', 'hospitalization', 'by', 'Implementation', 'of', 'Systems', 'of', 'Active', 'Monitoring', '.', '|', 'Physical', 'exercise', 'has', 'been', 'identified', 'as', 'a', 'major', 'item', 'of', 'many', 'affecting', 'many', 'chronic', 'diseases', 'and', 'stroke', 'rehabilitation', '.', 'It', 'contributes', 'to', 'an', 'improvement', 'in', 'the', 'quality', 'of', 'life', 'and', 'to', 'a', 'decrease', 'in', 'the', 'current', 'treatment', 'side', '-', 'effects', 'and', 'mortality', '.', 'Stroke', 'in', 'association', 'with', 'an', 'inactive', 'lifestyle', 'lead', 'to', 'a', 'decrease', 'in', 'physical', 'capability', 'and', 'causes', 'problems', 'in', 'daily', 'activities', '.', 'The', 'physical', 'capacity', 'and', 'the', 'tolerance', 'for', 'exercise', 'fall', 'simultaneously', 'leading', 'to', 'vicious', 'circle', 'of', 'less', 'and', 'less', 'mobility', '.', 'Therefore', ',', 'physical', 'activity', 'for', 'the', 'health', 'is', 'a', 'valid', 'and', 'relevant', 'way', 'to', 'improve', 'the', 'quality', 'of', 'life', 'and', 'to', 'recover', 'functional', 'capacity', '.', 'The', 'aim', 'of', 'the', 'study', 'is', 'the', 'assessment', 'of', 'the', 'effects', 'of', 'a', 'incentive', 'program', 'for', 'physical', 'activity', 'on', 'people', 'following', '/', 'with', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT01822938,NCT01822938,"Follow-up of Patients' Physical Activity in Post-hospitalization by Implementation of Systems of Active Monitoring. | Physical exercise has been identified as a major item of many affecting many chronic diseases and stroke rehabilitation. It contributes to an improvement in the quality of life and to a decrease in the current treatment side-effects and mortality. Stroke in association with an inactive lifestyle lead to a decrease in physical capability and causes problems in daily activities. The physical capacity and the tolerance for exercise fall simultaneously leading to vicious circle of less and less mobility. Therefore, physical activity for the health is a valid and relevant way to improve the quality of life and to recover functional capacity. The aim of the study is the assessment of the effects of a incentive program for physical activity on people following/with stroke.","[(86, 114, 'OTHER', 'Systems of Active Monitoring'), (216, 222, 'CONDITION', 'stroke'), (366, 372, 'CONDITION', 'Stroke'), (822, 861, 'OTHER', 'incentive program for physical activity'), (887, 893, 'CONDITION', 'stroke')]"
"['Effects', 'of', 'Neurodevelopment', 'Therapy', 'on', 'Gross', 'Motor', 'Function', 'and', 'Postural', 'Control', 'in', 'Children', 'With', 'Spastic', 'Cerebral', 'Palsy', ':', 'A', 'Randomized', 'Controlled', 'Trial', '|', 'This', 'study', 'was', 'conducted', 'to', 'find', 'out', 'the', 'Effects', 'of', 'Neurodevelopment', 'therapy', '(', 'a', 'rehabilitative', 'program', 'designed', 'by', 'Bobath', ')', 'on', 'Gross', 'Motor', 'Function', 'and', 'Postural', 'Control', 'in', 'Children', 'with', 'Spastic', 'Cerebral', 'Palsy', '.', 'To', 'investigate', 'either', 'there', 'was', 'a', 'significant', 'difference', 'between', 'the', 'effects', 'of', 'neurodevelopment', 'therapy', 'and', 'routine', 'physical', 'therapy', 'on', 'gross', 'motor', 'function', 'and', 'postural', 'control', 'in', 'children', 'with', 'Spastic', 'Cerebral', 'Palsy', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT05231538,NCT05231538,Effects of Neurodevelopment Therapy on Gross Motor Function and Postural Control in Children With Spastic Cerebral Palsy: A Randomized Controlled Trial | This study was conducted to find out the Effects of Neurodevelopment therapy (a rehabilitative program designed by Bobath) on Gross Motor Function and Postural Control in Children with Spastic Cerebral Palsy. To investigate either there was a significant difference between the effects of neurodevelopment therapy and routine physical therapy on gross motor function and postural control in children with Spastic Cerebral Palsy.,"[(11, 35, 'OTHER', 'Neurodevelopment Therapy'), (98, 120, 'CONDITION', 'Spastic Cerebral Palsy'), (206, 230, 'OTHER', 'Neurodevelopment therapy'), (339, 361, 'CONDITION', 'Spastic Cerebral Palsy'), (443, 467, 'OTHER', 'neurodevelopment therapy'), (559, 581, 'CONDITION', 'Spastic Cerebral Palsy')]"
"['Topiramate', '(', 'RWJ-17021', '-', '000', ')', 'Monotherapy', 'Clinical', 'Trial', 'in', 'Patients', 'With', 'Recently', 'Diagnosed', 'Partial', '-', 'Onset', 'Seizures', '|', 'The', 'purposes', 'of', 'this', 'study', 'are', '(', '1', ')', 'to', 'compare', 'the', 'effectiveness', 'of', 'two', 'doses', 'of', 'topiramate', 'and', '(', '2', ')', 'to', 'assess', 'the', 'safety', 'of', 'topiramate', 'alone', 'in', 'the', 'treatment', 'of', 'pediatric', 'and', 'adult', 'patients', 'with', 'recently', 'diagnosed', 'epilepsy', 'characterized', 'by', 'partial', '-', 'onset', 'seizures', '.']","['B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT00230698,NCT00230698,Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Patients With Recently Diagnosed Partial-Onset Seizures | The purposes of this study are (1) to compare the effectiveness of two doses of topiramate and (2) to assess the safety of topiramate alone in the treatment of pediatric and adult patients with recently diagnosed epilepsy characterized by partial-onset seizures.,"[(0, 10, 'DRUG', 'Topiramate'), (12, 25, 'DRUG', 'RWJ-17021-000'), (90, 112, 'CONDITION', 'Partial-Onset Seizures'), (195, 205, 'DRUG', 'topiramate'), (238, 248, 'DRUG', 'topiramate'), (328, 336, 'CONDITION', 'epilepsy'), (354, 376, 'CONDITION', 'partial-onset seizures')]"
"['A', 'Phase', 'II', 'Multicenter', ',', 'Randomized', '-', 'Controlled', 'Study', 'to', 'Evaluate', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Autologous', 'Incubated', 'Macrophages', 'for', 'the', 'Treatment', 'of', 'Patients', 'With', 'Complete', 'Spinal', 'Cord', 'Injuries', '|', 'Autologous', 'Incubated', 'Macrophages', '(', 'ProCord', ')', 'is', 'being', 'developed', 'as', 'a', 'therapy', 'for', 'acute', ',', 'complete', 'spinal', 'cord', 'injury', '(', 'SCI', ')', '.', 'The', 'therapy', 'is', 'intended', 'to', 'reverse', 'the', 'loss', 'of', 'motor', 'and', 'sensory', 'function', '.', '\n\n', 'Following', 'non', '-', 'CNS', 'tissue', 'injury', ',', 'macrophages', 'quickly', 'arrive', 'on', 'the', 'scene', ',', 'where', 'they', 'clean', 'up', 'cell', 'debris', ',', 'secrete', 'different', 'molecules', 'thus', 'promoting', 'a', 'controlled', 'inflammatory', 'reaction', 'that', 'forms', 'the', 'first', 'phase', 'of', 'the', 'wound', 'healing', 'process', '.', 'While', 'this', 'process', 'occurs', 'in', 'most', 'tissues', ',', 'including', 'peripheral', 'nerves', ',', 'it', 'does', 'not', 'occur', 'in', 'the', 'CNS', ',', 'where', 'macrophages', 'and', 'other', 'immune', 'cells', 'are', 'relatively', 'rare', ',', 'and', 'their', 'activities', 'curtailed', 'by', 'a', 'biochemical', 'mechanism', 'known', 'as', '""', 'immune', 'privilege', '.', '""', '\n\n', 'In', 'animal', 'studies', ',', 'it', 'appears', 'that', 'incubated', 'macrophages', 'circumvent', 'the', 'immune', 'privilege', ',', 'thus', 'supporting', 'the', 'regrowth', 'of', 'axons', 'through', 'the', 'injury', 'site', 'and', 'enabling', 'the', 'recovery', 'of', 'neurological', 'function', '.', 'The', 'concept', 'derives', 'from', 'the', 'pioneering', 'research', 'of', 'Prof.', 'Michal', 'Schwartz', 'at', 'the', 'Weizmann', 'Institute', 'of', 'Science', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00073853,NCT00073853,"A Phase II Multicenter, Randomized-Controlled Study to Evaluate the Safety and Efficacy of Autologous Incubated Macrophages for the Treatment of Patients With Complete Spinal Cord Injuries | Autologous Incubated Macrophages (ProCord) is being developed as a therapy for acute, complete spinal cord injury (SCI). The therapy is intended to reverse the loss of motor and sensory function.

Following non-CNS tissue injury, macrophages quickly arrive on the scene, where they clean up cell debris, secrete different molecules thus promoting a controlled inflammatory reaction that forms the first phase of the wound healing process. While this process occurs in most tissues, including peripheral nerves, it does not occur in the CNS, where macrophages and other immune cells are relatively rare, and their activities curtailed by a biochemical mechanism known as ""immune privilege.""

In animal studies, it appears that incubated macrophages circumvent the immune privilege, thus supporting the regrowth of axons through the injury site and enabling the recovery of neurological function. The concept derives from the pioneering research of Prof. Michal Schwartz at the Weizmann Institute of Science.","[(91, 123, 'SURGICAL', 'Autologous Incubated Macrophages'), (159, 188, 'CONDITION', 'Complete Spinal Cord Injuries'), (191, 223, 'SURGICAL', 'Autologous Incubated Macrophages'), (225, 232, 'SURGICAL', 'ProCord'), (270, 304, 'CONDITION', 'acute, complete spinal cord injury'), (306, 309, 'CONDITION', 'SCI')]"
"['Tryptophan', 'Depletion', 'in', 'Parkinson', ""'s"", 'Disease', 'Patients', 'Treated', 'With', 'Deep', 'Brain', 'Stimulation', 'of', 'the', 'Subthalamic', 'Nucleus', ':', 'Effects', 'on', 'Mood', 'and', 'Motor', 'Functions', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'effect', 'of', 'tryptophan', 'depletion', 'on', 'mood', 'and', 'behavior', 'in', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'patients', 'treated', 'with', 'deep', 'brain', 'stimulation', '(', 'DBS', ')', 'of', 'the', 'subthalamic', 'nucleus', '(', 'STN', ')', '.', 'By', 'doing', 'this', ',', 'the', 'investigators', 'hope', 'to', 'be', 'able', 'to', 'identify', 'risk', 'factors', 'for', 'and', 'mechanisms', 'underlying', 'psychiatric', 'side', 'effects', 'of', 'STN', 'DBS', '.', 'The', 'study', 'will', 'be', 'an', 'intervention', 'study', 'with', 'a', 'placebo', 'controlled', ',', 'randomized', 'cross', '-', 'over', 'design', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02632279,NCT02632279,"Tryptophan Depletion in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus: Effects on Mood and Motor Functions | The purpose of this study is to assess the effect of tryptophan depletion on mood and behavior in Parkinson's disease (PD) patients treated with deep brain stimulation (DBS) of the subthalamic nucleus (STN). By doing this, the investigators hope to be able to identify risk factors for and mechanisms underlying psychiatric side effects of STN DBS. The study will be an intervention study with a placebo controlled, randomized cross-over design.","[(0, 20, 'OTHER', 'Tryptophan Depletion'), (24, 43, 'CONDITION', ""Parkinson's Disease""), (66, 88, 'CONDITION', 'Deep Brain Stimulation'), (208, 228, 'OTHER', 'tryptophan depletion'), (253, 272, 'CONDITION', ""Parkinson's disease""), (274, 276, 'CONDITION', 'PD'), (300, 322, 'CONDITION', 'deep brain stimulation'), (324, 327, 'CONDITION', 'DBS'), (499, 502, 'CONDITION', 'DBS'), (551, 558, 'CONTROL', 'placebo')]"
"['Lifestyle', 'Intervention', 'for', 'Early', 'Alzheimer', ""'s"", 'Disease', '|', 'The', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'comprehensive', 'lifestyle', 'changes', 'may', 'slow', ',', 'stop', ',', 'or', 'reverse', 'the', 'progression', 'of', 'early', '-', 'stage', 'Alzheimer', ""'s"", 'disease', '.']","['B-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04606420,NCT04606420,"Lifestyle Intervention for Early Alzheimer's Disease | The objective of this study is to determine if comprehensive lifestyle changes may slow, stop, or reverse the progression of early-stage Alzheimer's disease.","[(0, 22, 'BEHAVIOURAL', 'Lifestyle Intervention'), (27, 52, 'CONDITION', ""Early Alzheimer's Disease""), (116, 133, 'BEHAVIOURAL', 'lifestyle changes'), (180, 211, 'CONDITION', ""early-stage Alzheimer's disease"")]"
"['A', 'Randomized', 'Double', '-', 'Blind', ',', 'Parallel', ',', 'Placebo', '-', 'Controlled', 'Trial', 'to', 'Examine', 'the', 'Efficacy', 'of', 'Oral', 'Donepezil', '(', '5', 'mg', 'QD', 'for', '6', 'Weeks', ')', 'After', 'Single', 'Dose', 'and', 'Steady', 'State', 'Therapy', '(', '2', 'Weeks', 'and', '6', 'Weeks', ')', 'in', 'Subjects', 'With', 'Mild', 'Cognitive', 'Impairment', '|', 'To', 'purpose', 'of', 'this', 'study', 'is', 'to', 'estimate', 'the', 'effect', 'of', 'donepezil', 'on', 'Neuropsychological', 'Testing', '(', 'NPT', ')', 'and', 'brain', 'Proton', 'Magnetic', 'Resonance', 'Spectroscopy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00483028,NCT00483028,"A Randomized Double-Blind, Parallel, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil (5 mg QD for 6 Weeks) After Single Dose and Steady State Therapy (2 Weeks and 6 Weeks) in Subjects With Mild Cognitive Impairment | To purpose of this study is to estimate the effect of donepezil on Neuropsychological Testing (NPT) and brain Proton Magnetic Resonance Spectroscopy.","[(37, 44, 'CONTROL', 'Placebo'), (94, 103, 'DRUG', 'Donepezil'), (208, 233, 'CONDITION', 'Mild Cognitive Impairment'), (290, 299, 'DRUG', 'donepezil')]"
"['Burden', 'of', 'Obstructive', 'Sleep', 'Apnea', 'in', 'Stroke', '(', 'BOSAST', ')', '|', 'There', 'are', 'two', 'purposes', 'of', 'this', 'study', '.', 'The', 'first', 'purpose', 'is', 'to', 'define', 'the', 'frequency', 'of', 'obstructive', 'sleep', 'apnea', 'in', 'stroke', 'survivors', 'as', 'well', 'as', 'its', 'association', 'with', 'fatigue', 'and', 'quality', 'of', 'life', '.', 'The', 'second', 'purpose', 'is', 'to', 'determine', 'if', 'continuous', 'positive', 'airways', 'pressure', '(', 'CPAP', ')', 'treatment', 'can', 'have', 'a', 'beneficial', 'effect', 'on', 'these', 'patients', ""'"", 'fatigue', 'and', 'quality', 'of', 'life', '.']","['O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O']",NCT00952211,NCT00952211,Burden of Obstructive Sleep Apnea in Stroke (BOSAST) | There are two purposes of this study. The first purpose is to define the frequency of obstructive sleep apnea in stroke survivors as well as its association with fatigue and quality of life. The second purpose is to determine if continuous positive airways pressure (CPAP) treatment can have a beneficial effect on these patients' fatigue and quality of life.,"[(10, 33, 'CONDITION', 'Obstructive Sleep Apnea'), (37, 43, 'CONDITION', 'Stroke'), (141, 164, 'CONDITION', 'obstructive sleep apnea'), (168, 174, 'CONDITION', 'stroke'), (217, 224, 'CONDITION', 'fatigue'), (284, 320, 'OTHER', 'continuous positive airways pressure'), (322, 326, 'OTHER', 'CPAP'), (386, 393, 'CONDITION', 'fatigue')]"
"['Cost', 'Effective', 'Strategy', 'to', 'Evaluate', 'Veterans', 'With', 'Sleep', 'Apnea', '|', 'This', 'research', 'study', 'is', 'comparing', 'home', 'and', 'in', '-', 'laboratory', 'testing', 'of', 'veterans', 'with', 'suspected', 'obstructive', 'sleep', 'apnea', ',', 'a', 'common', 'breathing', 'disorder', 'during', 'sleep', '.', 'It', 'is', 'hoped', 'that', 'home', 'testing', 'will', 'be', 'equally', 'effective', 'in', 'improving', 'quality', 'of', 'life', 'but', 'have', 'lower', 'cost', 'than', 'in', '-', 'lab', 'testing', '.', 'These', 'findings', 'will', 'allow', 'veterans', 'to', 'have', 'greater', 'access', 'to', 'diagnosis', 'and', 'treatment', 'of', 'their', 'sleep', 'apnea', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00880165,NCT00880165,"Cost Effective Strategy to Evaluate Veterans With Sleep Apnea | This research study is comparing home and in-laboratory testing of veterans with suspected obstructive sleep apnea, a common breathing disorder during sleep. It is hoped that home testing will be equally effective in improving quality of life but have lower cost than in-lab testing. These findings will allow veterans to have greater access to diagnosis and treatment of their sleep apnea.","[(50, 61, 'CONDITION', 'Sleep Apnea'), (97, 127, 'OTHER', 'home and in-laboratory testing'), (155, 178, 'CONDITION', 'obstructive sleep apnea'), (239, 251, 'OTHER', 'home testing'), (332, 346, 'OTHER', 'in-lab testing'), (442, 453, 'CONDITION', 'sleep apnea')]"
"['The', 'Debated', 'Role', 'of', 'Sleep', 'Studies', 'in', 'Patients', 'Under', 'Established', 'Home', 'Mechanical', 'Ventilation', '|', 'Patients', 'suffering', 'chronic', 'hypercapnic', 'respiratory', 'insufficiency', '(', 'e.g.', 'in', 'chronic', 'obstructive', 'pulmonary', 'disease', ',', 'obesity', 'hypoventilation', 'syndrome', ')', 'benefit', 'from', 'home', 'mechanical', 'ventilation', '.', 'These', 'patients', 'are', 'complex', ';', 'and', 'the', 'ventilator´s', 'parameters', 'should', 'be', 'set', '-', 'up', 'according', 'to', 'the', 'underlying', 'disease', 'and', 'particular', 'patient', ""'s"", 'characteristics', '.', 'The', 'non', '-', 'invasive', 'ventilation', 'therapy', 'is', 'mostly', 'titrated', 'while', 'the', 'patient', 'is', 'awake', ',', 'hence', 'Problems', ',', 'such', 'as', 'Patient', '-', 'Ventilator', 'asynchrony', ',', 'arising', 'while', 'sleeping', 'on', 'the', 'ventilator', 'therapy', 'would', 'remain', 'undetected', '.', '\n\n', 'Sleep', 'studies', ',', 'such', 'as', 'polysomnography', 'or', 'polygraphy', 'and', 'transcutaneous', 'carbon', 'dioxide', 'monitoring', 'could', 'be', 'valuable', 'tools', 'to', 'fine', '-', 'tune', 'the', 'ventilator', ""'s"", 'settings', '.', 'This', 'could', 'foster', 'the', 'ventilator´s', 'effectivity', 'and', 'patient', 'satisfaction', ',', 'thus', 'therapy', ""'s"", 'adherence', '.', 'Nevertheless', 'the', 'sleep', 'studies', 'are', 'expensive', ',', 'time', '-', 'consuming', 'and', 'not', 'widely', 'available', '.', '\n\n', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'learn', 'the', 'findings', 'of', 'sleep', 'studies', 'when', 'they', 'are', 'performed', 'on', 'stable', 'patients', 'on', 'home', 'mechanical', 'ventilation', 'as', 'part', 'of', 'their', 'routine', 'check', '-', 'ups', '.', 'In', 'this', 'context', ',', 'it', 'will', 'be', 'assessed', 'whether', 'the', 'sleep', 'studies', ""'"", 'findings', 'lead', 'to', 'a', 'change', '(', 'adjustment', ')', 'of', 'the', 'ventilator´s', 'therapy', '.', 'Moreover', ',', 'this', 'study', 'aims', 'to', 'investigate', 'whether', 'the', 'absence', 'of', 'sleep', 'studies', 'would', 'result', 'in', 'missing', 'important', 'events', 'that', 'require', 'an', 'adjustment', 'of', 'therapy', '.', 'The', 'results', 'of', 'this', 'study', 'could', 'provide', 'information', 'that', 'lead', 'to', 'a', 'more', 'standardized', 'protocol', 'of', 'follow', '-', 'up', 'checks', 'of', 'patients', 'on', 'home', 'mechanical', 'ventilation', 'in', 'a', 'cost', '-', 'effective', 'manner', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03506906,NCT03506906,"The Debated Role of Sleep Studies in Patients Under Established Home Mechanical Ventilation | Patients suffering chronic hypercapnic respiratory insufficiency (e.g. in chronic obstructive pulmonary disease, obesity hypoventilation syndrome) benefit from home mechanical ventilation. These patients are complex; and the ventilator´s parameters should be set-up according to the underlying disease and particular patient's characteristics. The non-invasive ventilation therapy is mostly titrated while the patient is awake, hence Problems, such as Patient-Ventilator asynchrony, arising while sleeping on the ventilator therapy would remain undetected.

Sleep studies, such as polysomnography or polygraphy and transcutaneous carbon dioxide monitoring could be valuable tools to fine-tune the ventilator's settings. This could foster the ventilator´s effectivity and patient satisfaction, thus therapy's adherence. Nevertheless the sleep studies are expensive, time-consuming and not widely available.

The aim of this study is to learn the findings of sleep studies when they are performed on stable patients on home mechanical ventilation as part of their routine check-ups. In this context, it will be assessed whether the sleep studies' findings lead to a change (adjustment) of the ventilator´s therapy. Moreover, this study aims to investigate whether the absence of sleep studies would result in missing important events that require an adjustment of therapy. The results of this study could provide information that lead to a more standardized protocol of follow-up checks of patients on home mechanical ventilation in a cost-effective manner.","[(64, 91, 'OTHER', 'Home Mechanical Ventilation'), (113, 158, 'CONDITION', 'chronic hypercapnic respiratory insufficiency'), (168, 205, 'CONDITION', 'chronic obstructive pulmonary disease'), (207, 239, 'CONDITION', 'obesity hypoventilation syndrome'), (254, 281, 'OTHER', 'home mechanical ventilation'), (442, 474, 'OTHER', 'non-invasive ventilation therapy'), (607, 625, 'OTHER', 'ventilator therapy'), (1111, 1138, 'OTHER', 'home mechanical ventilation'), (1285, 1305, 'OTHER', 'ventilator´s therapy'), (1599, 1621, 'OTHER', 'mechanical ventilation')]"
"['A', 'Comparison', 'of', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Topiramate', 'Versus', 'Placebo', 'for', 'the', 'Prophylaxis', 'of', 'Chronic', 'Migraine', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'assess', 'the', 'safety', 'and', 'effectiveness', 'of', 'topiramate', 'as', 'compared', 'to', 'placebo', 'for', 'the', 'prevention', 'of', 'headaches', 'in', 'patients', 'with', 'chronic', 'migraine', '.', 'Topiramate', 'has', 'been', 'approved', 'to', 'prevent', 'migraine', 'headaches', 'as', 'well', 'as', 'in', 'the', 'treatment', 'of', 'epilepsy', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00210912,NCT00210912,A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Chronic Migraine | The purpose of this study is to assess the safety and effectiveness of topiramate as compared to placebo for the prevention of headaches in patients with chronic migraine. Topiramate has been approved to prevent migraine headaches as well as in the treatment of epilepsy.,"[(43, 53, 'DRUG', 'Topiramate'), (61, 68, 'CONTROL', 'Placebo'), (92, 108, 'CONDITION', 'Chronic Migraine'), (182, 192, 'DRUG', 'topiramate'), (208, 215, 'CONTROL', 'placebo'), (238, 247, 'CONDITION', 'headaches'), (265, 281, 'CONDITION', 'chronic migraine'), (283, 293, 'DRUG', 'Topiramate'), (323, 341, 'CONDITION', 'migraine headaches')]"
"['Evaluation', 'of', 'the', 'Influence', 'of', 'Deep', 'Brain', 'Stimulation', 'on', 'the', 'Spinal', 'Deformities', 'Associated', 'With', 'Parkinson', ""'s"", 'Disease', '|', 'The', 'intention', 'of', 'the', 'study', 'is', 'to', 'investigate', 'whether', 'Deep', 'Brain', 'Stimulation', '(', 'DBS', ')', 'will', 'improve', 'postural', 'deformities', 'of', 'patients', 'with', 'Parkinson', ""'s"", 'disease', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04524377,NCT04524377,Evaluation of the Influence of Deep Brain Stimulation on the Spinal Deformities Associated With Parkinson's Disease | The intention of the study is to investigate whether Deep Brain Stimulation (DBS) will improve postural deformities of patients with Parkinson's disease.,"[(31, 53, 'OTHER', 'Deep Brain Stimulation'), (61, 79, 'CONDITION', 'Spinal Deformities'), (96, 115, 'CONDITION', ""Parkinson's Disease""), (171, 193, 'OTHER', 'Deep Brain Stimulation'), (195, 198, 'OTHER', 'DBS'), (213, 233, 'CONDITION', 'postural deformities'), (251, 270, 'CONDITION', ""Parkinson's disease"")]"
"['Physiological', 'Study', 'of', 'the', 'Critical', 'Closing', 'Airway', 'Pressure', 'in', 'a', 'Population', 'of', 'Didgeridoo', 'Players', '|', 'Obstructive', 'sleep', 'apnea', 'is', 'characterised', 'by', 'an', 'abnormal', 'upper', 'airway', 'collapsibility', '.', 'Upper', 'airway', 'collapsibility', 'can', 'be', 'evaluated', 'through', 'critical', 'closure', 'airway', 'pressure', '(', 'Pcrit', ')', '.', 'Didgeridoo', 'is', 'a', 'traditional', 'australian', 'musical', 'instrument', 'involving', 'circular', 'respiration', ',', 'a', 'breathing', 'technique', 'involving', 'mouth', 'muscles', '.', 'We', 'hypothesize', 'that', 'didgeridoo', 'players', 'have', 'a', 'lower', 'risk', 'of', 'airway', 'collapsibility', 'due', 'to', 'circular', 'breathing', 'technique']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O']",NCT05606653,NCT05606653,"Physiological Study of the Critical Closing Airway Pressure in a Population of Didgeridoo Players | Obstructive sleep apnea is characterised by an abnormal upper airway collapsibility. Upper airway collapsibility can be evaluated through critical closure airway pressure (Pcrit). Didgeridoo is a traditional australian musical instrument involving circular respiration, a breathing technique involving mouth muscles. We hypothesize that didgeridoo players have a lower risk of airway collapsibility due to circular breathing technique","[(79, 89, 'OTHER', 'Didgeridoo'), (100, 123, 'CONDITION', 'Obstructive sleep apnea'), (162, 183, 'CONDITION', 'airway collapsibility'), (280, 290, 'OTHER', 'Didgeridoo'), (437, 447, 'OTHER', 'didgeridoo'), (477, 498, 'CONDITION', 'airway collapsibility')]"
"['A', 'Placebo', 'Controlled', 'Double', 'Blind', 'Randomised', 'Controlled', 'Proof', 'of', 'Concept', 'Study', 'of', 'Zolpidem', 'for', 'the', 'Treatment', 'of', 'Motor', 'and', 'Cognitive', 'Deficits', 'in', 'Late', '-', 'stage', 'Parkinson', ""'s"", '|', 'This', 'study', 'will', 'evaluate', 'the', 'motor', 'and', 'cognitive', 'benefits', 'of', 'low', '-', 'dose', 'zolpidem', 'in', 'Parkinson', ""'s"", '.']","['O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O']",NCT03621046,NCT03621046,A Placebo Controlled Double Blind Randomised Controlled Proof of Concept Study of Zolpidem for the Treatment of Motor and Cognitive Deficits in Late-stage Parkinson's | This study will evaluate the motor and cognitive benefits of low-dose zolpidem in Parkinson's.,"[(2, 9, 'CONTROL', 'Placebo'), (82, 90, 'DRUG', 'Zolpidem'), (112, 140, 'CONDITION', 'Motor and Cognitive Deficits'), (144, 164, 'CONDITION', 'Late-stage Parkinson'), (239, 247, 'DRUG', 'zolpidem'), (251, 262, 'CONDITION', ""Parkinson's"")]"
"['The', 'Feasibility', 'and', 'Efficacy', 'of', 'Baduanjin', 'Exercise', 'on', 'Cognition', 'and', 'Physical', 'Fitness', 'Among', 'Patients', 'With', 'Schizophrenia', ':', 'Randomized', 'Controlled', 'Trial', '|', 'As', 'an', 'ancient', ',', 'popular', 'Chinese', 'exercise', ',', 'Baduanjin', 'is', 'characterized', 'by', 'symmetrical', 'posture', ',', 'deep', 'breathing', 'and', 'meditation', 'and', 'easy', 'to', 'learn', '.', 'Previous', 'studies', 'showed', 'immediate', 'effect', 'of', 'Baduanjin', 'on', 'cognition', 'in', 'patients', 'with', 'schizophrenia', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'the', 'immediate', 'effect', 'and', 'chronic', 'effect', 'of', 'Baduanjin', 'exercise', 'on', 'physical', 'fitness', ',', 'cognition', 'and', 'daily', 'functions', 'in', 'middle', '-', 'aged', 'and', 'older', 'adults', 'with', 'schizophrenia', '.']","['O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04430309,NCT04430309,"The Feasibility and Efficacy of Baduanjin Exercise on Cognition and Physical Fitness Among Patients With Schizophrenia:Randomized Controlled Trial | As an ancient, popular Chinese exercise, Baduanjin is characterized by symmetrical posture, deep breathing and meditation and easy to learn. Previous studies showed immediate effect of Baduanjin on cognition in patients with schizophrenia.The purpose of this study is to investigate the immediate effect and chronic effect of Baduanjin exercise on physical fitness, cognition and daily functions in middle-aged and older adults with schizophrenia.","[(32, 41, 'PHYSICAL', 'Baduanjin'), (105, 118, 'CONDITION', 'Schizophrenia'), (190, 199, 'PHYSICAL', 'Baduanjin'), (334, 343, 'PHYSICAL', 'Baduanjin'), (374, 387, 'CONDITION', 'schizophrenia'), (475, 484, 'PHYSICAL', 'Baduanjin'), (582, 595, 'CONDITION', 'schizophrenia')]"
"['Evaluating', 'the', 'Efficacy', 'of', 'PKU', 'Synergy', 'in', 'Patients', 'Expressing', 'Phenylketonuria', 'or', 'Hyperphenylalaninemia', '|', 'This', 'study', 'centres', 'around', 'a', 'new', 'one', '-', 'a', '-', 'day', 'phenylalanine', '-', 'free', 'protein', 'substitute', 'for', 'phenylketonuria', 'patients', '.', 'Fifty', 'eligible', 'adults', '(', '≥', '16', 'years', ')', 'with', 'proven', 'phenylketonuria', 'or', 'hyperphenylalaninemia', 'will', 'be', 'recruited', 'and', 'randomly', 'allocated', 'to', 'one', 'of', 'two', 'intervention', 'arms', '(', 'n', '=', '25', 'per', 'arm', ')', '.', 'Following', 'a', '3', '-', 'day', 'baseline', 'period', ',', 'and', 'in', 'addition', 'to', 'routine', 'nutritional', 'management', ',', 'patients', 'will', 'receive', 'either', 'one', 'sachet', 'of', 'the', 'new', 'protein', 'substitute', 'daily', '(', 'intervention', ')', 'or', 'continue', 'their', 'usual', 'dietary', 'and/or', 'protein', 'substitute', 'regimen', '(', 'maximum', 'of', '1', 'protein', 'substitute', 'per', 'day', '(', 'equal', 'to', '20', 'g', 'protein', 'equivalent', ')', 'control', ')', 'for', '28', 'days', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03167697,NCT03167697,"Evaluating the Efficacy of PKU Synergy in Patients Expressing Phenylketonuria or Hyperphenylalaninemia | This study centres around a new one-a-day phenylalanine-free protein substitute for phenylketonuria patients. Fifty eligible adults (≥ 16 years) with proven phenylketonuria or hyperphenylalaninemia will be recruited and randomly allocated to one of two intervention arms (n = 25 per arm). Following a 3-day baseline period, and in addition to routine nutritional management, patients will receive either one sachet of the new protein substitute daily (intervention) or continue their usual dietary and/or protein substitute regimen (maximum of 1 protein substitute per day (equal to 20g protein equivalent) control) for 28 days.","[(27, 38, 'OTHER', 'PKU Synergy'), (62, 77, 'CONDITION', 'Phenylketonuria'), (81, 102, 'CONDITION', 'Hyperphenylalaninemia'), (147, 184, 'OTHER', 'phenylalanine-free protein substitute'), (189, 204, 'CONDITION', 'phenylketonuria'), (262, 277, 'CONDITION', 'phenylketonuria'), (281, 302, 'CONDITION', 'hyperphenylalaninemia'), (448, 478, 'OTHER', 'routine nutritional management'), (531, 549, 'OTHER', 'protein substitute'), (589, 636, 'CONTROL', 'usual dietary and/or protein substitute regimen')]"
"['Phase', 'II', 'Double', '-', 'blind', 'Randomized', 'Placebo', '-', 'controlled', '1', '-', 'way', 'Crossover', 'Trial', 'to', 'Investigate', 'Safety', 'and', 'Efficacy', 'of', 'the', 'Ascorbic', 'Acid', 'and', 'Tocopherol', 'for', 'the', 'Treatment', 'of', 'the', 'Fragile', 'X', 'Syndrome', '|', 'The', 'Fragile', 'X', 'syndrome', '(', 'FXS', ')', 'was', 'first', 'described', 'by', 'Dr.', 'Martin', 'and', 'Dr.', 'Bell', 'in', '1943', ',', 'in', 'families', 'with', 'several', 'patients', 'affected', 'by', 'sex', '-', 'linked', 'mental', 'disability', '.', 'This', 'disorder', 'is', 'the', 'most', 'common', 'cause', 'of', 'inherited', 'mental', 'disability', '.', 'The', 'prevalence', 'of', 'the', 'Fragile', 'X', 'syndrome', 'has', 'been', 'established', 'at', '1', 'in', '2,500', 'males', 'and', '1', 'in', '4000', 'females', '.', '\n\n', 'Despite', 'moderate', 'to', 'severe', 'mental', 'retardation', ',', 'fragile', 'X', 'patients', 'exhibit', 'macroorchidism', ',', 'an', 'elongated', 'face', ',', 'long', 'ears', ',', 'connective', 'tissue', 'dysplasia', ',', 'hyperactivity', ',', 'autistic', '-', 'like', 'and', 'stereotypical', 'behaviours', ',', 'speech', 'delay', 'and', 'increased', 'sensory', 'sensitivity', '.', '\n\n', 'Objective', ':', 'To', 'evaluate', 'the', 'effect', 'of', 'the', 'combination', 'of', 'the', 'antioxidant', 'Ascorbic', 'acid', 'and', 'tocopherol', ',', 'as', 'therapy', 'of', 'the', 'Fragile', 'X', 'Syndrome', 'in', 'young', 'males', '.', '\n\n', 'Hypothesis', ':', 'It', 'is', 'proposed', 'that', 'part', 'of', 'the', 'pathophysiology', 'of', 'the', 'central', 'nervous', 'system', 'in', 'the', 'animal', 'model', 'of', 'the', 'fragile', 'X', 'syndrome', 'may', 'be', 'determined', 'by', 'oxidative', 'stress', '.', 'In', 'addition', ',', 'Fragile', 'X', 'patients', 'showed', 'a', 'significantly', 'low', 'level', 'of', 'ascorbic', 'acid', 'in', 'plasma', '.', 'The', 'biochemical', 'characteristics', 'of', 'oxidative', 'stress', 'may', 'be', 'reversed', 'in', 'the', 'FMR1', '-', 'KO', 'mice', ',', 'by', 'a', 'chronic', 'treatment', 'with', 'antioxidant', 'compounds', 'such', 'as', 'tocopherol', 'or', 'melatonin', ',', 'it', 'may', 'also', 'normalize', 'several', 'hallmarks', 'of', 'the', 'Syndrome', 'such', 'as', 'hyperactivity', ',', 'anxiety', 'and', 'cognitive', 'deficits', '.', 'The', 'normalization', 'of', 'the', 'oxidative', 'stress', 'is', 'proposed', 'as', 'a', 'new', 'therapeutic', 'pathway', 'to', 'alleviate', 'conditions', 'caused', 'by', 'an', 'excess', 'of', 'free', 'radicals', 'that', 'are', 'crucial', 'in', 'neurodevelopmental', 'diseases', 'such', 'as', 'autism', ',', 'down', 'syndrome', 'and', 'other', 'diseases', 'of', 'the', 'central', 'nervous', 'system', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01329770,NCT01329770,"Phase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X Syndrome | The Fragile X syndrome (FXS) was first described by Dr. Martin and Dr. Bell in 1943, in families with several patients affected by sex-linked mental disability. This disorder is the most common cause of inherited mental disability. The prevalence of the Fragile X syndrome has been established at 1 in 2,500 males and 1 in 4000 females.

Despite moderate to severe mental retardation, fragile X patients exhibit macroorchidism, an elongated face, long ears, connective tissue dysplasia, hyperactivity, autistic-like and stereotypical behaviours, speech delay and increased sensory sensitivity.

Objective: To evaluate the effect of the combination of the antioxidant Ascorbic acid and tocopherol, as therapy of the Fragile X Syndrome in young males.

Hypothesis: It is proposed that part of the pathophysiology of the central nervous system in the animal model of the fragile X syndrome may be determined by oxidative stress. In addition, Fragile X patients showed a significantly low level of ascorbic acid in plasma. The biochemical characteristics of oxidative stress may be reversed in the FMR1-KO mice, by a chronic treatment with antioxidant compounds such as tocopherol or melatonin, it may also normalize several hallmarks of the Syndrome such as hyperactivity, anxiety and cognitive deficits. The normalization of the oxidative stress is proposed as a new therapeutic pathway to alleviate conditions caused by an excess of free radicals that are crucial in neurodevelopmental diseases such as autism, down syndrome and other diseases of the central nervous system.","[(33, 40, 'CONTROL', 'Placebo'), (116, 129, 'DRUG', 'Ascorbic Acid'), (134, 144, 'DRUG', 'Tocopherol'), (170, 188, 'CONDITION', 'Fragile X Syndrome'), (195, 213, 'CONDITION', 'Fragile X syndrome'), (215, 218, 'CONDITION', 'FXS'), (445, 463, 'CONDITION', 'Fragile X syndrome'), (576, 585, 'CONDITION', 'fragile X'), (846, 857, 'DRUG', 'antioxidant'), (858, 871, 'DRUG', 'Ascorbic acid'), (876, 886, 'DRUG', 'tocopherol'), (906, 924, 'CONDITION', 'Fragile X Syndrome'), (1059, 1068, 'CONDITION', 'fragile X'), (1099, 1115, 'CONDITION', 'oxidative stress'), (1130, 1139, 'CONDITION', 'Fragile X'), (1245, 1261, 'CONDITION', 'oxidative stress'), (1327, 1338, 'DRUG', 'antioxidant'), (1446, 1459, 'CONDITION', 'hyperactivity'), (1461, 1468, 'CONDITION', 'anxiety'), (1473, 1491, 'CONDITION', 'cognitive deficits'), (1518, 1534, 'CONDITION', 'oxidative stress')]"
"['A', 'Multi', '-', 'Center', ',', 'Randomized', ',', 'Double', '-', 'Blind', ',', 'Placebo', '-', 'Controlled', ',', 'Five', '-', 'Arm', 'Parallel', '-', 'Group', 'Trial', 'to', 'Investigate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Four', 'Different', 'Transdermal', 'Doses', 'of', 'Rotigotine', 'in', 'Subjects', 'With', 'Idiopathic', 'Restless', 'Legs', 'Syndrome', '|', 'Subjects', 'who', 'meet', 'the', 'diagnosis', 'of', 'idiopathic', 'restless', 'legs', 'syndrome', '(', 'RLS', ')', 'based', 'on', 'the', '4', 'cardinal', 'clinical', 'features', 'according', 'to', 'the', 'International', 'Restless', 'Legs', 'Syndrome', 'Study', 'Group', '(', 'IRLSSG', ')', 'are', 'allowed', 'to', 'enroll', 'in', 'this', 'trial', '.', '\n\n', 'The', 'primary', 'objective', 'of', 'this', 'trial', 'is', 'to', 'demonstrate', 'that', 'rotigotine', '(', 'SPM', '936', ')', 'is', 'efficacious', 'in', 'subjects', 'with', 'idiopathic', 'restless', 'legs', 'syndrome', '.', 'Additional', 'objectives', 'are', 'to', 'investigate', 'the', 'safety', 'and', 'tolerability', 'of', 'rotigotine', '.', '\n\n', 'Subjects', 'will', 'be', 'randomized', 'to', 'receive', 'either', 'placebo', ',', '1.125', ',', '2.25', ',', '4.5', ',', 'or', '6.75mg', '/', 'day', 'rotigotine', 'in', 'a', '1:1:1:1:1', '(', 'active', ':', 'placebo', ')', 'fashion', '.', 'Approximately', '600', 'subjects', 'will', 'be', 'enrolled', 'in', 'this', 'trial', ',', 'participating', 'at', 'approximately', '60', 'sites', '.', 'The', 'maximum', 'duration', 'of', 'the', 'trial', 'is', 'approximately', '8', 'months', '(', 'consisting', 'of', 'a', '4', '-', 'week', 'Titration', 'Period', ',', 'a', '6', '-', 'month', 'Maintenance', 'Period', ',', 'a', '7', '-', 'day', 'Taper', 'Period', ',', 'and', 'a', '30', '-', 'day', 'Safety', 'Follow', '-', 'Up', 'Period', ')', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00135993,NCT00135993,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome | Subjects who meet the diagnosis of idiopathic restless legs syndrome (RLS) based on the 4 cardinal clinical features according to the International Restless Legs Syndrome Study Group (IRLSSG) are allowed to enroll in this trial.

The primary objective of this trial is to demonstrate that rotigotine (SPM 936) is efficacious in subjects with idiopathic restless legs syndrome. Additional objectives are to investigate the safety and tolerability of rotigotine.

Subjects will be randomized to receive either placebo, 1.125, 2.25, 4.5, or 6.75mg/day rotigotine in a 1:1:1:1:1 (active:placebo) fashion. Approximately 600 subjects will be enrolled in this trial, participating at approximately 60 sites. The maximum duration of the trial is approximately 8 months (consisting of a 4-week Titration Period, a 6-month Maintenance Period, a 7-day Taper Period, and a 30-day Safety Follow-Up Period).","[(42, 49, 'CONTROL', 'Placebo'), (170, 180, 'DRUG', 'Rotigotine'), (198, 231, 'CONDITION', 'Idiopathic Restless Legs Syndrome'), (269, 302, 'CONDITION', 'idiopathic restless legs syndrome'), (304, 307, 'CONDITION', 'RLS'), (523, 533, 'DRUG', 'rotigotine'), (535, 542, 'DRUG', 'SPM 936'), (576, 610, 'CONDITION', 'idiopathic restless legs syndrome.'), (683, 693, 'DRUG', 'rotigotine'), (742, 749, 'CONTROL', 'placebo'), (783, 793, 'DRUG', 'rotigotine')]"
"['Clinical', 'Feasibility', 'of', 'Transcranial', 'Direct', 'Current', 'Stimulation', '[', 'tDCS', ']', 'With', 'Standard', 'Aphasia', 'Therapy', '|', 'Study', 'Design', ':', 'This', 'is', 'a', 'within', '-', 'subjects', 'crossover', 'design', '.', 'Subjects', 'will', 'participate', 'in', 'the', 'procedures', 'twice', ',', 'once', 'under', 'each', 'condition', '(', 'active', 'vs.', 'sham', 'stimulation', ')', '.', 'The', 'order', 'of', 'conditions', 'will', 'be', 'counter', '-', 'balanced', 'across', 'subjects', '.', 'Stimulation', 'will', 'target', 'ventral', 'inferior', 'frontal', 'gyrus', '(', 'IFG', ')', 'and', 'will', 'be', 'paired', 'with', 'standard', 'speech', '-', 'language', 'therapy', '.', 'Outcome', 'measures', 'will', 'be', 'acquired', 'at', 'the', 'beginning', 'and', 'end', 'of', 'a', 'semester', 'of', 'standard', 'speech', '-', 'language', 'therapy', ',', 'and', 'at', 'follow', '-', 'up', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03272906,NCT03272906,"Clinical Feasibility of Transcranial Direct Current Stimulation [tDCS] With Standard Aphasia Therapy | Study Design: This is a within-subjects crossover design. Subjects will participate in the procedures twice, once under each condition (active vs. sham stimulation). The order of conditions will be counter-balanced across subjects. Stimulation will target ventral inferior frontal gyrus (IFG) and will be paired with standard speech-language therapy. Outcome measures will be acquired at the beginning and end of a semester of standard speech-language therapy, and at follow-up.","[(24, 63, 'OTHER', 'Transcranial Direct Current Stimulation'), (65, 69, 'OTHER', 'tDCS'), (85, 92, 'CONDITION', 'Aphasia'), (250, 266, 'CONTROL', 'sham stimulation'), (429, 452, 'OTHER', 'speech-language therapy'), (539, 562, 'OTHER', 'speech-language therapy')]"
"['Assessing', 'the', 'Efficacy', 'of', 'Transcutaneous', 'Auricular', 'Vagus', 'Nerve', 'Stimulation', 'as', 'an', 'Anti', '-', 'inflammatory', 'Treatment', 'Following', 'Spinal', 'Cord', 'Injury', '|', 'The', 'goal', 'of', 'this', 'single', '-', 'blinded', 'randomized', ',', 'controlled', 'trial', 'is', 'to', 'assess', 'the', 'impact', 'of', '1', '-', 'hour', 'of', 'active', 'transcutaneous', 'auricular', 'vagus', 'nerve', 'stimulation', '(', 'taVNS', ')', 'vs', 'sham', 'taVNS', 'on', 'serum', 'biomarkers', 'of', 'the', 'inflammatory', 'reflex', 'and', 'inflammation', 'in', 'individuals', 'with', 'spinal', 'cord', 'injury', '.', '\n\n', 'The', 'main', 'question', 'it', 'aims', 'to', 'answer', 'is', ':', 'whether', 'taVNS', 'is', 'a', 'safe', 'and', 'effective', 'anti', '-', 'inflammatory', 'intervention', 'for', 'individuals', 'with', 'SCI', '.', 'Participants', 'will', 'perform', 'a', 'single', '1', '-', 'hour', 'bout', 'of', 'the', 'respective', 'taVNS', 'treatment', 'with', 'blood', 'draws', 'prior', 'to', 'treatment', ',', 'immediately', 'following', 'treatment', ',', 'and', '24', 'hours', 'following', 'treatment', '.', 'Changes', 'in', 'biomarkers', 'between', 'the', 'active', 'and', 'sham', 'taVNS', 'conditions', 'will', 'be', 'compared', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O']",NCT05730049,NCT05730049,"Assessing the Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation as an Anti-inflammatory Treatment Following Spinal Cord Injury | The goal of this single-blinded randomized, controlled trial is to assess the impact of 1-hour of active transcutaneous auricular vagus nerve stimulation (taVNS) vs sham taVNS on serum biomarkers of the inflammatory reflex and inflammation in individuals with spinal cord injury.

The main question it aims to answer is: whether taVNS is a safe and effective anti-inflammatory intervention for individuals with SCI. Participants will perform a single 1-hour bout of the respective taVNS treatment with blood draws prior to treatment, immediately following treatment, and 24 hours following treatment. Changes in biomarkers between the active and sham taVNS conditions will be compared.","[(26, 74, 'OTHER', 'Transcutaneous Auricular Vagus Nerve Stimulation'), (119, 137, 'CONDITION', 'Spinal Cord Injury'), (238, 293, 'OTHER', 'active transcutaneous auricular vagus nerve stimulation'), (295, 300, 'OTHER', 'taVNS'), (305, 315, 'CONTROL', 'sham taVNS'), (367, 379, 'CONDITION', 'inflammation'), (400, 418, 'CONDITION', 'spinal cord injury'), (469, 474, 'OTHER', 'taVNS'), (551, 554, 'CONDITION', 'SCI'), (621, 626, 'OTHER', 'taVNS'), (786, 796, 'CONTROL', 'sham taVNS')]"
"['The', 'Motor', 'Control', 'Consequences', 'of', 'Excessive', 'Physical', 'Therapist', 'Support', 'in', 'Individuals', 'With', 'Stroke', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'systematically', 'determine', 'the', 'effect', 'of', 'unnecessary', 'physical', 'therapist', 'assistance', 'in', 'individuals', 'after', 'stroke', 'during', 'the', 'practice', 'of', 'an', 'upper', 'limb', 'task', 'on', 'an', 'individual', ""'s"", 'task', 'performance', 'and', 'their', 'underlying', 'motor', 'control', 'patterns', 'when', 'learning', '(', 'or', 're', '-', 'learning', ')', 'motor', 'skills', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04856527,NCT04856527,The Motor Control Consequences of Excessive Physical Therapist Support in Individuals With Stroke | The purpose of this study is to systematically determine the effect of unnecessary physical therapist assistance in individuals after stroke during the practice of an upper limb task on an individual's task performance and their underlying motor control patterns when learning (or re-learning) motor skills.,"[(91, 97, 'CONDITION', 'Stroke'), (234, 240, 'CONDITION', 'stroke')]"
"['Dual', 'Transcranial', 'Direct', 'Current', 'Stimulation', '(', 'dTDCS)-Enhanced', 'Therapy', 'After', 'Hemorrhagic', 'Strokes', 'and', 'VEGF', '|', 'This', 'study', 'will', 'evaluate', 'the', 'feasibility', 'of', 'dual', 'tDCS', 'to', 'improve', 'arm', 'motor', 'function', 'in', 'chronic', 'stroke', 'patients', '.', 'In', 'addition', 'it', 'will', 'collect', 'pilot', 'data', 'on', 'the', 'blood', 'biomarkers', 'associated', 'with', 'treatment', 'effect', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03857243,NCT03857243,Dual Transcranial Direct Current Stimulation (dTDCS)-Enhanced Therapy After Hemorrhagic Strokes and VEGF | This study will evaluate the feasibility of dual tDCS to improve arm motor function in chronic stroke patients. In addition it will collect pilot data on the blood biomarkers associated with treatment effect.,"[(0, 69, 'OTHER', 'Dual Transcranial Direct Current Stimulation (dTDCS)-Enhanced Therapy'), (76, 95, 'CONDITION', 'Hemorrhagic Strokes'), (100, 104, 'DRUG', 'VEGF'), (151, 160, 'OTHER', 'dual tDCS'), (194, 208, 'CONDITION', 'chronic stroke')]"
"['A', 'Randomised', ',', 'Double', '-', 'blind', ',', 'Multiple', 'Dose', '-', 'ascending', ',', 'Placebo', '-', 'controlled', 'Study', 'in', 'Healthy', 'Volunteers', 'and', 'Parkinson', ""'s"", 'Disease', 'Patients', 'to', 'Assess', 'the', 'Safety', ',', 'Tolerability', 'and', 'PK', 'of', 'Daily', 'Oral', 'Administration', 'of', 'Cogane', '™', 'Over', 'One', 'Month', '|', 'Phytopharm', 'plc', 'is', 'developing', 'Cogane', '™', 'which', 'is', 'a', 'new', 'medicine', 'for', 'the', 'treatment', 'of', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', '.', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'find', 'out', 'if', 'Cogane', 'is', 'safe', 'and', 'well', 'tolerated', 'in', 'both', 'healthy', 'volunteers', 'and', 'Parkinson', ""'s"", 'disease', 'patients', 'and', 'to', 'determine', 'if', 'there', 'is', 'a', 'difference', 'in', 'the', 'way', 'that', 'the', 'body', 'deals', 'with', 'Cogane', '(', 'pharmacokinetics', ')', 'between', 'these', 'two', 'groups', '.', '\n\n', 'It', 'is', 'expected', 'that', 'the', 'study', 'will', 'prove', 'that', 'Cogane', '™', 'is', 'safe', 'and', 'well', 'tolerated', 'and', 'will', 'provide', 'us', 'with', 'a', 'pharmacokinetic', 'profile', 'for', 'both', 'subject', 'groups', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00875316,NCT00875316,"A Randomised, Double-blind, Multiple Dose-ascending, Placebo-controlled Study in Healthy Volunteers and Parkinson's Disease Patients to Assess the Safety, Tolerability and PK of Daily Oral Administration of Cogane™ Over One Month | Phytopharm plc is developing Cogane™ which is a new medicine for the treatment of Parkinson's disease (PD). The purpose of the study is to find out if Cogane is safe and well tolerated in both healthy volunteers and Parkinson's disease patients and to determine if there is a difference in the way that the body deals with Cogane (pharmacokinetics) between these two groups.

It is expected that the study will prove that Cogane™ is safe and well tolerated and will provide us with a pharmacokinetic profile for both subject groups.","[(53, 60, 'CONTROL', 'Placebo'), (104, 123, 'CONDITION', ""Parkinson's Disease""), (207, 213, 'DRUG', 'Cogane'), (261, 267, 'DRUG', 'Cogane'), (314, 333, 'CONDITION', ""Parkinson's disease""), (335, 337, 'CONDITION', 'PD'), (383, 389, 'DRUG', 'Cogane'), (448, 467, 'CONDITION', ""Parkinson's disease""), (555, 561, 'DRUG', 'Cogane'), (654, 660, 'DRUG', 'Cogane')]"
"['Cognitive', 'Reserve', 'and', 'Linguistic', 'Resilience', 'in', 'Bilingual', 'Hispanics', 'With', 'Primary', 'Progressive', 'Aphasia', '|', 'Difficulties', 'with', 'speech', 'and', 'language', 'are', 'the', 'first', 'and', 'most', 'notable', 'symptoms', 'of', 'primary', 'progressive', 'aphasia', '(', 'PPA', ')', '.', 'While', 'there', 'is', 'evidence', 'that', 'demonstrates', 'positive', 'effects', 'of', 'speech', '-', 'language', 'treatment', 'for', 'individuals', 'with', 'PPA', 'who', 'only', 'speak', 'one', 'language', '(', 'monolinguals', ')', ',', 'there', 'is', 'a', 'significant', 'need', 'for', 'investigating', 'the', 'effects', 'of', 'treatment', 'that', 'is', 'optimized', 'for', 'bilingual', 'speakers', 'with', 'PPA', '.', 'This', 'stage', '2', 'efficacy', 'clinical', 'trial', 'seeks', 'to', 'establish', 'the', 'effects', 'of', 'culturally', 'and', 'linguistically', 'tailored', 'speech', '-', 'language', 'interventions', 'administered', 'to', 'bilingual', 'individuals', 'with', 'PPA', '.', '\n\n', 'The', 'overall', 'aim', 'of', 'the', 'intervention', 'component', 'of', 'this', 'study', 'is', 'to', 'establish', 'the', 'relationships', 'between', 'the', 'bilingual', 'experience', '(', 'e.g.', ',', 'how', 'often', 'each', 'language', 'is', 'used', ',', 'how', '""', 'strong', '""', 'each', 'language', 'is', ')', 'and', 'treatment', 'response', 'of', 'bilinguals', 'with', 'PPA', '.', 'Specifically', ',', 'the', 'investigators', 'will', 'evaluate', 'the', 'benefits', 'of', 'tailored', 'speech', '-', 'language', 'intervention', 'administered', 'in', 'both', 'languages', 'to', 'bilingual', 'individuals', 'with', 'PPA', '(', '60', 'individuals', 'will', 'be', 'recruited', ')', '.', 'The', 'investigators', 'will', 'conduct', 'an', 'assessment', 'before', 'treatment', ',', 'after', 'treatment', 'and', 'at', 'two', 'follow', '-', 'ups', '(', '6', 'and', '12', '-', 'months', 'post', '-', 'treatment', ')', 'in', 'both', 'languages', '.', 'When', 'possible', ',', 'a', 'structural', 'scan', 'of', 'the', 'brain', '(', 'magnetic', 'resonance', 'image', ')', 'will', 'be', 'collected', 'before', 'treatment', 'in', 'order', 'to', 'identify', 'if', 'brain', 'regions', 'implicated', 'in', 'bilingualism', 'are', 'associated', 'with', 'response', 'to', 'treatment', '.', 'In', 'addition', 'to', 'the', 'intervention', 'described', 'herein', ',', '30', 'bilingual', 'individuals', 'with', 'PPA', 'will', 'be', 'recruited', 'to', 'complete', 'behavioral', 'cognitive', '-', 'linguistic', 'testing', 'and', 'will', 'not', 'receive', 'intervention', '.', 'Results', 'will', 'provide', 'important', 'knowledge', 'about', 'the', 'neural', 'mechanisms', 'of', 'language', 're', '-', 'learning', 'and', 'will', 'address', 'how', 'specific', 'characteristics', 'of', 'bilingualism', 'influence', 'cognitive', 'reserve', 'and', 'linguistic', 'resilience', 'in', 'PPA', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT05741853,NCT05741853,"Cognitive Reserve and Linguistic Resilience in Bilingual Hispanics With Primary Progressive Aphasia | Difficulties with speech and language are the first and most notable symptoms of primary progressive aphasia (PPA). While there is evidence that demonstrates positive effects of speech-language treatment for individuals with PPA who only speak one language (monolinguals), there is a significant need for investigating the effects of treatment that is optimized for bilingual speakers with PPA. This stage 2 efficacy clinical trial seeks to establish the effects of culturally and linguistically tailored speech-language interventions administered to bilingual individuals with PPA.

The overall aim of the intervention component of this study is to establish the relationships between the bilingual experience (e.g., how often each language is used, how ""strong"" each language is) and treatment response of bilinguals with PPA. Specifically, the investigators will evaluate the benefits of tailored speech-language intervention administered in both languages to bilingual individuals with PPA (60 individuals will be recruited). The investigators will conduct an assessment before treatment, after treatment and at two follow-ups (6 and 12-months post-treatment) in both languages. When possible, a structural scan of the brain (magnetic resonance image) will be collected before treatment in order to identify if brain regions implicated in bilingualism are associated with response to treatment. In addition to the intervention described herein, 30 bilingual individuals with PPA will be recruited to complete behavioral cognitive-linguistic testing and will not receive intervention. Results will provide important knowledge about the neural mechanisms of language re-learning and will address how specific characteristics of bilingualism influence cognitive reserve and linguistic resilience in PPA.","[(72, 99, 'CONDITION', 'Primary Progressive Aphasia'), (183, 210, 'CONDITION', 'primary progressive aphasia'), (212, 215, 'CONDITION', 'PPA'), (327, 330, 'CONDITION', 'PPA'), (492, 495, 'CONDITION', 'PPA'), (568, 636, 'OTHER', 'culturally and linguistically tailored speech-language interventions'), (680, 683, 'CONDITION', 'PPA'), (926, 929, 'CONDITION', 'PPA'), (993, 1030, 'OTHER', 'tailored speech-language intervention'), (1092, 1095, 'CONDITION', 'PPA'), (1581, 1584, 'CONDITION', 'PPA'), (1664, 1688, 'CONTROL', 'not receive intervention'), (1902, 1905, 'CONDITION', 'PPA')]"
"['A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Parallel', '-', 'group', 'Multi', '-', 'center', 'Comparative', 'Flexible', '-', 'dose', 'Trial', 'Of', 'Pregabalin', 'Versus', 'Gabapentin', 'As', 'Adjunctive', 'Therapy', 'In', 'Subjects', 'With', 'Partial', 'Seizures', '.', '|', 'To', 'compare', 'the', 'efficacy', 'of', 'pregabalin', 'and', 'gabapentin', ',', 'as', 'adjunctive', 'therapy', 'in', 'subjects', 'with', 'partial', 'seizures', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT00537940,NCT00537940,"A Randomized, Double-blind, Parallel-group Multi-center Comparative Flexible-dose Trial Of Pregabalin Versus Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures. | To compare the efficacy of pregabalin and gabapentin, as adjunctive therapy in subjects with partial seizures.","[(91, 101, 'DRUG', 'Pregabalin'), (109, 119, 'DRUG', 'Gabapentin'), (159, 175, 'CONDITION', 'Partial Seizures'), (206, 216, 'DRUG', 'pregabalin'), (221, 231, 'DRUG', 'gabapentin'), (272, 288, 'CONDITION', 'partial seizures')]"
"['An', 'Internet', 'Intervention', 'for', 'Insomnia', ':', 'Efficacy', 'and', 'Dissemination', '|', 'This', 'study', 'will', 'compare', 'the', 'efficacy', 'of', 'an', 'interactive', 'Internet', 'intervention', 'for', 'adult', 'insomnia', '(', 'Sleep', 'Healthy', 'Using', 'the', 'Internet', ';', 'SHUTi', ')', 'to', 'that', 'of', 'a', 'static', 'educational', 'website', 'to', 'improve', 'sleep', ',', 'mood', 'related', 'symptoms', ',', 'perceived', 'health', 'status', ',', 'and', 'overall', 'quality', 'of', 'life', '.']","['O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01438697,NCT01438697,"An Internet Intervention for Insomnia: Efficacy and Dissemination | This study will compare the efficacy of an interactive Internet intervention for adult insomnia (Sleep Healthy Using the Internet; SHUTi) to that of a static educational website to improve sleep, mood related symptoms, perceived health status, and overall quality of life.","[(3, 24, 'OTHER', 'Internet Intervention'), (29, 37, 'CONDITION', 'Insomnia'), (111, 144, 'OTHER', 'interactive Internet intervention'), (155, 163, 'CONDITION', 'insomnia'), (219, 245, 'CONTROL', 'static educational website')]"
"['Effects', 'of', 'Empagliflozin', 'an', 'SGLT2', '-', 'Inhibitor', 'on', 'Healthy', 'Volunteers', 'With', 'Induced', 'Hypotonic', 'Hyponatremia', '-', 'the', 'DIVE', 'Study', '|', 'Empagliflozin', '(', 'Jardiance', ')', '®', 'is', 'a', 'sodium', 'glucose', 'co', '-', 'transporter', '2', '(', 'SGLT2)-Inhibitor', ',', 'which', 'is', 'a', 'new', 'treatment', 'option', 'developed', 'for', 'patients', 'with', 'diabetes', 'mellitus', 'type', '2', '.', 'The', 'SGLT2', 'is', 'expressed', 'in', 'the', 'proximal', 'tubule', 'and', 'reabsorbs', 'approximately', '90', 'percent', 'of', 'the', 'filtered', 'glucose', '.', 'The', 'inhibition', 'of', 'SGLT2', 'results', 'in', 'renal', 'excretion', 'of', 'glucose', 'with', 'subsequent', 'osmotic', 'diuresis', '.', 'This', 'mechanism', 'could', 'result', 'in', 'a', 'therapeutic', 'effect', 'in', 'patients', 'with', 'hypotonic', 'hyponatremia', 'as', 'in', 'the', 'syndrome', 'of', 'inappropriate', 'antidiuretic', 'hormone', '(', 'ADH', ')', 'secretion', '(', 'SIAD', ')', '.', 'Because', 'patients', 'with', 'SIAD', 'usually', 'have', 'several', 'comorbidities', 'and', 'different', 'medications', ',', 'studies', 'investigating', 'the', 'physiological', 'effects', 'are', 'difficult', 'to', 'interpret', '.', 'Therefore', 'a', 'model', 'to', 'study', 'the', 'possible', 'physiological', 'effect', 'of', 'SGLT2', '-', 'inhibitors', 'in', 'hypotonic', 'hyponatremia', 'as', 'in', 'SIAD', 'is', 'needed', '.', '\n\n', 'The', 'aim', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'whether', 'empagliflozin', '(', 'Jardiance', ')', '®', 'has', 'an', 'effect', 'on', 'serum', 'sodium', 'levels', 'of', 'healthy', 'volunteers', 'with', 'induced', 'hypotonic', 'hyponatremia', '.']","['O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT02729766,NCT02729766,"Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study | Empagliflozin (Jardiance)® is a sodium glucose co-transporter 2 (SGLT2)-Inhibitor, which is a new treatment option developed for patients with diabetes mellitus type 2. The SGLT2 is expressed in the proximal tubule and reabsorbs approximately 90 percent of the filtered glucose. The inhibition of SGLT2 results in renal excretion of glucose with subsequent osmotic diuresis. This mechanism could result in a therapeutic effect in patients with hypotonic hyponatremia as in the syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIAD). Because patients with SIAD usually have several comorbidities and different medications, studies investigating the physiological effects are difficult to interpret. Therefore a model to study the possible physiological effect of SGLT2-inhibitors in hypotonic hyponatremia as in SIAD is needed.

The aim of this study is to evaluate whether empagliflozin (Jardiance)® has an effect on serum sodium levels of healthy volunteers with induced hypotonic hyponatremia.","[(11, 24, 'DRUG', 'Empagliflozin'), (28, 43, 'DRUG', 'SGLT2-Inhibitor'), (79, 101, 'CONDITION', 'Hypotonic Hyponatremia'), (121, 134, 'DRUG', 'Empagliflozin'), (136, 145, 'DRUG', 'Jardiance'), (153, 202, 'DRUG', 'sodium glucose co-transporter 2 (SGLT2)-Inhibitor'), (565, 587, 'CONDITION', 'hypotonic hyponatremia'), (898, 914, 'DRUG', 'SGLT2-inhibitors'), (918, 940, 'CONDITION', 'hypotonic hyponatremia'), (1009, 1022, 'DRUG', 'empagliflozin'), (1024, 1033, 'DRUG', 'Jardiance'), (1108, 1130, 'CONDITION', 'hypotonic hyponatremia')]"
"['Evaluation', 'of', 'a', 'Program', 'to', 'Increase', 'Upper', 'Limb', 'Recovery', 'After', 'Stroke', '|', 'This', 'study', 'will', 'examine', 'the', 'feasibility', 'and', 'effect', 'of', 'a', 'program', 'that', 'combines', 'exercise', 'and', 'feedback', 'from', 'a', 'wearable', 'device', 'on', 'upper', 'limb', 'movement', 'practice', 'and', 'function', 'in', 'individuals', 'with', 'stroke', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT04232163,NCT04232163,Evaluation of a Program to Increase Upper Limb Recovery After Stroke | This study will examine the feasibility and effect of a program that combines exercise and feedback from a wearable device on upper limb movement practice and function in individuals with stroke.,"[(62, 68, 'CONDITION', 'Stroke'), (149, 157, 'PHYSICAL', 'exercise'), (162, 193, 'OTHER', 'feedback from a wearable device'), (259, 265, 'CONDITION', 'stroke')]"
"['Benefice', 'Assessment', 'of', 'Repetitive', 'Transcranial', 'Magnetic', 'Stimulation', 'Used', 'as', 'an', 'Additional', 'Procedure', 'to', 'Rehabilitation', 'Exercises', 'in', 'Patients', 'Suffering', 'From', 'Fibromyalgia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'analgesic', 'effectiveness', 'of', 'Repetitive', 'Transcranial', 'Magnetic', 'Stimulation', '(', 'rTMS', ')', 'used', 'as', 'an', 'additional', 'procedure', 'to', 'rehabilitation', 'exercises', 'in', 'patient', 'suffering', 'from', 'fibromyalgia', '.', '\n\n', 'A', 'double', 'blind', 'clinical', 'trial', 'with', 'two', 'randomized', 'parallel', 'groups', ':', '\n\n', 'Placebo', 'rTMS', 'and', 'rehabilitation', 'exercise', '\n', 'Active', 'rTMS', 'and', 'rehabilitation', 'exercise']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS']",NCT01308801,NCT01308801,"Benefice Assessment of Repetitive Transcranial Magnetic Stimulation Used as an Additional Procedure to Rehabilitation Exercises in Patients Suffering From Fibromyalgia | The purpose of this study is to determine the analgesic effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) used as an additional procedure to rehabilitation exercises in patient suffering from fibromyalgia.

A double blind clinical trial with two randomized parallel groups:

Placebo rTMS and rehabilitation exercise
Active rTMS and rehabilitation exercise","[(23, 67, 'OTHER', 'Repetitive Transcranial Magnetic Stimulation'), (103, 127, 'PHYSICAL', 'Rehabilitation Exercises'), (155, 167, 'CONDITION', 'Fibromyalgia'), (243, 287, 'OTHER', 'Repetitive Transcranial Magnetic Stimulation'), (289, 293, 'OTHER', 'rTMS'), (330, 354, 'PHYSICAL', 'rehabilitation exercises'), (381, 393, 'CONDITION', 'fibromyalgia'), (464, 476, 'CONTROL', 'Placebo rTMS'), (481, 504, 'PHYSICAL', 'rehabilitation exercise'), (505, 516, 'OTHER', 'Active rTMS'), (521, 544, 'PHYSICAL', 'rehabilitation exercise')]"
"['The', 'Effect', 'of', 'Amantadine', 'on', 'Movement', 'Disorder', 'in', 'Ataxia', '-', 'Telangiectasia', '|', 'Ataxia', '-', 'Telangiectasia', 'A', '-', 'T', 'is', 'a', 'neurodegenerative', 'disorder', 'of', 'the', 'cerebellum', ',', 'manifesting', 'with', 'ataxia', ',', 'as', 'well', 'as', 'extrapyramidal', 'features', '.', 'Treatment', 'of', 'A', '-', 'T', 'is', 'discouraging', ',', 'since', 'no', 'treatment', 'seems', 'to', 'change', 'the', 'course', 'of', 'disease', ',', 'but', 'improvement', 'can', 'be', 'achieved', 'by', 'symptomatic', 'treatment', 'of', 'the', 'bothersome', 'movement', 'disorder', '.', 'While', 'various', 'dopaminergic', 'agents', 'are', 'occasionally', 'used', ',', 'reports', 'of', 'benefit', 'are', 'rather', 'sparse', 'and', 'anecdotal', '.', 'Amantadine', ',', 'a', 'well', 'known', 'drug', 'used', 'in', 'influenza', 'as', 'well', 'as', 'movement', 'disorder', 'of', 'Parkinson', ',', 'has', 'been', 'proved', 'to', 'improve', 'various', 'other', 'types', 'of', 'movement', 'disorder', 'as', 'ataxia', ',', 'chorea', ',', 'dystonia', ',', 'akinesia', 'and', 'attention', 'span', '.', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'investigate', 'weather', 'amantadine', 'sulphate', 'improves', 'ataxia', 'and', 'the', 'movement', 'disorder', '(', 'bradykinesia', ',', 'parkinsonism', ',', 'dystonia', ',', 'chorea', ')', ',', 'as', 'well', 'as', 'the', 'general', 'well', 'being', 'in', 'patients', 'with', 'A', '-', 'T.']","['O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND']",NCT00950196,NCT00950196,"The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia | Ataxia-Telangiectasia A-T is a neurodegenerative disorder of the cerebellum, manifesting with ataxia, as well as extrapyramidal features. Treatment of A-T is discouraging, since no treatment seems to change the course of disease, but improvement can be achieved by symptomatic treatment of the bothersome movement disorder . While various dopaminergic agents are occasionally used, reports of benefit are rather sparse and anecdotal. Amantadine, a well known drug used in influenza as well as movement disorder of Parkinson, has been proved to improve various other types of movement disorder as ataxia, chorea, dystonia, akinesia and attention span. The purpose of this study is to investigate weather amantadine sulphate improves ataxia and the movement disorder (bradykinesia, parkinsonism, dystonia, chorea), as well as the general well being in patients with A-T.","[(14, 24, 'DRUG', 'Amantadine'), (28, 45, 'CONDITION', 'Movement Disorder'), (49, 70, 'CONDITION', 'Ataxia-Telangiectasia'), (73, 94, 'CONDITION', 'Ataxia-Telangiectasia'), (95, 98, 'CONDITION', 'A-T'), (167, 173, 'CONDITION', 'ataxia'), (224, 227, 'CONDITION', 'A-T'), (507, 517, 'DRUG', 'Amantadine'), (587, 596, 'CONDITION', 'Parkinson'), (669, 675, 'CONDITION', 'ataxia'), (677, 683, 'CONDITION', 'chorea'), (685, 693, 'CONDITION', 'dystonia'), (695, 703, 'CONDITION', 'akinesia'), (776, 795, 'DRUG', 'amantadine sulphate'), (805, 811, 'CONDITION', 'ataxia'), (820, 837, 'CONDITION', 'movement disorder'), (839, 851, 'CONDITION', 'bradykinesia'), (853, 865, 'CONDITION', 'parkinsonism'), (867, 875, 'CONDITION', 'dystonia'), (877, 883, 'CONDITION', 'chorea'), (937, 941, 'CONDITION', 'A-T.')]"
"['The', 'Effect', 'of', 'Niacin', 'Supplementation', 'on', 'Systemic', 'Nicotinamide', 'Adenine', 'Dinucleotide', '(', 'NAD+', ')', 'Metabolism', ',', 'Physiology', 'and', 'Muscle', 'Performance', 'in', 'Healthy', 'Controls', 'and', 'Mitochondrial', 'Myopathy', 'Patients', '|', 'The', 'most', 'frequent', 'form', 'of', 'adult', '-', 'onset', 'mitochondrial', 'disorders', 'is', 'mitochondrial', 'myopathy', ',', 'often', 'manifesting', 'with', 'progressive', 'external', 'ophthalmoplegia', '(', 'PEO', ')', ',', 'progressive', 'muscle', 'weakness', 'and', 'exercise', 'intolerance', '.', 'Mitochondrial', 'myopathy', 'is', 'often', 'caused', 'by', 'single', 'heteroplasmic', 'mitochondrial', 'DNA', '(', 'mtDNA', ')', 'deletions', 'or', 'multiple', 'mtDNA', 'deletions', ',', 'the', 'former', 'being', 'sporadic', 'and', 'latter', 'caused', 'by', 'mutations', 'in', 'nuclear', '-', 'encoded', 'proteins', 'of', 'mtDNA', 'maintenance', '.', 'Currently', ',', 'no', 'curative', 'treatment', 'exists', 'for', 'this', 'disease', '.', 'The', 'investigators', 'have', 'previously', 'observed', 'that', 'supplementation', 'with', 'an', 'NAD+', 'precursor', 'vitamin', 'B3', ',', 'nicotinamide', 'riboside', ',', 'prevented', 'and', 'delayed', 'disease', 'symptoms', 'by', 'increasing', 'mitochondrial', 'biogenesis', 'in', 'a', 'mouse', 'model', 'for', 'mitochondrial', 'myopathy', '.', 'Vitamin', 'B3', 'exists', 'in', 'several', 'forms', ':', 'nicotinic', 'acid', '(', 'niacin', ')', ',', 'nicotinamide', ',', 'and', 'nicotinamide', 'riboside', ',', 'and', 'it', 'has', 'been', 'demonstrated', 'to', 'give', 'power', 'to', 'diseased', 'mitochondria', 'in', 'animal', 'studies', 'by', 'increasing', 'intracellular', 'levels', 'of', 'NAD+', ',', 'the', 'important', 'cofactor', 'required', 'for', 'the', 'cellular', 'energy', 'metabolism', '.', '\n\n', 'In', 'this', 'study', ',', 'the', 'form', 'of', 'vitamin', 'B3', ',', 'niacin', ',', 'was', 'used', 'to', 'activate', 'dysfunctional', 'mitochondria', 'and', 'to', 'rescue', 'signs', 'of', 'mitochondrial', 'myopathy', '.', 'Of', 'the', 'vitamin', 'B3', 'forms', ',', 'niacin', ',', 'is', 'employed', ',', 'because', 'it', 'has', 'been', 'used', 'in', 'large', 'doses', 'to', 'treat', 'hypercholesterolemia', 'patients', ',', 'and', 'has', 'a', 'proven', 'safety', 'record', 'in', 'humans', '.', 'Phenotypically', 'similar', 'mitochondrial', 'myopathy', 'patients', 'are', 'studied', ',', 'as', 'the', 'investigator', ""'s"", 'previous', 'expertise', 'indicates', 'that', 'similar', 'presenting', 'phenotypes', 'predict', 'uniform', 'physiological', 'and', 'clinical', 'responses', 'to', 'interventions', ',', 'despite', 'varying', 'genetic', 'backgrounds', '.', 'Patients', 'either', 'with', 'sporadic', 'single', 'mtDNA', 'deletions', 'or', 'a', 'mutation', 'in', 'a', 'Twinkle', 'gene', 'causing', 'multiple', 'mtDNA', 'deletions', 'were', 'recruited', '.', 'In', 'addition', ',', 'for', 'every', 'patient', ',', 'two', 'gender-', 'and', 'age', '-', 'matched', 'healthy', 'controls', 'are', 'recruited', '.', 'Clinical', 'examinations', 'and', 'collection', 'of', 'muscle', 'biopsies', 'are', 'performed', 'at', 'the', 'time', 'points', '0', ',', '4', 'and', '10', 'months', '(', 'patients', ')', 'or', 'at', '0', 'and', '4', 'months', '(', 'controls', ')', '.', 'Fasting', 'blood', 'samples', 'are', 'collected', 'every', 'second', 'week', 'until', '4', 'months', 'and', 'thereafter', 'every', 'six', 'weeks', 'until', 'the', 'end', 'of', 'the', 'study', '.', 'The', 'effects', 'of', 'niacin', 'on', 'disease', 'markers', ',', 'muscle', 'mitochondrial', 'biogenesis', ',', 'muscle', 'strength', 'and', 'the', 'metabolism', 'of', 'the', 'whole', 'body', 'are', 'studied', 'in', 'patients', 'and', 'healthy', 'controls', '.', '\n\n', 'The', 'hypothesis', 'is', 'that', 'an', 'NAD+', 'precursor', ',', 'niacin', ',', 'will', 'increase', 'intracellular', 'NAD+', 'levels', ',', 'improve', 'mitochondrial', 'biogenesis', 'and', 'alleviate', 'the', 'symptoms', 'of', 'mitochondrial', 'myopathy', 'in', 'humans', '.']","['O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O']",NCT03973203,NCT03973203,"The Effect of Niacin Supplementation on Systemic Nicotinamide Adenine Dinucleotide (NAD+) Metabolism, Physiology and Muscle Performance in Healthy Controls and Mitochondrial Myopathy Patients | The most frequent form of adult-onset mitochondrial disorders is mitochondrial myopathy, often manifesting with progressive external ophthalmoplegia (PEO), progressive muscle weakness and exercise intolerance. Mitochondrial myopathy is often caused by single heteroplasmic mitochondrial DNA (mtDNA) deletions or multiple mtDNA deletions, the former being sporadic and latter caused by mutations in nuclear-encoded proteins of mtDNA maintenance. Currently, no curative treatment exists for this disease. The investigators have previously observed that supplementation with an NAD+ precursor vitamin B3, nicotinamide riboside, prevented and delayed disease symptoms by increasing mitochondrial biogenesis in a mouse model for mitochondrial myopathy. Vitamin B3 exists in several forms: nicotinic acid (niacin), nicotinamide, and nicotinamide riboside, and it has been demonstrated to give power to diseased mitochondria in animal studies by increasing intracellular levels of NAD+, the important cofactor required for the cellular energy metabolism.

In this study, the form of vitamin B3, niacin, was used to activate dysfunctional mitochondria and to rescue signs of mitochondrial myopathy. Of the vitamin B3 forms, niacin, is employed, because it has been used in large doses to treat hypercholesterolemia patients, and has a proven safety record in humans. Phenotypically similar mitochondrial myopathy patients are studied, as the investigator's previous expertise indicates that similar presenting phenotypes predict uniform physiological and clinical responses to interventions, despite varying genetic backgrounds. Patients either with sporadic single mtDNA deletions or a mutation in a Twinkle gene causing multiple mtDNA deletions were recruited. In addition, for every patient, two gender- and age-matched healthy controls are recruited. Clinical examinations and collection of muscle biopsies are performed at the time points 0, 4 and 10 months (patients) or at 0 and 4 months (controls). Fasting blood samples are collected every second week until 4 months and thereafter every six weeks until the end of the study. The effects of niacin on disease markers, muscle mitochondrial biogenesis, muscle strength and the metabolism of the whole body are studied in patients and healthy controls.

The hypothesis is that an NAD+ precursor, niacin, will increase intracellular NAD+ levels, improve mitochondrial biogenesis and alleviate the symptoms of mitochondrial myopathy in humans.","[(14, 20, 'DRUG', 'Niacin'), (160, 182, 'CONDITION', 'Mitochondrial Myopathy'), (259, 281, 'CONDITION', 'mitochondrial myopathy'), (404, 426, 'CONDITION', 'Mitochondrial myopathy'), (918, 940, 'CONDITION', 'mitochondrial myopathy'), (978, 992, 'DRUG', 'nicotinic acid'), (994, 1000, 'DRUG', 'niacin'), (1282, 1288, 'DRUG', 'niacin'), (1361, 1383, 'CONDITION', 'mitochondrial myopathy'), (1410, 1416, 'DRUG', 'niacin'), (1576, 1598, 'CONDITION', 'mitochondrial myopathy'), (2336, 2342, 'DRUG', 'niacin'), (2538, 2544, 'DRUG', 'niacin'), (2650, 2672, 'CONDITION', 'mitochondrial myopathy')]"
"['The', 'Effects', 'of', 'a', 'Sub', '-', 'maximal', 'Exercise', 'Program', 'on', 'Adolescents', 'Who', 'Sustained', 'a', 'Concussion', '|', 'Patients', 'who', 'sustain', 'a', 'concussion', 'will', 'undergo', 'a', 'sub', '-', 'maximal', 'exercise', 'protocol', 'throughout', 'their', 'recovery', '.', 'Cerebrovascular', 'function', ',', 'heart', 'rate', ',', 'and', 'symptom', 'severity', ',', 'and', 'exercise', 'volume', 'will', 'be', 'monitored', 'throughout', '.']","['O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03170856,NCT03170856,"The Effects of a Sub-maximal Exercise Program on Adolescents Who Sustained a Concussion | Patients who sustain a concussion will undergo a sub-maximal exercise protocol throughout their recovery. Cerebrovascular function, heart rate, and symptom severity, and exercise volume will be monitored throughout.","[(17, 45, 'PHYSICAL', 'Sub-maximal Exercise Program'), (77, 87, 'CONDITION', 'Concussion'), (113, 123, 'CONDITION', 'concussion'), (139, 168, 'PHYSICAL', 'sub-maximal exercise protocol')]"
"['Spine', 'Stereotactic', 'Body', 'Radiation', 'Therapy', 'for', 'Metastatic', 'Epidural', 'Spinal', 'Cord', ':', 'Prospective', 'Phase', 'II', 'Study', '|', 'Metastatic', 'epidural', 'spinal', 'cord', 'compression', '(', 'MESCC', ')', 'is', 'a', 'frequent', 'oncologic', 'emergency', 'that', 'requires', 'to', 'be', 'treated', 'promptly', '.', 'Although', 'direct', 'decompressive', 'surgery', 'is', 'the', 'most', 'effective', 'treatment', ',', 'surgery', 'is', 'only', 'used', 'in', 'selected', 'patients', 'because', 'most', 'patients', 'have', 'a', 'poor', 'overall', 'condition', 'and', 'short', 'life', 'expectancy', '.', 'Radiation', 'therapy', '(', 'RT', ')', ',', 'therefore', ',', 'is', 'the', 'most', 'commonly', 'used', 'for', 'patients', 'with', 'MESCC', ',', 'but', 'conventional', 'RT', 'alone', 'can', 'achieve', 'modest', 'neurologic', 'outcomes', '.', '\n\n', 'The', 'hypothesis', 'to', 'use', 'stereotactic', 'body', 'radiation', 'therapy', '(', 'SBRT', ')', 'for', 'MESCC', 'is', 'that', 'the', 'rapid', 'decompression', 'of', 'epidural', 'mass', ',', 'durable', 'local', 'control', 'and', 'subsequently', 'improved', 'neurologic', 'outcomes', 'compared', 'to', 'conventional', 'RT', 'are', 'expected', 'when', 'MESCC', 'is', 'treated', 'with', 'SBRT', '.']","['B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-RADIO', 'I-RADIO', 'I-RADIO', 'I-RADIO', 'O', 'B-RADIO', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-RADIO', 'O']",NCT01826058,NCT01826058,"Spine Stereotactic Body Radiation Therapy for Metastatic Epidural Spinal Cord: Prospective Phase II Study | Metastatic epidural spinal cord compression (MESCC) is a frequent oncologic emergency that requires to be treated promptly. Although direct decompressive surgery is the most effective treatment, surgery is only used in selected patients because most patients have a poor overall condition and short life expectancy. Radiation therapy (RT), therefore, is the most commonly used for patients with MESCC, but conventional RT alone can achieve modest neurologic outcomes.

The hypothesis to use stereotactic body radiation therapy (SBRT) for MESCC is that the rapid decompression of epidural mass, durable local control and subsequently improved neurologic outcomes compared to conventional RT are expected when MESCC is treated with SBRT.","[(0, 41, 'RADIOTHERAPY', 'Spine Stereotactic Body Radiation Therapy'), (46, 77, 'CONDITION', 'Metastatic Epidural Spinal Cord'), (108, 151, 'CONDITION', 'Metastatic epidural spinal cord compression'), (153, 158, 'CONDITION', 'MESCC'), (424, 441, 'RADIOTHERAPY', 'Radiation therapy'), (443, 445, 'RADIOTHERAPY', 'RT'), (503, 508, 'CONDITION', 'MESCC'), (514, 535, 'CONTROL', 'conventional RT alone'), (599, 634, 'RADIOTHERAPY', 'stereotactic body radiation therapy'), (636, 640, 'RADIOTHERAPY', 'SBRT'), (646, 651, 'CONDITION', 'MESCC'), (782, 797, 'CONTROL', 'conventional RT'), (816, 821, 'CONDITION', 'MESCC'), (838, 842, 'RADIOTHERAPY', 'SBRT')]"
"['A', 'Randomised', ',', 'Double', '-', 'Blind', ',', 'Parallel', '-', 'Group', 'Placebo', '-', 'Controlled', 'Phase', 'III', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', 'Desmoteplase', 'in', 'Subjects', 'With', 'Acute', 'Ischemic', 'Stroke', '|', 'The', 'purpose', 'of', 'the', 'study', 'is', 'to', 'determine', 'whether', 'desmoteplase', 'is', 'effective', 'and', 'safe', 'in', 'the', 'treatment', 'of', 'patients', 'with', 'acute', 'ischaemic', 'stroke', 'when', 'given', 'within', '3', 'to', '9', 'hours', 'from', 'onset', 'of', 'stroke', 'symptoms', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O']",NCT00856661,NCT00856661,"A Randomised, Double-Blind, Parallel-Group Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects With Acute Ischemic Stroke | The purpose of the study is to determine whether desmoteplase is effective and safe in the treatment of patients with acute ischaemic stroke when given within 3 to 9 hours from onset of stroke symptoms.","[(43, 50, 'CONTROL', 'Placebo'), (117, 129, 'DRUG', 'Desmoteplase'), (147, 168, 'CONDITION', 'Acute Ischemic Stroke'), (220, 232, 'DRUG', 'desmoteplase'), (289, 311, 'CONDITION', 'acute ischaemic stroke'), (357, 363, 'CONDITION', 'stroke')]"
"['Robotic', 'Walking', 'for', 'Children', 'Who', 'Can', 'not', 'Walk', '|', 'A', 'common', 'problem', 'among', 'children', 'with', 'nervous', 'system', 'disorders', 'is', 'difficulty', 'walking', 'on', 'their', 'own', '.', 'This', 'has', 'impacts', 'beyond', 'mobility', 'including', 'short', 'and', 'long', '-', 'term', 'health', 'conditions', 'associated', 'with', 'physical', 'inactivity', 'and', 'different', 'developmental', 'experiences', 'as', 'a', 'result', 'of', 'the', 'mobility', 'impairments', '.', 'A', 'robotic', 'trainer', 'can', 'both', 'provide', 'rehabilitation', 'and', 'be', 'an', 'assistive', 'device', 'to', 'help', 'compensate', 'for', 'difficulties', '.', 'Figuring', 'out', 'how', 'to', 'prescribe', 'it', 'is', 'critical', 'to', 'improve', 'daily', 'life', 'for', 'children', 'with', 'significant', 'disabilities', '.', 'Preliminary', 'use', 'of', 'robotic', 'trainers', 'have', 'shown', 'many', 'benefits', ',', 'such', 'as', 'better', 'head', 'control', 'and', 'improved', 'independence', 'in', 'transfers', ',', 'which', 'greatly', 'increases', 'ability', 'to', 'live', 'independently', '.', 'Additionally', ',', 'vital', 'functions', 'that', 'are', 'frequently', 'impaired', 'in', 'those', 'with', 'less', 'physical', 'activity', ',', 'such', 'as', 'sleep', 'and', 'bowel', 'habits', ',', 'seem', 'to', 'improve', '.', 'Finally', ',', 'these', 'children', 'enjoy', 'using', 'them', '.', '\n\n', 'This', 'project', 'aims', 'to', 'determine', 'who', 'is', 'most', 'likely', 'to', 'benefit', 'from', 'training', 'with', 'a', 'robotic', 'trainer', 'and', 'investigate', 'key', 'details', 'about', 'the', 'dose', 'of', 'training', 'that', 'is', 'needed', '.', 'Families', 'that', 'are', 'already', 'using', 'or', 'hope', 'to', 'use', 'robotic', 'training', 'need', 'this', 'data', 'to', 'help', 'improve', 'their', 'access', 'to', 'the', 'intervention', '.', 'Clinicians', 'need', 'this', 'systematic', 'approach', 'to', 'building', 'evidence', 'to', 'ensure', 'a', 'future', 'multi', '-', 'centre', 'randomized', 'control', 'trial', 'is', 'well', 'designed', '.', 'This', 'study', 'is', 'needed', 'to', 'help', 'improve', 'the', 'lives', 'of', 'those', 'who', 'live', 'with', 'significant', 'disabilities', '.', 'The', 'objective', 'is', 'to', 'evaluate', 'the', 'feasibility', 'and', 'impacts', 'of', 'delivering', 'robotic', 'gait', 'training', 'at', 'home', '.', 'Integral', 'in', 'this', 'study', 'is', 'capturing', 'the', 'user', 'perspectives', '.', 'This', 'will', 'both', 'provide', 'preliminary', 'evidence', '-', 'based', 'advice', 'to', 'potential', 'users', ',', 'their', 'families', ',', 'and', 'clinicians', 'as', 'well', 'as', 'provide', 'key', 'metrics', 'to', 'design', 'a', 'definitive', 'multi', '-', 'centre', 'randomized', 'control', 'trial', '.', '\n\n', 'The', 'investigators', 'will', 'provide', 'robotic', 'gait', 'trainers', ',', 'specifically', 'Trexo', 'robotic', 'gait', 'trainers', ',', 'to', 'participants', 'and', 'their', 'families', 'to', 'use', 'in', 'their', 'home', 'communities', 'for', '12', 'weeks', 'to', 'evaluate', 'the', 'feasibility', 'and', 'impacts', 'of', 'intensive', 'robotic', 'gait', 'training', 'in', 'people', 'who', 'can', 'not', 'walk', 'independently', '.', 'Assessments', 'will', 'be', 'completed', 'throughout', 'the', 'duration', 'of', 'study', ',', 'including', 'before', ',', 'during', ',', 'and', 'after', 'the', 'training', 'intervention', ',', 'with', 'the', 'goal', 'of', 'evaluating', 'a', 'wide', 'range', 'of', 'feasibility', 'considerations', 'and', 'impacts', 'from', 'robotic', 'training', '.']","['B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O']",NCT05473676,NCT05473676,"Robotic Walking for Children Who Cannot Walk | A common problem among children with nervous system disorders is difficulty walking on their own. This has impacts beyond mobility including short and long-term health conditions associated with physical inactivity and different developmental experiences as a result of the mobility impairments. A robotic trainer can both provide rehabilitation and be an assistive device to help compensate for difficulties. Figuring out how to prescribe it is critical to improve daily life for children with significant disabilities. Preliminary use of robotic trainers have shown many benefits, such as better head control and improved independence in transfers, which greatly increases ability to live independently. Additionally, vital functions that are frequently impaired in those with less physical activity, such as sleep and bowel habits, seem to improve. Finally, these children enjoy using them.

This project aims to determine who is most likely to benefit from training with a robotic trainer and investigate key details about the dose of training that is needed. Families that are already using or hope to use robotic training need this data to help improve their access to the intervention. Clinicians need this systematic approach to building evidence to ensure a future multi-centre randomized control trial is well designed. This study is needed to help improve the lives of those who live with significant disabilities. The objective is to evaluate the feasibility and impacts of delivering robotic gait training at home. Integral in this study is capturing the user perspectives. This will both provide preliminary evidence-based advice to potential users, their families, and clinicians as well as provide key metrics to design a definitive multi-centre randomized control trial.

The investigators will provide robotic gait trainers, specifically Trexo robotic gait trainers, to participants and their families to use in their home communities for 12 weeks to evaluate the feasibility and impacts of intensive robotic gait training in people who cannot walk independently. Assessments will be completed throughout the duration of study, including before, during, and after the training intervention, with the goal of evaluating a wide range of feasibility considerations and impacts from robotic training.","[(0, 15, 'PHYSICAL', 'Robotic Walking'), (321, 341, 'CONDITION', 'mobility impairments'), (345, 360, 'PHYSICAL', 'robotic trainer'), (587, 603, 'PHYSICAL', 'robotic trainers'), (1024, 1039, 'PHYSICAL', 'robotic trainer'), (1158, 1174, 'PHYSICAL', 'robotic training'), (1544, 1565, 'PHYSICAL', 'robotic gait training'), (1867, 1888, 'PHYSICAL', 'robotic gait trainers'), (1903, 1930, 'PHYSICAL', 'Trexo robotic gait trainers'), (2066, 2087, 'PHYSICAL', 'robotic gait training'), (2344, 2360, 'PHYSICAL', 'robotic training')]"
"['Evaluation', 'of', 'the', 'Effects', 'of', 'Neuromuscular', 'Electrical', 'Stimulation', 'and', 'Mirror', 'Therapy', 'in', 'Hemiplegia', 'Rehabilitation', ';', 'Prospective', ',', 'Randomized', ',', 'Controlled', ',', 'Single', '-', 'Blinded', 'Study', '|', 'In', 'this', 'study', ',', 'it', 'was', 'aimed', 'to', 'evaluate', 'whether', 'or', 'not', 'NMES', 'in', 'front', 'of', 'the', 'mirror', 'brings', 'an', 'additional', 'benefit', 'to', 'mirror', 'therapy', 'alone', 'or', 'NMES', 'alone', 'on', 'upper', 'extremity', 'motor', 'and', 'functional', 'development', ',', 'spasticity', ',', 'anxiety', ',', 'depression', ',', 'cognitive', 'function', 'and', 'activities', 'of', 'daily', 'living', ',', 'and', 'neuropathic', 'pain', '.']","['O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04913506,NCT04913506,"Evaluation of the Effects of Neuromuscular Electrical Stimulation and Mirror Therapy in Hemiplegia Rehabilitation; Prospective, Randomized, Controlled, Single-Blinded Study | In this study, it was aimed to evaluate whether or not NMES in front of the mirror brings an additional benefit to mirror therapy alone or NMES alone on upper extremity motor and functional development, spasticity, anxiety, depression, cognitive function and activities of daily living, and neuropathic pain.","[(29, 65, 'OTHER', 'Neuromuscular Electrical Stimulation'), (70, 84, 'OTHER', 'Mirror Therapy'), (88, 98, 'CONDITION', 'Hemiplegia'), (230, 257, 'OTHER', 'NMES in front of the mirror'), (290, 310, 'CONTROL', 'mirror therapy alone'), (314, 324, 'CONTROL', 'NMES alone'), (378, 388, 'CONDITION', 'spasticity'), (390, 397, 'CONDITION', 'anxiety'), (399, 409, 'CONDITION', 'depression'), (466, 482, 'CONDITION', 'neuropathic pain')]"
"['Comprehensive', 'Fall', 'Prevention', 'and', 'Detection', 'in', 'Multiple', 'Sclerosis', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'examine', 'whether', 'an', 'exercise', 'and', 'educational', 'classroom', 'program', 'can', 'help', 'reduce', 'falls', 'in', 'people', 'with', 'Multiple', 'Sclerosis', 'who', 'fall', 'frequently', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O']",NCT02583386,NCT02583386,Comprehensive Fall Prevention and Detection in Multiple Sclerosis | The purpose of this study is to examine whether an exercise and educational classroom program can help reduce falls in people with Multiple Sclerosis who fall frequently.,"[(0, 29, 'OTHER', 'Comprehensive Fall Prevention'), (47, 65, 'CONDITION', 'Multiple Sclerosis'), (119, 127, 'PHYSICAL', 'exercise'), (132, 161, 'BEHAVIOURAL', 'educational classroom program'), (199, 217, 'CONDITION', 'Multiple Sclerosis')]"
"['Assessment', 'of', 'Cerebellar', 'Stimulation', 'Effect', 'on', 'Motor', 'Learning', 'in', 'Ageing', 'Population', 'and', 'Stroke', 'Patients', '|', 'This', 'study', 'will', 'assess', 'the', 'putative', 'advantages', 'of', 'cerebellar', 'stimulation', 'on', 'motor', 'learning', 'abilities', 'of', 'stroke', 'patients', '.', 'In', 'order', 'to', 'have', 'a', 'control', 'group', 'to', 'refer', 'to', ',', 'the', 'effect', 'of', 'cerebellar', 'stimulation', 'on', 'healthy', 'young', 'and', 'old', 'participants', 'will', 'also', 'be', 'assessed', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03092570,NCT03092570,"Assessment of Cerebellar Stimulation Effect on Motor Learning in Ageing Population and Stroke Patients | This study will assess the putative advantages of cerebellar stimulation on motor learning abilities of stroke patients. In order to have a control group to refer to, the effect of cerebellar stimulation on healthy young and old participants will also be assessed.","[(14, 36, 'OTHER', 'Cerebellar Stimulation'), (87, 93, 'CONDITION', 'Stroke'), (155, 177, 'OTHER', 'cerebellar stimulation'), (209, 215, 'CONDITION', 'stroke'), (286, 308, 'OTHER', 'cerebellar stimulation')]"
"['Visual', 'Field', 'Restoration', 'in', 'Patients', 'With', 'Post', '-', 'stroke', 'Homonymous', 'Hemianopsia', '|', 'This', 'study', 'will', 'assess', 'the', 'effectiveness', 'of', 'a', 'stimulus', ',', 'in', 'the', 'blind', 'field', 'of', 'hemianopsic', 'patients', ',', 'to', 'restore', 'the', 'vision', 'of', 'patients', 'with', 'homonymous', 'hemianopsia', 'consecutive', 'to', 'stroke', '(', 'unilateral', 'occipital', 'lesion', ')', '.', 'Hemianopsia', 'occurs', 'in', '30', '%', 'of', 'strokes', 'regardless', 'of', 'the', 'cerebral', 'localization', 'and', 'in', '60', '%', 'of', 'stroke', 'interesting', 'the', 'territory', 'of', 'the', 'posterior', 'cerebral', 'artery', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02886663,NCT02886663,"Visual Field Restoration in Patients With Post-stroke Homonymous Hemianopsia | This study will assess the effectiveness of a stimulus, in the blind field of hemianopsic patients, to restore the vision of patients with homonymous hemianopsia consecutive to stroke (unilateral occipital lesion). Hemianopsia occurs in 30% of strokes regardless of the cerebral localization and in 60% of stroke interesting the territory of the posterior cerebral artery.","[(0, 24, 'OTHER', 'Visual Field Restoration'), (42, 53, 'CONDITION', 'Post-stroke'), (54, 76, 'CONDITION', 'Homonymous Hemianopsia'), (125, 133, 'OTHER', 'stimulus'), (157, 168, 'CONDITION', 'hemianopsic'), (218, 240, 'CONDITION', 'homonymous hemianopsia'), (256, 262, 'CONDITION', 'stroke'), (294, 305, 'CONDITION', 'Hemianopsia'), (323, 330, 'CONDITION', 'strokes'), (385, 391, 'CONDITION', 'stroke')]"
"['Positive', 'Airway', 'Pressure', 'for', 'the', 'Treatment', 'of', 'the', 'Obstructive', 'Sleep', 'Apnea', 'Syndrome', 'in', 'Children', 'With', 'Down', 'Syndrome', '(', 'Stage', '1', ')', '|', 'To', 'identify', 'the', 'perceptions', ',', 'beliefs', ',', 'and', 'family', '-', 'relevant', 'outcomes', 'regarding', 'the', 'treatment', 'of', 'obstructive', 'sleep', 'apnea', 'syndrome', '(', 'OSAS', ')', 'with', 'positive', 'airway', 'pressure', '(', 'PAP', ')', 'in', 'children', 'with', 'Down', ""'s"", 'Syndrome', '(', 'DS', ')', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O']",NCT04124471,NCT04124471,"Positive Airway Pressure for the Treatment of the Obstructive Sleep Apnea Syndrome in Children With Down Syndrome (Stage 1) | To identify the perceptions, beliefs, and family-relevant outcomes regarding the treatment of obstructive sleep apnea syndrome (OSAS) with positive airway pressure (PAP) in children with Down's Syndrome (DS).","[(0, 24, 'OTHER', 'Positive Airway Pressure'), (50, 82, 'CONDITION', 'Obstructive Sleep Apnea Syndrome'), (100, 113, 'CONDITION', 'Down Syndrome'), (220, 252, 'CONDITION', 'obstructive sleep apnea syndrome'), (254, 258, 'CONDITION', 'OSAS'), (265, 289, 'OTHER', 'positive airway pressure'), (291, 294, 'OTHER', 'PAP'), (313, 328, 'CONDITION', ""Down's Syndrome""), (330, 332, 'CONDITION', 'DS')]"
"['A', 'Prospective', ',', 'Double', '-', 'blind', ',', 'Randomized', 'Controlled', 'Trial', 'of', 'FMT', 'Combined', 'With', 'Antipsychotic', 'Drugs', 'to', 'Improve', 'the', 'Efficacy', 'of', 'Schizophrenia', '|', 'The', 'purpose', 'of', 'this', 'study', 'was', 'to', 'explore', 'whether', 'repeated', 'oral', 'fecal', 'capsules', 'could', 'improve', 'outcomes', 'in', 'patients', 'with', 'schizophrenia', 'receiving', 'conventional', 'antipsychotic', 'drugs', '.', 'This', 'study', 'was', 'divided', 'into', 'screening', 'period', '(', '1', 'week', ')', 'and', 'treatment', 'period', '(', '8', 'weeks', ')', '.', 'Subjects', 'who', 'met', 'the', 'inclusion', 'criteria', 'during', 'the', 'screening', 'period', 'entered', 'the', 'treatment', 'period', '.', 'During', 'the', 'treatment', 'period', ',', 'the', 'patients', 'were', 'divided', 'into', 'two', 'groups', ':', 'oral', 'fecal', 'bacteria', 'capsules', '+', 'antipsychotics', 'group', ';', 'Oral', 'placebo', '+', 'antipsychotic', 'group', '.', 'During', 'the', 'follow', '-', 'up', 'period', ',', 'both', 'groups', 'were', 'treated', 'with', 'stable', 'dose', 'of', 'antipsychotic', 'drugs', 'during', 'the', 'treatment', 'period', '.', 'Before', 'and', 'after', 'the', 'intervention', ',', 'venous', 'blood', 'samples', 'of', 'patients', 'were', 'collected', 'for', 'routine', 'tests', 'such', 'as', 'liver', 'and', 'kidney', 'function', 'to', 'determine', 'the', 'safety', 'of', 'treatment', '.', 'The', 'scale', 'evaluated', 'the', 'improvement', 'of', 'patients', ""'"", 'psychotic', 'symptoms', 'to', 'determine', 'the', 'efficacy', 'and', 'safety', 'of', 'FMT', 'combined', 'with', 'antipsychotics', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-CTRL', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-DRUG', 'O']",NCT05850585,NCT05850585,"A Prospective, Double-blind, Randomized Controlled Trial of FMT Combined With Antipsychotic Drugs to Improve the Efficacy of Schizophrenia | The purpose of this study was to explore whether repeated oral fecal capsules could improve outcomes in patients with schizophrenia receiving conventional antipsychotic drugs. This study was divided into screening period (1 week) and treatment period (8 weeks). Subjects who met the inclusion criteria during the screening period entered the treatment period. During the treatment period, the patients were divided into two groups: oral fecal bacteria capsules + antipsychotics group; Oral placebo + antipsychotic group. During the follow-up period, both groups were treated with stable dose of antipsychotic drugs during the treatment period. Before and after the intervention, venous blood samples of patients were collected for routine tests such as liver and kidney function to determine the safety of treatment. The scale evaluated the improvement of patients' psychotic symptoms to determine the efficacy and safety of FMT combined with antipsychotics.","[(60, 63, 'OTHER', 'FMT'), (78, 91, 'DRUG', 'Antipsychotic'), (125, 138, 'CONDITION', 'Schizophrenia'), (199, 218, 'OTHER', 'oral fecal capsules'), (259, 272, 'CONDITION', 'schizophrenia'), (296, 309, 'DRUG', 'antipsychotic'), (573, 601, 'OTHER', 'oral fecal bacteria capsules'), (604, 618, 'DRUG', 'antipsychotics'), (631, 638, 'CONTROL', 'placebo'), (641, 654, 'DRUG', 'antipsychotic'), (736, 749, 'DRUG', 'antipsychotic'), (1007, 1016, 'CONDITION', 'psychotic'), (1066, 1069, 'OTHER', 'FMT'), (1084, 1098, 'DRUG', 'antipsychotics')]"
"['Robot', 'Based', 'Gait', 'Training', 'Therapy', 'for', 'Pediatric', 'Population', 'With', 'Cerebral', 'Palsy', 'Using', 'the', 'CPWalker', '|', 'This', 'trial', 'is', 'being', 'conducted', 'to', 'determine', 'if', 'the', 'CPWalker', 'can', 'be', 'used', 'as', 'a', 'gait', 'training', 'intervention', 'for', 'pediatric', 'patients', 'with', 'gait', 'impairments', 'due', 'to', 'cerebral', 'palsy']","['B-PHYS', 'I-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND']",NCT03937700,NCT03937700,Robot Based Gait Training Therapy for Pediatric Population With Cerebral Palsy Using the CPWalker | This trial is being conducted to determine if the CPWalker can be used as a gait training intervention for pediatric patients with gait impairments due to cerebral palsy,"[(0, 25, 'PHYSICAL', 'Robot Based Gait Training'), (64, 78, 'CONDITION', 'Cerebral Palsy'), (89, 97, 'PHYSICAL', 'CPWalker'), (150, 158, 'PHYSICAL', 'CPWalker'), (176, 189, 'PHYSICAL', 'gait training'), (255, 269, 'CONDITION', 'cerebral palsy')]"
"['CoMBat', 'Insomnia', ':', 'A', 'Randomized', 'Controlled', 'Trial', 'of', 'Cognitive', '-', 'Behavioral', 'vs.', 'Mindfulness', '-', 'Based', 'Treatment', 'for', 'TBI', '-', 'Related', 'Insomnia', 'and', 'Post', '-', 'Traumatic', 'Stress', 'Symptoms', '|', 'This', 'study', 'is', 'a', 'prospective', 'two', '-', 'arm', ',', 'single', 'blind', 'randomized', 'controlled', 'trial', 'design', 'to', 'compare', 'the', 'clinical', 'effectiveness', 'of', 'telemedicine', '-', 'delivered', ',', '6', '-', 'session', ',', 'standardized', 'cognitive', 'behavioral', 'therapy', 'for', 'insomnia', '(', 'CBT', '-', 'I', ')', 'and', 'mindfulness', '-', 'based', 'treatment', 'for', 'insomnia', '(', 'MBTI', ')', 'in', 'treating', 'insomnia', 'symptoms', 'and', 'ameliorating', 'depressive', 'symptoms', 'in', 'persons', 'with', 'mild', 'to', 'moderate', 'TBI', 'and', 'comorbid', 'Post', '-', 'Traumatic', 'Stress', 'Symptoms', '(', 'PTSS', ')', 'and', 'insomnia', 'symptoms', 'in', 'a', '360', 'patients', '.', 'Participants', 'will', 'undergo', 'assessment', '(', 'psychosocial', 'questionnaires', ',', 'neurocognitive', 'testing', ',', 'sleep', 'monitoring', ')', 'at', 'baseline', ',', 'at', 'the', 'end', 'of', 'treatment', ',', 'and', 'at', '6-', 'and', '12', '-', 'weeks', 'post', '-', 'treatment', '.', 'The', 'primary', 'outcome', 'is', 'sleep', 'as', 'measured', 'by', 'the', 'Insomnia', 'Severity', 'Index', '(', 'ISI', ')', '.']","['O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'B-BEH', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'B-COND', 'O', 'B-BEH', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT05663034,NCT05663034,"CoMBat Insomnia: A Randomized Controlled Trial of Cognitive-Behavioral vs. Mindfulness-Based Treatment for TBI-Related Insomnia and Post-Traumatic Stress Symptoms | This study is a prospective two-arm, single blind randomized controlled trial design to compare the clinical effectiveness of telemedicine-delivered, 6-session, standardized cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based treatment for insomnia (MBTI) in treating insomnia symptoms and ameliorating depressive symptoms in persons with mild to moderate TBI and comorbid Post-Traumatic Stress Symptoms (PTSS) and insomnia symptoms in a 360 patients. Participants will undergo assessment (psychosocial questionnaires, neurocognitive testing, sleep monitoring) at baseline, at the end of treatment, and at 6- and 12-weeks post-treatment. The primary outcome is sleep as measured by the Insomnia Severity Index (ISI).","[(7, 15, 'CONDITION', 'Insomnia'), (50, 102, 'BEHAVIOURAL', 'Cognitive-Behavioral vs. Mindfulness-Based Treatment'), (107, 127, 'CONDITION', 'TBI-Related Insomnia'), (132, 153, 'CONDITION', 'Post-Traumatic Stress'), (339, 367, 'BEHAVIOURAL', 'cognitive behavioral therapy'), (372, 380, 'CONDITION', 'insomnia'), (382, 385, 'BEHAVIOURAL', 'CBT'), (393, 420, 'BEHAVIOURAL', 'mindfulness-based treatment'), (425, 433, 'CONDITION', 'insomnia'), (435, 439, 'BEHAVIOURAL', 'MBTI'), (453, 461, 'CONDITION', 'insomnia'), (488, 498, 'CONDITION', 'depressive'), (524, 544, 'CONDITION', 'mild to moderate TBI'), (558, 588, 'CONDITION', 'Post-Traumatic Stress Symptoms'), (590, 594, 'CONDITION', 'PTSS'), (600, 608, 'CONDITION', 'insomnia')]"
"['Mind', '-', 'Body', 'Interventions', 'to', 'Mitigate', 'Effects', 'of', 'Media', 'Use', 'on', 'Sleep', '(', 'Sleepazoid', 'Study', ')', '|', 'Eliminating', 'media', 'use', 'is', 'neither', 'feasible', 'at', 'a', 'public', 'health', 'level', 'nor', 'perhaps', 'even', 'desirable', 'given', 'the', 'role', 'it', 'plays', 'in', 'the', 'lives', 'of', 'youth', 'and', 'adults', ',', 'but', 'mind', '-', 'body', 'interventions', 'have', 'the', 'potential', 'to', 'mitigate', 'state', 'arousal', 'effects', 'and', 'thus', 'reduce', 'negative', 'impacts', 'on', 'sleep', '.', 'Given', 'emerging', 'literature', 'on', 'links', 'between', 'intensive', 'media', 'use', ',', 'sensory', 'and', 'interoceptive', 'awareness', ',', 'and', 'self', '-', 'regulation', ',', 'this', 'study', 'will', 'examine', 'two', 'related', 'mind', '-', 'body', 'approaches', '--', 'a', 'mindfulness', 'sensory', 'awareness', 'exercises', 'and', 'mindful', 'body', 'awareness', 'check', '-', 'ins', '--', 'in', 'a', 'randomized', 'clinical', 'trial', 'of', 'early', 'adolescents', 'with', 'evening', 'media', 'use', 'and', 'sleep', 'problems', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O']",NCT04550507,NCT04550507,"Mind-Body Interventions to Mitigate Effects of Media Use on Sleep (Sleepazoid Study) | Eliminating media use is neither feasible at a public health level nor perhaps even desirable given the role it plays in the lives of youth and adults, but mind-body interventions have the potential to mitigate state arousal effects and thus reduce negative impacts on sleep. Given emerging literature on links between intensive media use, sensory and interoceptive awareness, and self-regulation, this study will examine two related mind-body approaches -- a mindfulness sensory awareness exercises and mindful body awareness check-ins -- in a randomized clinical trial of early adolescents with evening media use and sleep problems.","[(0, 23, 'OTHER', 'Mind-Body Interventions'), (243, 266, 'OTHER', 'mind-body interventions'), (521, 541, 'OTHER', 'mind-body approaches'), (547, 586, 'OTHER', 'mindfulness sensory awareness exercises'), (591, 623, 'OTHER', 'mindful body awareness check-ins'), (706, 720, 'CONDITION', 'sleep problems')]"
"['A', 'Positron', 'Emission', 'Tomography', 'Study', 'to', 'Assess', 'the', 'Level', 'and', 'Duration', 'of', 'Occupancy', 'of', 'Serotonin-1A', 'Receptors', 'Produced', 'by', 'Single', 'Oral', 'Doses', 'of', 'SRA-444', 'in', 'Healthy', 'Elderly', 'Subjects', 'and', 'in', 'Subjects', 'With', 'Alzheimer', 'Disease', '|', 'The', 'study', 'will', 'include', 'a', 'preliminary', 'pharmacokinetics', '(', 'PK', ')', '/', 'safety', '/', 'tolerability', 'evaluation', 'in', 'healthy', 'elderly', 'subjects', 'followed', 'by', 'the', 'Receptor', 'Occupancy', '(', 'RO', ')', 'evaluations', 'in', 'healthy', 'elderly', 'subjects', 'and', 'in', 'Alzheimer', ""'s"", 'Disease', '(', 'AD', ')', 'subjects', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O']",NCT00499200,NCT00499200,A Positron Emission Tomography Study to Assess the Level and Duration of Occupancy of Serotonin-1A Receptors Produced by Single Oral Doses of SRA-444 in Healthy Elderly Subjects and in Subjects With Alzheimer Disease | The study will include a preliminary pharmacokinetics (PK) / safety / tolerability evaluation in healthy elderly subjects followed by the Receptor Occupancy (RO) evaluations in healthy elderly subjects and in Alzheimer's Disease (AD) subjects.,"[(142, 149, 'DRUG', 'SRA-444'), (199, 216, 'CONDITION', 'Alzheimer Disease'), (428, 447, 'CONDITION', ""Alzheimer's Disease""), (449, 451, 'CONDITION', 'AD')]"
"['Anakinra', 'in', 'Patients', 'With', 'Refractory', 'Idiopathic', 'Inflammatory', 'Myopathies', '|', 'To', 'investigate', 'the', 'effect', 'of', 'the', 'interleukin-1', '(', 'IL-1', ')', 'blocking', 'agent', ',', 'anakinra', ',', 'in', 'patients', 'with', 'treatment', '-', 'resistant', 'inflammatory', 'myopathies', '.', '\n\n', 'Patients', 'and', 'methods', ':', 'Fifteen', 'patients', 'with', 'refractory', 'polymyositis', '(', 'PM', ')', ',', 'dermatomyositis', '(', 'DM', ')', ',', 'or', 'inclusion', 'body', 'myositis', '(', 'IBM', ')', 'were', 'treated', 'with', '100', 'mg', 'anakinra', 'subcutaneously', 'per', 'day', 'during', '12', 'months', '.', 'Outcome', 'measures', 'included', 'myositis', 'disease', 'activity', 'score', 'with', 'improvement', 'defined', 'according', 'to', 'The', 'International', 'Myositis', 'Assessment', 'and', 'Clinical', 'Studies', 'Group', '(', 'IMACS', ')', 'and', 'for', 'muscle', 'performance', 'the', 'functional', 'index', 'of', 'myositis', '(', 'FI', ')', '.', 'In', 'addition', 'repeat', 'muscle', 'biopsies', 'were', 'performed']","['B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01165008,NCT01165008,"Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies | To investigate the effect of the interleukin-1 (IL-1) blocking agent, anakinra, in patients with treatment-resistant inflammatory myopathies.

Patients and methods: Fifteen patients with refractory polymyositis (PM), dermatomyositis (DM), or inclusion body myositis (IBM) were treated with 100 mg anakinra subcutaneously per day during 12 months. Outcome measures included myositis disease activity score with improvement defined according to The International Myositis Assessment and Clinical Studies Group (IMACS) and for muscle performance the functional index of myositis (FI). In addition repeat muscle biopsies were performed","[(0, 8, 'DRUG', 'Anakinra'), (26, 71, 'CONDITION', 'Refractory Idiopathic Inflammatory Myopathies'), (107, 142, 'DRUG', 'interleukin-1 (IL-1) blocking agent'), (144, 152, 'DRUG', 'anakinra'), (171, 214, 'CONDITION', 'treatment-resistant inflammatory myopathies'), (261, 284, 'CONDITION', 'refractory polymyositis'), (286, 288, 'CONDITION', 'PM'), (291, 306, 'CONDITION', 'dermatomyositis'), (308, 310, 'CONDITION', 'DM'), (316, 339, 'CONDITION', 'inclusion body myositis'), (341, 344, 'CONDITION', 'IBM'), (371, 379, 'DRUG', 'anakinra'), (447, 455, 'CONDITION', 'myositis'), (641, 649, 'CONDITION', 'myositis')]"
"['Effects', 'of', 'Long', 'Term', 'Adaptive', 'Servo', 'Ventilation', 'Therapy', 'on', 'Myocardial', 'Energetics', 'and', 'Sympathetic', 'Nerve', 'Function', 'in', 'Heart', 'Failure', 'and', 'Sleep', 'Apnea', '.', 'The', 'AMEND', 'Sub', '-', 'study', '|', 'Obstructive', 'sleep', 'apnea', '(', 'OSA', ')', ',', 'central', 'sleep', 'apnea', '(', 'CSA', ')', 'and', 'heart', 'failure', '(', 'HF', ')', 'are', 'states', 'of', 'metabolic', 'demand', 'and', 'sympathetic', 'nervous', 'system', '(', 'SNS', ')', 'activation', '.', 'In', 'patients', 'with', 'sleep', 'apnea', 'and', 'HF', ',', 'continuous', 'positive', 'airway', 'pressure', '(', 'CPAP', ')', 'initially', 'may', 'reduce', 'left', 'ventricular', '(', 'LV)stroke', 'volume', '(', 'SV', ')', 'but', 'subsequently', 'improves', 'and', 'LV', 'function', '.', 'This', 'may', 'relate', 'to', 'an', 'early', 'beneficial', 'effect', 'on', 'myocardial', 'energetics', 'through', 'early', 'reduction', 'in', 'metabolic', 'demand', 'that', 'subsequently', 'leads', 'to', 'improved', 'efficiency', 'of', 'LV', 'contraction', '.', 'However', ',', 'it', 'is', 'not', 'clear', 'whether', 'long', '-', 'term', 'adaptive', 'servo', '-', 'ventilation', '(', 'ASV', ')', 'favorably', 'affects', 'cardiac', 'energetics', '.', 'Any', 'such', 'benefit', 'may', 'also', 'relate', 'to', 'reduced', 'sympathetic', 'nervous', 'system', '(', 'SNS', ')', 'activation', '.', 'However', 'its', 'effect', 'on', 'myocardial', 'SNS', 'function', 'is', 'also', 'not', 'well', 'studied', '.', '\n\n', 'In', 'a', 'pilot', 'study', 'we', 'demonstrated', 'early', '(', '6', 'week', ')', 'beneficial', 'effects', 'of', 'CPAP', 'in', 'patients', 'with', 'OSA', 'and', 'HF', '.', 'The', 'current', 'proposal', '(', 'AMEND', ')', 'is', 'a', 'unique', 'substudy', 'of', 'the', 'recently', 'funded', 'ADVENT', '-', 'HF', 'trial', '(', 'Adaptive', 'Servo', 'Ventilation', 'for', 'Therapy', 'of', 'Sleep', 'Apnea', 'in', 'HeartFailure', ')', '(', 'NCT01128816', ';', 'CIHR', ';', 'D.', 'Bradley', ',', 'PI', ')', '.', '\n\n', 'We', 'propose', 'to', 'evaluate', 'the', 'long', '-', 'term', '(', '6', 'month', ')', 'effects', 'of', 'ASV', 'on', 'daytime', '1', ')', 'oxidative', 'metabolism', ';', '2', ')', 'the', 'work', 'metabolic', 'index', '(', 'WMI', ')', 'as', 'an', 'estimate', 'of', 'mechanical', 'efficiency', ';', '3', ')', 'myocardial', 'sympathetic', 'nerve', '(', 'SN', ')', 'pre', '-', 'synaptic', 'function', ';', 'and', '4', ')', 'heart', 'rate', '(', 'HR', ')', 'variability', 'in', 'patients', 'with', 'HF', 'and', 'coexisting', 'OSA', 'or', 'CSA', '.', 'In', 'conjunction', 'with', 'echocardiographic', 'measures', 'of', 'LV', 'stroke', 'work', ',', 'positron', 'emission', 'tomography', '(', 'PET', ')', 'derived', '[', '11C', ']', 'acetate', 'kinetics', 'will', 'be', 'used', 'as', 'a', 'measure', 'of', 'oxidative', 'metabolism', ',', 'to', 'determine', 'the', 'WMI', '.', '[', '11C', ']', 'hydroxyephedrine', '(', 'HED', ')', 'retention', 'will', 'be', 'used', 'to', 'measure', 'cardiac', 'SN', 'pre', '-', 'synaptic', 'function', '.', '\n\n', 'Primary', 'Hypotheses', ':', 'In', 'patients', 'with', 'chronic', 'stable', 'HF', 'and', 'CSA', 'or', 'OSA', 'without', 'excessive', 'daytime', 'sleepiness', '(', 'EDS', ')', ',', 'long', '-', 'term', '(', '6', '-', 'month', ')', 'ASV', 'therapy', 'yields', ':', '\n\n', 'Beneficial', 'effects', 'on', 'daytime', 'myocardial', 'metabolism', 'leading', 'to', 'a', 'reduction', 'in', 'the', 'rate', 'of', 'oxidative', 'metabolism', 'as', 'measured', 'by', '[', '11C]acetate', 'kinetics', 'using', 'PET', 'imaging', ';', '\n', 'Improvement', 'in', 'energy', 'transduction', 'from', 'oxidative', 'metabolism', 'to', 'stroke', 'work', 'as', 'measured', 'by', 'an', 'increase', 'in', 'the', 'daytime', 'work', '-', 'metabolic', 'index', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02116140,NCT02116140,"Effects of Long Term Adaptive Servo Ventilation Therapy on Myocardial Energetics and Sympathetic Nerve Function in Heart Failure and Sleep Apnea. The AMEND Sub-study | Obstructive sleep apnea (OSA), central sleep apnea (CSA) and heart failure (HF) are states of metabolic demand and sympathetic nervous system (SNS) activation. In patients with sleep apnea and HF, continuous positive airway pressure (CPAP) initially may reduce left ventricular (LV)stroke volume (SV) but subsequently improves and LV function. This may relate to an early beneficial effect on myocardial energetics through early reduction in metabolic demand that subsequently leads to improved efficiency of LV contraction. However, it is not clear whether long-term adaptive servo-ventilation (ASV) favorably affects cardiac energetics. Any such benefit may also relate to reduced sympathetic nervous system (SNS) activation. However its effect on myocardial SNS function is also not well studied.

In a pilot study we demonstrated early (6 week) beneficial effects of CPAP in patients with OSA and HF. The current proposal (AMEND) is a unique substudy of the recently funded ADVENT-HF trial (Adaptive Servo Ventilation for Therapy of Sleep Apnea in HeartFailure) (NCT01128816; CIHR; D. Bradley, PI).

We propose to evaluate the long-term (6 month) effects of ASV on daytime 1) oxidative metabolism; 2) the work metabolic index (WMI) as an estimate of mechanical efficiency; 3) myocardial sympathetic nerve (SN) pre-synaptic function; and 4) heart rate (HR) variability in patients with HF and coexisting OSA or CSA. In conjunction with echocardiographic measures of LV stroke work, positron emission tomography (PET) derived [11C] acetate kinetics will be used as a measure of oxidative metabolism, to determine the WMI. [11C] hydroxyephedrine (HED) retention will be used to measure cardiac SN pre-synaptic function.

Primary Hypotheses: In patients with chronic stable HF and CSA or OSA without excessive daytime sleepiness (EDS), long-term (6-month) ASV therapy yields:

Beneficial effects on daytime myocardial metabolism leading to a reduction in the rate of oxidative metabolism as measured by [11C]acetate kinetics using PET imaging;
Improvement in energy transduction from oxidative metabolism to stroke work as measured by an increase in the daytime work-metabolic index.","[(21, 55, 'OTHER', 'Adaptive Servo Ventilation Therapy'), (115, 128, 'CONDITION', 'Heart Failure'), (133, 144, 'CONDITION', 'Sleep Apnea'), (168, 191, 'CONDITION', 'Obstructive sleep apnea'), (193, 196, 'CONDITION', 'OSA'), (199, 218, 'CONDITION', 'central sleep apnea'), (220, 223, 'CONDITION', 'CSA'), (229, 242, 'CONDITION', 'heart failure'), (244, 246, 'CONDITION', 'HF'), (345, 356, 'CONDITION', 'sleep apnea'), (361, 363, 'CONDITION', 'HF'), (365, 400, 'OTHER', 'continuous positive airway pressure'), (402, 406, 'OTHER', 'CPAP'), (736, 762, 'OTHER', 'adaptive servo-ventilation'), (764, 767, 'OTHER', 'ASV'), (1039, 1043, 'OTHER', 'CPAP'), (1061, 1064, 'CONDITION', 'OSA'), (1069, 1071, 'CONDITION', 'HF'), (1163, 1189, 'OTHER', 'Adaptive Servo Ventilation'), (1205, 1216, 'CONDITION', 'Sleep Apnea'), (1220, 1232, 'CONDITION', 'HeartFailure'), (1330, 1333, 'OTHER', 'ASV'), (1557, 1559, 'CONDITION', 'HF'), (1575, 1578, 'CONDITION', 'OSA'), (1582, 1585, 'CONDITION', 'CSA'), (1927, 1944, 'CONDITION', 'chronic stable HF'), (1949, 1952, 'CONDITION', 'CSA'), (1956, 1959, 'CONDITION', 'OSA'), (2024, 2027, 'OTHER', 'ASV')]"
"['Phase', 'I', '/', 'II', 'Study', 'of', 'Oral', 'Capecitabine', 'and', 'Temozolomide', '(', 'CAPTEM', ')', 'for', 'Newly', 'Diagnosed', 'Glioblastoma', '(', 'GBM', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'safety', 'and', 'efficacy', 'of', 'administering', 'the', 'medication', 'capecitabine', 'along', 'with', 'temozolomide', 'when', 'you', 'start', 'your', 'monthly', 'regimen', 'of', 'oral', 'temozolomide', 'for', 'the', 'treatment', 'of', 'your', 'newly', 'diagnosed', 'glioblastoma', 'multiforme', '(', 'GBM', ')', '.', '\n\n', 'Capecitabine', 'is', 'an', 'oral', 'chemotherapy', 'that', 'is', 'given', 'to', 'patients', 'with', 'other', 'types', 'of', 'cancer', '.', 'The', 'study', 'will', 'evaluate', 'whether', 'the', 'dosage', 'of', '1500', 'mg', '/', 'm2', 'of', 'capecitabine', 'is', 'tolerable', 'after', 'radiation', ',', 'when', 'taken', 'along', 'with', 'temozolomide', '.', 'It', 'will', 'also', 'try', 'to', 'determine', 'if', 'the', 'medication', 'capecitabine', 'helps', 'patients', 'respond', 'to', 'treatment', 'for', 'a', 'longer', 'period', 'of', 'time', 'compared', 'to', 'just', 'temozolomide', 'alone', ',', 'which', 'is', 'the', 'standard', 'of', 'care', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03213002,NCT03213002,"Phase I/II Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed Glioblastoma (GBM) | The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM).

Capecitabine is an oral chemotherapy that is given to patients with other types of cancer. The study will evaluate whether the dosage of 1500 mg/m2 of capecitabine is tolerable after radiation, when taken along with temozolomide. It will also try to determine if the medication capecitabine helps patients respond to treatment for a longer period of time compared to just temozolomide alone, which is the standard of care.","[(25, 37, 'DRUG', 'Capecitabine'), (42, 54, 'DRUG', 'Temozolomide'), (56, 62, 'DRUG', 'CAPTEM'), (84, 96, 'CONDITION', 'Glioblastoma'), (98, 101, 'CONDITION', 'GBM'), (202, 214, 'DRUG', 'capecitabine'), (226, 238, 'DRUG', 'temozolomide'), (283, 295, 'DRUG', 'temozolomide'), (338, 361, 'CONDITION', 'glioblastoma multiforme'), (363, 366, 'CONDITION', 'GBM'), (370, 382, 'DRUG', 'Capecitabine'), (521, 533, 'DRUG', 'capecitabine'), (553, 562, 'RADIOTHERAPY', 'radiation'), (586, 598, 'DRUG', 'temozolomide'), (648, 660, 'DRUG', 'capecitabine'), (742, 754, 'DRUG', 'temozolomide')]"
"['Early', 'Behavioral', 'Intervention', 'to', 'Improve', 'Social', 'Communication', 'Function', 'in', 'Infants', 'With', 'Tuberous', 'Sclerosis', 'Complex', '|', 'The', 'investigators', 'are', 'running', 'an', 'intervention', 'study', 'for', 'young', 'children', 'with', 'Tuberous', 'Sclerosis', 'Complex', '(', 'TSC', ')', '.', 'The', 'study', 'will', 'include', 'free', 'play', '-', 'based', 'behavioral', 'intervention', 'that', 'may', 'improve', 'social', 'and', 'communication', 'skills', 'in', 'children', 'with', 'TSC', '.', 'Eligible', 'families', 'will', 'have', 'a', 'child', 'in', 'the', 'age', 'range', 'of', '12', '-', '36', 'months', ',', 'with', 'a', 'diagnosis', 'of', 'TSC', '.', 'A', 'parent', 'must', 'also', 'be', 'available', 'to', 'attend', 'the', 'weekly', 'intervention', 'sessions', 'at', 'UCLA', '.', '\n\n', 'The', 'intervention', 'will', 'focus', 'on', 'teaching', 'caregivers', 'skills', 'to', 'improve', 'the', 'social', 'and', 'communication', 'outcomes', 'of', 'their', 'children', '.', 'The', 'content', 'of', 'the', 'intervention', 'will', 'be', 'individually', 'tailored', 'to', 'the', 'child', ""'s"", 'developmental', 'level', '.', 'The', 'intervention', 'involves', 'pre', '-', 'assessments', ',', 'an', 'intervention', 'period', 'of', 'daily', '60', 'minute', 'sessions', 'for', '10', 'days', ',', 'followed', 'by', 'weekly', '60', 'minute', 'sessions', 'for', '10', 'weeks', ',', 'and', 'post', '-', 'assessments', '.', 'The', 'classroom', 'can', 'have', 'up', 'to', '3', 'parent', '-', 'child', 'dyad', 'and', 'the', 'curriculum', 'focuses', 'on', 'improving', 'social', '-', 'communication', 'and', 'play', 'skills', '.']","['B-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'I-BEH', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02687633,NCT02687633,"Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex | The investigators are running an intervention study for young children with Tuberous Sclerosis Complex (TSC). The study will include free play-based behavioral intervention that may improve social and communication skills in children with TSC. Eligible families will have a child in the age range of 12-36 months, with a diagnosis of TSC. A parent must also be available to attend the weekly intervention sessions at UCLA.

The intervention will focus on teaching caregivers skills to improve the social and communication outcomes of their children. The content of the intervention will be individually tailored to the child's developmental level. The intervention involves pre-assessments, an intervention period of daily 60 minute sessions for 10 days, followed by weekly 60 minute sessions for 10 weeks, and post-assessments. The classroom can have up to 3 parent-child dyad and the curriculum focuses on improving social-communication and play skills.","[(0, 29, 'BEHAVIOURAL', 'Early Behavioral Intervention'), (87, 113, 'CONDITION', 'Tuberous Sclerosis Complex'), (192, 218, 'CONDITION', 'Tuberous Sclerosis Complex'), (220, 223, 'CONDITION', 'TSC'), (249, 288, 'BEHAVIOURAL', 'free play-based behavioral intervention'), (355, 358, 'CONDITION', 'TSC'), (450, 453, 'CONDITION', 'TSC')]"
"['Music', 'Intervention', 'and', 'Transcranial', 'Electrical', 'Stimulation', 'for', 'Treating', 'Neurological', 'Diseases', '|', 'The', 'goal', 'of', 'this', 'clinical', 'trial', 'is', 'to', 'evaluate', 'the', 'efficacy', 'of', 'a', 'musical', 'interventionand', 'non', '-', 'invasive', 'brain', 'stimulation', 'in', 'neurological', 'patients', '.', 'The', 'main', 'questions', 'it', 'aims', 'to', 'answer', 'are', ':', '\n\n', 'to', 'evaluate', 'the', 'residual', 'neuroplastic', 'processes', 'in', 'DOC', 'state', 'related', 'to', 'music', 'exposure', '\n', 'to', 'determine', 'the', 'putative', 'modulation', 'of', 'the', 'aforementioned', 'processes', 'and', 'the', 'clinical', 'outcome', 'of', 'DOC', 'patients', 'by', 'non', '-', 'pharmacological', 'strategies', ',', 'i.e.', ',', 'electric', '(', 'tDCS', ')', 'and', 'music', 'stimulation', '\n', 'to', 'evaluate', 'the', 'impact', 'of', 'this', 'intervention', 'on', 'caregiver', ""'s"", 'burden', 'and', 'psychological', 'distress', '.', '\n\n', 'Participants', 'will', 'be', 'randomly', 'assigned', 'to', 'one', 'of', 'three', 'different', 'music', '-', 'listening', 'intervention', 'groups', '.', 'Primary', 'outcomes', 'will', 'be', 'clinical', ',', 'that', 'is', 'based', 'on', 'the', 'neurologist', ""'s"", 'observations', 'of', 'clinical', 'improvement', ',', 'and', 'neurophysiological', ',', 'collected', 'pre', '-', 'intervention', ',', 'post', '-', 'intervention', 'and', 'post', '-', 'placebo', '.']","['B-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O']",NCT05706831,NCT05706831,"Music Intervention and Transcranial Electrical Stimulation for Treating Neurological Diseases | The goal of this clinical trial is to evaluate the efficacy of a musical interventionand non-invasive brain stimulation in neurological patients. The main questions it aims to answer are:

to evaluate the residual neuroplastic processes in DOC state related to music exposure
to determine the putative modulation of the aforementioned processes and the clinical outcome of DOC patients by non-pharmacological strategies, i.e., electric (tDCS) and music stimulation
to evaluate the impact of this intervention on caregiver's burden and psychological distress.

Participants will be randomly assigned to one of three different music-listening intervention groups. Primary outcomes will be clinical, that is based on the neurologist's observations of clinical improvement, and neurophysiological, collected pre-intervention, post-intervention and post-placebo.","[(0, 18, 'OTHER', 'Music Intervention'), (23, 58, 'OTHER', 'Transcranial Electrical Stimulation'), (72, 93, 'CONDITION', 'Neurological Diseases'), (185, 215, 'OTHER', 'non-invasive brain stimulation'), (357, 371, 'OTHER', 'music exposure'), (523, 560, 'OTHER', 'electric (tDCS) and music stimulation'), (721, 736, 'OTHER', 'music-listening'), (945, 952, 'CONTROL', 'placebo')]"
"['An', 'Open', 'Label', 'Conversion', 'Study', 'of', 'Pramipexole', 'to', 'Ropinirole', 'Controlled', 'Release', '(', 'CR', ')', 'in', 'Patients', 'With', 'Parkinson', ""'s"", 'Disease', '.', '|', 'A', 'conversion', 'study', 'of', 'Mirapex', '(', 'pramipexole', ')', 'to', 'Requip', '(', 'ropinirole', ')', 'controlled', 'release', '(', 'CR', ')', 'in', 'patients', 'with', 'Parkinson', ""'s"", 'disease', 'to', 'determine', 'the', 'appropriate', 'conversion', 'ratio', 'and', 'side', 'effects', 'related', 'to', 'the', 'drug', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00275275,NCT00275275,An Open Label Conversion Study of Pramipexole to Ropinirole Controlled Release (CR) in Patients With Parkinson's Disease. | A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio and side effects related to the drug.,"[(34, 45, 'DRUG', 'Pramipexole'), (49, 59, 'DRUG', 'Ropinirole'), (101, 120, 'CONDITION', ""Parkinson's Disease""), (146, 153, 'DRUG', 'Mirapex'), (155, 166, 'DRUG', 'pramipexole'), (171, 177, 'DRUG', 'Requip'), (179, 189, 'DRUG', 'ropinirole'), (232, 251, 'CONDITION', ""Parkinson's disease"")]"
"['Acupuncture', 'for', 'the', 'Prevention', 'of', 'Emergence', 'Delirium', 'in', 'Children', 'Undergoing', 'Myringotomy', 'Tube', 'Placement', '|', 'Myringotomy', 'tube', 'placement', 'is', 'one', 'of', 'the', 'most', 'commonly', 'performed', 'operations', 'in', 'children', '.', 'Emergence', 'delirium', 'after', 'such', 'procedures', 'is', 'common', '.', 'During', 'emergence', 'delirium', 'children', 'can', 'become', 'both', 'a', 'danger', 'to', 'themselves', 'and', 'others', 'around', 'them', ',', 'including', 'family', 'members', 'and', 'hospital', 'staff', '.', '\n\n', 'The', 'primary', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'if', 'acupuncture', ',', 'when', 'used', 'in', 'combination', 'with', 'standard', 'anesthetic', 'management', ',', 'decreases', 'the', 'incidence', 'of', 'emergence', 'delirium', 'in', 'pediatric', 'patients', 'following', 'myringotomy', 'tube', 'placement', '.', 'Patients', 'with', 'and', 'without', 'premedication', 'of', 'midazolam', 'will', 'be', 'included', '.', 'A', 'secondary', 'objective', 'of', 'this', 'study', 'is', 'to', 'determine', 'our', 'institution', ""'s"", 'actual', 'incidence', 'of', 'emergence', 'delirium', 'for', 'this', 'operation', 'using', 'a', 'validated', 'scale', ',', 'the', 'Pediatric', 'Anesthesia', 'Emergence', 'Delirium', '(', 'PAED', ')', 'scale', '.', 'We', 'will', 'also', 'compare', 'rates', 'of', 'emergence', 'delirium', 'in', 'patients', 'that', 'received', 'a', 'premedication', 'of', 'midazolam', 'versus', '(', 'V', ')', 'those', 'that', 'did', 'not', '(', 'NV', ')', '.', '\n\n', 'This', 'is', 'a', 'randomized', 'double', '-', 'blinded', 'trial', '.', 'We', 'will', 'enroll', '100', 'children', 'aged', '1', '-', '6', 'years', 'old', '.', 'Premedication', 'with', 'midazolam', 'will', 'be', 'decided', 'by', 'the', 'anesthesiologist', '.', 'If', 'needed', ',', 'the', 'patient', 'will', 'receive', 'a', 'standard', 'does', 'of', 'oral', 'midazolam', 'plus', 'acetaminophen', '(', 'V', ')', '.', 'If', 'the', 'patient', 'does', 'not', 'require', 'premedication', 'with', 'midazolam', ',', 'oral', 'acetaminophen', 'will', 'be', 'given', 'alone', '(', 'NV', ')', '.', '\n\n', 'Patients', 'will', 'then', 'be', 'randomized', 'to', 'receive', 'either', 'acupuncture', 'with', 'standard', 'general', 'anesthesia', 'care', '(', 'A', ')', 'or', 'to', 'receive', 'standard', 'anesthetic', 'care', 'alone', '(', 'S', ')', '.', 'Patients', ',', 'their', 'family', 'members', 'and', 'recovery', 'registered', 'nurses', '(', 'RNs', ')', 'will', 'not', 'know', 'if', 'acupuncture', 'was', 'performed', '.', 'Intraoperative', 'anesthetic', 'techniques', 'will', 'be', 'standardized', 'and', 'include', 'inhaled', 'inductions', 'with', 'nitrous', 'oxide', 'and', 'sevoflurane', '.', 'Anesthesia', 'maintenance', 'will', 'be', 'inhaled', 'sevoflurane', 'and', 'the', 'usual', 'pain', 'medication', 'ketorolac', 'will', 'be', 'given', 'intramuscularly', 'prior', 'to', 'emergence', '.', 'Acupuncture', 'needles', 'will', 'be', 'placed', 'after', 'anesthesia', 'induction', 'and', 'removed', 'prior', 'to', 'leaving', 'the', 'operating', 'room', '.', 'A', 'total', 'of', '4', 'needles', 'will', 'be', 'placed', ',', 'one', 'in', 'each', 'wrist', 'at', 'the', 'Heart', '7', '(', 'HT7', ')', 'point', 'and', 'one', 'in', 'each', 'ear', 'at', 'the', 'Shen', 'Men', 'point', '.', 'The', 'needles', 'will', 'be', 'inserted', 'bilaterally', 'to', 'a', 'depth', 'of', '1.8', 'mm', '.', '\n\n', 'In', 'the', 'PACU', ',', 'a', 'blinded', 'study', 'observer', 'will', 'evaluate', 'the', 'patient', 'at', 'four', 'time', 'points', 'using', 'the', 'PAED', 'scale', ':', 'time', 'of', 'awakening', 'and', '5', ',', '10', '&', '15', 'minutes', 'after', 'awakening', '.', 'Follow', 'up', 'phone', 'calls', 'will', 'be', 'made', 'one', 'day', 'and', 'one', 'week', 'after', 'surgery', '.', 'Families', 'will', 'be', 'asked', 'about', 'behavior', 'after', 'discharge', ',', 'sleep', 'and', 'bed', '-', 'wetting', '.']","['B-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02383004,NCT02383004,"Acupuncture for the Prevention of Emergence Delirium in Children Undergoing Myringotomy Tube Placement | Myringotomy tube placement is one of the most commonly performed operations in children. Emergence delirium after such procedures is common. During emergence delirium children can become both a danger to themselves and others around them, including family members and hospital staff.

The primary objective of this study is to determine if acupuncture, when used in combination with standard anesthetic management, decreases the incidence of emergence delirium in pediatric patients following myringotomy tube placement. Patients with and without premedication of midazolam will be included. A secondary objective of this study is to determine our institution's actual incidence of emergence delirium for this operation using a validated scale, the Pediatric Anesthesia Emergence Delirium (PAED) scale. We will also compare rates of emergence delirium in patients that received a premedication of midazolam versus (V) those that did not (NV).

This is a randomized double-blinded trial. We will enroll 100 children aged 1-6 years old. Premedication with midazolam will be decided by the anesthesiologist. If needed, the patient will receive a standard does of oral midazolam plus acetaminophen (V). If the patient does not require premedication with midazolam, oral acetaminophen will be given alone (NV).

Patients will then be randomized to receive either acupuncture with standard general anesthesia care (A) or to receive standard anesthetic care alone (S). Patients, their family members and recovery registered nurses (RNs) will not know if acupuncture was performed. Intraoperative anesthetic techniques will be standardized and include inhaled inductions with nitrous oxide and sevoflurane. Anesthesia maintenance will be inhaled sevoflurane and the usual pain medication ketorolac will be given intramuscularly prior to emergence. Acupuncture needles will be placed after anesthesia induction and removed prior to leaving the operating room. A total of 4 needles will be placed, one in each wrist at the Heart 7 (HT7) point and one in each ear at the Shen Men point. The needles will be inserted bilaterally to a depth of 1.8 mm.

In the PACU, a blinded study observer will evaluate the patient at four time points using the PAED scale: time of awakening and 5, 10 & 15 minutes after awakening. Follow up phone calls will be made one day and one week after surgery. Families will be asked about behavior after discharge, sleep and bed-wetting.","[(0, 11, 'OTHER', 'Acupuncture'), (34, 52, 'CONDITION', 'Emergence Delirium'), (76, 102, 'CONDITION', 'Myringotomy Tube Placement'), (105, 131, 'CONDITION', 'Myringotomy tube placement'), (194, 212, 'CONDITION', 'Emergence delirium'), (253, 271, 'CONDITION', 'emergence delirium'), (445, 456, 'OTHER', 'acupuncture'), (488, 518, 'OTHER', 'standard anesthetic management'), (598, 624, 'CONDITION', 'myringotomy tube placement'), (669, 678, 'DRUG', 'midazolam'), (787, 805, 'CONDITION', 'emergence delirium'), (938, 956, 'CONDITION', 'emergence delirium'), (1002, 1011, 'DRUG', 'midazolam'), (1159, 1168, 'DRUG', 'midazolam'), (1270, 1279, 'DRUG', 'midazolam'), (1285, 1298, 'DRUG', 'acetaminophen'), (1355, 1364, 'DRUG', 'midazolam'), (1371, 1384, 'DRUG', 'acetaminophen'), (1463, 1474, 'OTHER', 'acupuncture'), (1480, 1512, 'OTHER', 'standard general anesthesia care'), (1531, 1561, 'CONTROL', 'standard anesthetic care alone'), (1652, 1663, 'OTHER', 'acupuncture'), (1773, 1786, 'DRUG', 'nitrous oxide'), (1791, 1802, 'DRUG', 'sevoflurane'), (1843, 1854, 'DRUG', 'sevoflurane'), (1885, 1894, 'DRUG', 'ketorolac'), (1945, 1956, 'OTHER', 'Acupuncture')]"
"['A', 'Study', 'to', 'Evaluate', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Effect', 'of', 'Risperidone', 'Extended', '-', 'Release', 'Injectable', 'Suspension', '(', 'TV-46000', ')', 'for', 'Subcutaneous', 'Use', 'as', 'Maintenance', 'Treatment', 'in', 'Adult', 'and', 'Adolescent', 'Patients', 'With', 'Schizophrenia', '|', 'The', 'primary', 'objective', 'of', 'the', 'study', 'is', 'to', 'evaluate', 'the', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'of', 'TV-46000', '.', 'The', 'primary', 'safety', 'and', 'tolerability', 'endpoint', 'is', 'the', 'frequency', 'of', 'all', 'adverse', 'events', ',', 'including', 'serious', 'adverse', 'events', '.', 'For', 'new', 'participants', ',', 'the', 'total', 'duration', 'of', 'participant', 'participation', 'in', 'the', 'study', 'is', 'planned', 'to', 'be', 'up', 'to', '80', 'weeks', '(', 'including', 'a', 'screening', 'period', 'of', 'up', 'to', '4', 'weeks', ',', 'a', '12', '-', 'week', 'oral', 'conversion', '/', 'stabilization', 'stage', '[', 'Stage', '1', ']', ',', 'a', '56', '-', 'week', 'double', '-', 'blind', 'maintenance', 'stage', '[', 'Stage', '2', ']', ',', 'and', 'a', 'follow', '-', 'up', 'period', '[', '8', 'weeks', ']', ')', '.', 'For', 'roll', '-', 'over', 'participants', ',', 'the', 'total', 'duration', 'of', 'participant', 'participation', 'in', 'the', 'study', 'is', 'planned', 'to', 'be', 'up', 'to', '64', 'weeks', '(', 'including', 'up', 'to', '56', 'weeks', 'in', 'the', 'maintenance', 'stage', '[', 'Stage', '2', ']', 'and', 'a', 'follow', '-', 'up', 'period', '[', '8', 'weeks', ']', ')', '.', 'Participants', 'who', 'started', 'Stage', '2', 'who', 'relapse', 'or', 'meet', '1', 'or', 'more', 'of', 'the', 'withdrawal', 'criteria', 'should', 'be', 'invited', 'to', 'perform', 'the', 'Early', 'Termination', 'visit', 'as', 'soon', 'as', 'possible', 'within', '4', 'weeks', 'of', 'the', 'last', 'injection', '.', 'Participants', 'who', 'withdraw', 'from', 'the', 'study', 'before', 'completing', 'the', '56', '-', 'week', 'maintenance', 'stage', 'will', 'have', 'follow', '-', 'up', 'procedures', 'and', 'assessments', 'performed', 'at', 'their', 'follow', '-', 'up', 'visits', '.', 'During', 'the', 'follow', '-', 'up', 'period', ',', 'participants', 'will', 'be', 'treated', 'according', 'to', 'the', 'investigator', ""'s"", 'judgment', '.', '\n\n', 'All', 'participants', 'will', 'be', 'treated', 'with', 'active', 'drug', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03893825,NCT03893825,"A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia | The primary objective of the study is to evaluate the long-term safety and tolerability of TV-46000. The primary safety and tolerability endpoint is the frequency of all adverse events, including serious adverse events. For new participants, the total duration of participant participation in the study is planned to be up to 80 weeks (including a screening period of up to 4 weeks, a 12-week oral conversion/stabilization stage [Stage 1], a 56-week double-blind maintenance stage [Stage 2], and a follow-up period [8 weeks]). For roll-over participants, the total duration of participant participation in the study is planned to be up to 64 weeks (including up to 56 weeks in the maintenance stage [Stage 2] and a follow-up period [8 weeks]). Participants who started Stage 2 who relapse or meet 1 or more of the withdrawal criteria should be invited to perform the Early Termination visit as soon as possible within 4 weeks of the last injection. Participants who withdraw from the study before completing the 56-week maintenance stage will have follow-up procedures and assessments performed at their follow-up visits. During the follow-up period, participants will be treated according to the investigator's judgment.

All participants will be treated with active drug.","[(60, 71, 'DRUG', 'Risperidone'), (112, 120, 'DRUG', 'TV-46000'), (206, 219, 'CONDITION', 'Schizophrenia'), (313, 321, 'DRUG', 'TV-46000')]"
"['Exploring', 'the', 'Effects', 'of', 'Spinal', 'Cord', 'Stimulation', 'in', 'Parkinson', ""'s"", 'Disease', '.', '|', 'Parkinson', 'Disease', '(', 'PD', ')', 'patients', 'experience', 'a', 'variety', 'of', 'motor', 'issues', 'such', 'as', 'walking', 'difficulties', ',', 'loss', 'of', 'balance', ',', 'and', 'freezing', 'while', 'walking', ',', 'which', 'impacts', 'their', 'quality', 'of', 'life', '.', 'Some', 'symptoms', ',', 'like', 'freezing', 'of', 'gait', '(', 'FOG', ')', ',', 'do', 'not', 'respond', 'to', 'medications', 'typically', 'used', 'to', 'treat', 'PD', '.', 'Current', 'surgical', 'procedures', 'used', 'to', 'alleviate', 'PD', 'symptoms', 'also', 'do', 'not', 'always', 'improve', 'FOG', '.', 'Since', 'many', 'traditional', 'therapies', 'have', 'failed', 'for', 'the', 'treatment', 'of', 'FOG', ',', 'researchers', 'have', 'proposed', 'the', 'use', 'of', 'newer', 'treatments', '.', 'Recent', 'research', 'in', 'animal', 'models', 'and', 'clinical', 'human', 'data', 'using', 'SCS', 'has', 'produced', 'promising', 'results', ',', 'specifically', 'showing', 'improvement', 'in', 'FOG', 'with', 'the', 'use', 'of', 'SCS', 'in', 'patients', 'with', 'PD', '.', '\n\n', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'evaluate', 'the', 'effectiveness', 'of', 'spinal', 'cord', 'stimulation', '(', 'SCS', ')', 'for', 'the', 'management', 'of', 'freezing', 'of', 'gait', '(', 'FOG', ')', 'that', 'does', 'not', 'respond', 'to', 'conventional', 'treatments', 'in', 'subjects', 'with', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', '.', 'The', 'investigators', 'hypothesize', 'that', 'SCS', 'significantly', 'decreases', 'FOG', 'episodes', 'in', 'patients', 'with', 'PD', '.', '\n\n', 'Assess', 'the', 'safety', ',', 'tolerability', 'and', 'preliminary', 'evidence', 'of', 'effectiveness', 'of', 'upper', 'thoracic', 'spinal', 'cord', 'stimulation', 'for', 'freezing', 'of', 'gait', 'in', 'Parkinson', ""'s"", '(', 'PD', ')', 'patients', '.', '\n', 'Explore', 'the', 'effects', 'of', 'two', 'SCS', 'programming', 'paradigms', 'on', 'motor', ',', 'nonmotor', 'and', 'quality', 'of', 'life', 'measures', 'in', 'PD', 'patients', 'with', 'freezing', 'of', 'gait', '.']","['O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT03526991,NCT03526991,"Exploring the Effects of Spinal Cord Stimulation in Parkinson's Disease. | Parkinson Disease (PD) patients experience a variety of motor issues such as walking difficulties, loss of balance, and freezing while walking, which impacts their quality of life. Some symptoms, like freezing of gait (FOG), do not respond to medications typically used to treat PD. Current surgical procedures used to alleviate PD symptoms also do not always improve FOG. Since many traditional therapies have failed for the treatment of FOG, researchers have proposed the use of newer treatments. Recent research in animal models and clinical human data using SCS has produced promising results, specifically showing improvement in FOG with the use of SCS in patients with PD.

The purpose of this study is to evaluate the effectiveness of spinal cord stimulation (SCS) for the management of freezing of gait (FOG) that does not respond to conventional treatments in subjects with Parkinson's disease (PD). The investigators hypothesize that SCS significantly decreases FOG episodes in patients with PD.

Assess the safety, tolerability and preliminary evidence of effectiveness of upper thoracic spinal cord stimulation for freezing of gait in Parkinson's (PD) patients.
Explore the effects of two SCS programming paradigms on motor, nonmotor and quality of life measures in PD patients with freezing of gait.","[(25, 48, 'OTHER', 'Spinal Cord Stimulation'), (52, 71, 'CONDITION', ""Parkinson's Disease""), (75, 92, 'CONDITION', 'Parkinson Disease'), (94, 96, 'CONDITION', 'PD'), (195, 217, 'CONDITION', 'freezing while walking'), (276, 292, 'CONDITION', 'freezing of gait'), (294, 297, 'CONDITION', 'FOG'), (354, 356, 'CONDITION', 'PD'), (404, 406, 'CONDITION', 'PD'), (443, 446, 'CONDITION', 'FOG'), (514, 517, 'CONDITION', 'FOG'), (637, 640, 'OTHER', 'SCS'), (709, 712, 'CONDITION', 'FOG'), (729, 732, 'OTHER', 'SCS'), (750, 752, 'CONDITION', 'PD'), (817, 840, 'OTHER', 'spinal cord stimulation'), (842, 845, 'OTHER', 'SCS'), (869, 885, 'CONDITION', 'freezing of gait'), (887, 890, 'CONDITION', 'FOG'), (958, 977, 'CONDITION', ""Parkinson's disease""), (979, 981, 'CONDITION', 'PD'), (1019, 1022, 'OTHER', 'SCS'), (1047, 1050, 'CONDITION', 'FOG'), (1077, 1079, 'CONDITION', 'PD'), (1159, 1197, 'OTHER', 'upper thoracic spinal cord stimulation'), (1202, 1218, 'CONDITION', 'freezing of gait'), (1222, 1233, 'CONDITION', ""Parkinson's""), (1235, 1237, 'CONDITION', 'PD'), (1276, 1279, 'OTHER', 'SCS'), (1353, 1355, 'CONDITION', 'PD'), (1370, 1386, 'CONDITION', 'freezing of gait')]"
"['Effectiveness', 'of', 'Bio', '-', 'Electro', 'Stimulation', 'Therapy', 'for', 'the', 'Treatment', 'of', 'Motor', 'and', 'Non', '-', 'Motor', 'Symptoms', 'in', 'Parkinson', ""'s"", 'Disease', '-', 'A', 'Pilot', 'Study', '|', 'Parkinson', ""'s"", 'disease', '(', 'PD', ')', 'is', 'a', 'neurodegenerative', 'disorder', 'characterized', 'by', 'motor', 'dysfunction', 'and', 'non', '-', 'motor', 'symptoms', '.', 'Here', ',', 'the', 'investigators', 'propose', 'in', 'a', 'pilot', 'device', 'feasibility', 'trial', 'to', 'examine', 'whether', '""', 'Bio', 'Electro', 'Stimulation', 'Therapy', '""', '(', 'B.E.S.T.', ')', 'with', 'a', 'small', ',', 'non', '-', 'invasive', ',', 'handheld', 'electronic', 'device', 'designed', 'to', 'apply', 'micro', 'current', 'stimulation', 'to', 'a', 'person', ""'s"", 'hand', 'can', 'ameliorate', 'some', 'of', 'the', 'symptoms', 'of', 'PD', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O']",NCT03014050,NCT03014050,"Effectiveness of Bio-Electro Stimulation Therapy for the Treatment of Motor and Non-Motor Symptoms in Parkinson's Disease - A Pilot Study | Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction and non-motor symptoms. Here, the investigators propose in a pilot device feasibility trial to examine whether ""Bio Electro Stimulation Therapy"" (B.E.S.T.) with a small, non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hand can ameliorate some of the symptoms of PD.","[(17, 48, 'OTHER', 'Bio-Electro Stimulation Therapy'), (102, 121, 'CONDITION', ""Parkinson's Disease""), (140, 159, 'CONDITION', ""Parkinson's disease""), (161, 163, 'CONDITION', 'PD'), (344, 375, 'OTHER', 'Bio Electro Stimulation Therapy'), (378, 386, 'OTHER', 'B.E.S.T.'), (545, 547, 'CONDITION', 'PD')]"
"['Fetoscopic', 'Spina', 'Bifida', 'Repair', 'Using', 'a', 'Cryopreserved', 'Human', 'Umbilical', 'Cord', 'Allograft', '(', 'NEOX', 'Cord', '1', 'K', '®', ')', 'as', 'a', 'Meningeal', 'Patch', '|', 'To', 'fetoscopically', 'use', 'cryopreserved', 'human', 'umbilical', 'cord', 'allografts', ',', 'named', 'NEOX', 'Cord', '1', 'K', '®', ',', 'as', 'a', 'spinal', 'cord', 'cover', 'of', 'spina', 'bifida', 'defects', '.', 'This', 'procedure', 'will', 'be', 'performed', 'to', 'create', 'a', 'watertight', 'seal', 'covering', 'over', 'the', 'spinal', 'cord', 'in', 'order', 'to', 'decrease', 'the', 'incidence', 'rates', 'of', 'postnatal', 'morbidities', '.', 'For', 'larger', 'skin', 'defects', ',', 'NEOX', 'Cord', '1', 'K', '®', 'may', 'be', 'used', 'as', 'a', 'skin', 'cover', '.']","['B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT04243889,NCT04243889,"Fetoscopic Spina Bifida Repair Using a Cryopreserved Human Umbilical Cord Allograft (NEOX Cord 1K®) as a Meningeal Patch | To fetoscopically use cryopreserved human umbilical cord allografts, named NEOX Cord 1K®, as a spinal cord cover of spina bifida defects. This procedure will be performed to create a watertight seal covering over the spinal cord in order to decrease the incidence rates of postnatal morbidities. For larger skin defects, NEOX Cord 1K® may be used as a skin cover.","[(0, 30, 'SURGICAL', 'Fetoscopic Spina Bifida Repair'), (39, 83, 'SURGICAL', 'Cryopreserved Human Umbilical Cord Allograft'), (85, 97, 'SURGICAL', 'NEOX Cord 1K'), (145, 191, 'SURGICAL', 'cryopreserved human umbilical cord allografts,'), (198, 210, 'SURGICAL', 'NEOX Cord 1K'), (239, 251, 'CONDITION', 'spina bifida'), (430, 442, 'CONDITION', 'skin defects'), (444, 456, 'SURGICAL', 'NEOX Cord 1K')]"
"['Effects', 'of', 'Exercise', 'Training', 'on', 'Learning', 'and', 'Memory', 'Outcomes', 'in', 'Multiple', 'Sclerosis', '|', 'The', 'two', 'primary', 'study', 'objectives', 'involve', 'examining', 'the', 'effects', 'of', 'treadmill', 'walking', 'exercise', 'training', 'versus', 'stretching', '-', 'and', '-', 'toning', 'activities', 'on', 'the', 'primary', 'and', 'secondary', 'outcomes', '.', '\n\n', 'Specific', 'Aim', '1', ':', 'The', 'first', 'specific', 'aim', 'is', 'to', 'examine', 'the', 'effects', 'of', '3', '-', 'months', 'of', 'treadmill', 'walking', 'exercise', 'training', 'compared', 'with', 'an', 'active', 'control', 'condition', 'on', 'learning', 'and', 'memory', 'outcomes', 'in', 'fully', '-', 'ambulatory', 'persons', 'with', 'MS', 'who', 'have', 'impairment', 'in', 'learning', 'new', 'information', '.', 'We', 'hypothesize', 'that', 'those', 'who', 'undergo', 'treadmill', 'walking', 'exercise', 'training', 'will', 'demonstrate', 'improvements', 'in', 'learning', 'and', 'memory', 'relative', 'to', 'those', 'who', 'undergo', 'stretching', '-', 'and', '-', 'toning', 'activities', '.', '\n\n', 'Specific', 'Aim', '2', ':', 'The', 'second', 'specific', 'aim', 'is', 'to', 'examine', 'the', 'effects', 'of', '3', '-', 'months', 'of', 'treadmill', 'walking', 'exercise', 'training', 'compared', 'with', 'an', 'active', 'control', 'condition', 'on', 'hippocampal', 'volume', ',', 'hippocampal', 'resting', '-', 'state', 'functional', 'connectivity', ',', 'and', 'cardiorespiratory', 'fitness', 'in', 'those', 'persons', 'with', 'MS', '.', 'We', 'hypothesize', 'that', 'those', 'who', 'are', 'randomly', 'assigned', 'to', 'the', 'treadmill', 'walking', 'exercise', 'condition', 'will', 'demonstrate', 'increases', 'in', 'hippocampal', 'volume', 'and', 'resting', '-', 'state', 'functional', 'connectivity', '(', 'i.e.', ',', 'adaptive', 'increases', ')', 'and', 'improved', 'cardiorespiratory', 'fitness', 'relative', 'to', 'those', 'in', 'the', 'stretching', '-', 'and', '-', 'toning', 'condition', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'O']",NCT03319771,NCT03319771,"Effects of Exercise Training on Learning and Memory Outcomes in Multiple Sclerosis | The two primary study objectives involve examining the effects of treadmill walking exercise training versus stretching-and-toning activities on the primary and secondary outcomes.

Specific Aim 1: The first specific aim is to examine the effects of 3-months of treadmill walking exercise training compared with an active control condition on learning and memory outcomes in fully-ambulatory persons with MS who have impairment in learning new information. We hypothesize that those who undergo treadmill walking exercise training will demonstrate improvements in learning and memory relative to those who undergo stretching-and-toning activities.

Specific Aim 2: The second specific aim is to examine the effects of 3-months of treadmill walking exercise training compared with an active control condition on hippocampal volume, hippocampal resting-state functional connectivity, and cardiorespiratory fitness in those persons with MS. We hypothesize that those who are randomly assigned to the treadmill walking exercise condition will demonstrate increases in hippocampal volume and resting-state functional connectivity (i.e., adaptive increases) and improved cardiorespiratory fitness relative to those in the stretching-and-toning condition.","[(11, 28, 'PHYSICAL', 'Exercise Training'), (64, 82, 'CONDITION', 'Multiple Sclerosis'), (151, 177, 'PHYSICAL', 'treadmill walking exercise'), (194, 226, 'CONTROL', 'stretching-and-toning activities'), (347, 373, 'PHYSICAL', 'treadmill walking exercise'), (400, 414, 'CONTROL', 'active control'), (490, 492, 'CONDITION', 'MS'), (580, 606, 'PHYSICAL', 'treadmill walking exercise'), (699, 731, 'CONTROL', 'stretching-and-toning activities'), (815, 841, 'PHYSICAL', 'treadmill walking exercise'), (868, 882, 'CONTROL', 'active control'), (1019, 1021, 'CONDITION', 'MS'), (1082, 1108, 'PHYSICAL', 'treadmill walking exercise'), (1301, 1322, 'CONTROL', 'stretching-and-toning')]"
"['A', 'Multicenter', ',', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', 'Study', 'Evaluating', 'the', 'Safety', 'and', 'Efficacy', 'of', 'Fixed', '-', 'Dose', 'Once', '-', 'weekly', 'Oral', 'Aripiprazole', 'in', 'Children', 'and', 'Adolescents', 'With', 'Tourette', ""'s"", 'Disorder', '|', 'The', 'goal', 'of', 'the', 'current', 'trial', 'is', 'to', 'determine', 'efficacy', 'and', 'safety', 'of', 'once', '-', 'weekly', 'aripiprazole', 'in', 'reducing', 'Total', 'Tic', 'Severity', '(', 'TTS', ')', 'score', 'in', 'children', 'and', 'adolescents', 'with', 'Tourette', ""'s"", 'Disorder', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT01418352,NCT01418352,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder | The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.","[(41, 48, 'CONTROL', 'Placebo'), (132, 144, 'DRUG', 'Aripiprazole'), (178, 197, 'CONDITION', ""Tourette's Disorder""), (281, 293, 'DRUG', 'aripiprazole'), (370, 389, 'CONDITION', ""Tourette's Disorder"")]"
"['Effect', 'of', 'Inspiratory', 'Muscle', 'Training', '(', 'IMT', ')', 'on', 'Breathing', ',', 'Balance', ',', 'and', 'Blood', 'Pressure', 'Maintenance', 'in', 'Spinal', 'Cord', 'Injury', '(', 'SCI', ')', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'help', 'understand', 'how', 'training', 'breathing', 'muscles', 'will', 'impact', 'balance', ',', 'blood', 'pressure', ',', 'and', 'quality', 'of', 'life', 'of', 'participants', 'with', 'spinal', 'cord', 'injury', '.']","['O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'B-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-PHYS', 'I-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT04210063,NCT04210063,"Effect of Inspiratory Muscle Training (IMT) on Breathing, Balance, and Blood Pressure Maintenance in Spinal Cord Injury (SCI) | The purpose of this study is to help understand how training breathing muscles will impact balance, blood pressure, and quality of life of participants with spinal cord injury.","[(10, 37, 'PHYSICAL', 'Inspiratory Muscle Training'), (39, 42, 'PHYSICAL', 'IMT'), (101, 119, 'CONDITION', 'Spinal Cord Injury'), (121, 124, 'CONDITION', 'SCI'), (180, 206, 'PHYSICAL', 'training breathing muscles'), (285, 303, 'CONDITION', 'spinal cord injury')]"
"['The', 'Effect', 'of', 'Functional', 'Electrical', 'Stimulation', 'and', 'Therapeutic', 'Exercise', 'on', 'Functional', 'Properties', 'of', 'Skeletal', 'Muscles', ',', 'Sitting', 'Postural', 'Stability', 'and', 'Quality', 'of', 'Life', 'in', 'Traumatic', 'Spinal', 'Cord', 'Injury', 'Patients', '|', 'Aim', 'of', 'the', 'current', 'study', 'is', 'to', 'evaluate', 'the', 'effect', 'functional', 'electrical', 'stimulation', 'and', 'therapeutic', 'exercise', 'on', 'traumatic', 'spinal', 'cord', 'injured', ""participants'skeletal"", 'muscle', 'characteristics', ',', 'sitting', 'balance', ',', 'lung', 'function', 'and', 'quality', 'of', 'life', '.']","['O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-PHYS', 'I-PHYS', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03517787,NCT03517787,"The Effect of Functional Electrical Stimulation and Therapeutic Exercise on Functional Properties of Skeletal Muscles, Sitting Postural Stability and Quality of Life in Traumatic Spinal Cord Injury Patients | Aim of the current study is to evaluate the effect functional electrical stimulation and therapeutic exercise on traumatic spinal cord injured participants'skeletal muscle characteristics, sitting balance, lung function and quality of life.","[(14, 47, 'OTHER', 'Functional Electrical Stimulation'), (52, 72, 'PHYSICAL', 'Therapeutic Exercise'), (169, 197, 'CONDITION', 'Traumatic Spinal Cord Injury'), (260, 293, 'OTHER', 'functional electrical stimulation'), (298, 318, 'PHYSICAL', 'therapeutic exercise'), (322, 351, 'CONDITION', 'traumatic spinal cord injured')]"
"['Neural', 'Signatures', 'of', 'Tremor', ',', 'Bradykinesia', 'and', 'Freezing', 'in', 'the', 'Subthalamic', 'Region', 'on', 'Parkinson', ""'s"", 'Disease', 'and', 'Their', 'Acute', 'and', 'Long', '-', 'Term', 'Modulation', 'by', 'Subthalamic', 'Deep', 'Brain', 'Stimulation', '.', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'provide', 'objective', 'measurements', 'of', 'abnormal', 'movements', 'of', 'the', 'body', 'in', 'correlation', 'with', 'neural', 'activity', 'of', 'the', 'brain', 'and', 'track', 'how', 'these', 'change', 'over', 'time', '.', 'This', 'may', 'allow', 'for', 'the', 'development', 'of', 'objective', 'evaluation', 'of', 'the', 'neural', 'activity', 'causing', 'abnormal', 'movements', ',', 'which', 'may', 'lead', 'to', 'the', 'ability', 'of', 'the', 'DBS', 'system', 'to', 'stimulate', 'the', 'brain', 'by', 'sensing', 'the', 'abnormal', 'neural', 'activity', 'that', 'is', 'causing', 'abnormal', 'movements', '.']","['O', 'O', 'O', 'B-COND', 'O', 'B-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01990313,NCT01990313,"Neural Signatures of Tremor, Bradykinesia and Freezing in the Subthalamic Region on Parkinson's Disease and Their Acute and Long-Term Modulation by Subthalamic Deep Brain Stimulation. | The purpose of this study is to provide objective measurements of abnormal movements of the body in correlation with neural activity of the brain and track how these change over time. This may allow for the development of objective evaluation of the neural activity causing abnormal movements, which may lead to the ability of the DBS system to stimulate the brain by sensing the abnormal neural activity that is causing abnormal movements.","[(21, 27, 'CONDITION', 'Tremor'), (29, 41, 'CONDITION', 'Bradykinesia'), (46, 80, 'CONDITION', 'Freezing in the Subthalamic Region'), (84, 103, 'CONDITION', ""Parkinson's Disease""), (160, 182, 'OTHER', 'Deep Brain Stimulation'), (517, 520, 'OTHER', 'DBS')]"
"['A', 'Randomized', 'Evaluation', 'of', 'Short', 'Term', 'and', 'Long', 'Term', 'Outcome', 'After', 'Endovascular', 'Repair', 'by', 'Stenting', 'of', 'Carotid', 'Artery', 'Stenosis', 'in', 'Patients', 'With', 'Severe', '(', '70', '%', 'and', 'Higher', ')', 'Asymptomatic', 'Carotid', 'Stenosis', '|', 'Purpose', 'of', 'this', 'study', ':', '\n\n', 'Primary', ':', '\n\n', '•', 'Comparison', 'of', 'cardiovascular', 'mortality', 'and', 'morbidity', 'which', 'includes', 'cardiac', 'and', 'neurological', 'morbidity', '(', 'TIA', 'and', 'CVA', ')', 'in', 'the', 'two', 'invasive', 'treatments', 'of', 'asymptomatic', 'carotid', 'artery', 'stenosis', '\n\n', 'Secondary', ':', '\n\n', 'Comparison', 'of', 'non', 'cardiovascular', 'morbidity', 'caused', 'by', 'the', 'two', 'invasive', 'techniques', '\n\n', 'morbidity', 'at', 'the', 'site', 'of', 'incision', '(', 'infection', 'or', 'local', 'hematoma', ')', '\n', 'damage', 'to', 'cranial', 'nerves', '(', 'hypoglossus', ',', 'vagus', ')', '\n', 'brain', 'hyperperfusion', 'which', 'is', 'defined', 'as', 'severe', 'headache', 'which', 'is', 'not', 'responsive', 'to', 'analgesics', 'with', 'or', 'without', 'nausea', 'and', 'vomiting', '.', '\n', 'events', 'of', 'bradycardia', 'within', 'the', 'first', '24', 'hours', ',', 'clinically', 'evident', 'and/or', 'silent', '\n', 'microembolic', 'brain', 'events', 'immediately', 'after', 'the', 'procedure', 'and', 'their', 'relationship', 'with', 'morbidity', 'and/or', 'mortality', 'due', 'to', 'TIA', ""'s"", 'or', 'CVA', ""'s"", '\n', 'the', 'change', 'in', 'the', 'stenotic', 'carotid', 'artery', 'at', 'the', 'time', 'of', 'follow', 'up', 'with', 'duplex', 'of', 'neck', 'arteries', '\n', 'the', 'comparison', 'of', 'the', 'affect', 'of', 'the', 'two', 'procedures', 'on', 'patient', 'life', 'style']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-SURG', 'I-SURG', 'I-SURG', 'I-SURG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00772278,NCT00772278,"A Randomized Evaluation of Short Term and Long Term Outcome After Endovascular Repair by Stenting of Carotid Artery Stenosis in Patients With Severe (70% and Higher) Asymptomatic Carotid Stenosis | Purpose of this study:

Primary:

• Comparison of cardiovascular mortality and morbidity which includes cardiac and neurological morbidity (TIA and CVA) in the two invasive treatments of asymptomatic carotid artery stenosis

Secondary:

Comparison of non cardiovascular morbidity caused by the two invasive techniques

morbidity at the site of incision (infection or local hematoma)
damage to cranial nerves (hypoglossus, vagus)
brain hyperperfusion which is defined as severe headache which is not responsive to analgesics with or without nausea and vomiting.
events of bradycardia within the first 24 hours, clinically evident and/or silent
microembolic brain events immediately after the procedure and their relationship with morbidity and/or mortality due to TIA's or CVA's
the change in the stenotic carotid artery at the time of follow up with duplex of neck arteries
the comparison of the affect of the two procedures on patient life style","[(66, 97, 'SURGICAL', 'Endovascular Repair by Stenting'), (101, 124, 'CONDITION', 'Carotid Artery Stenosis'), (142, 195, 'CONDITION', 'Severe (70% and Higher) Asymptomatic Carotid Stenosis'), (385, 421, 'CONDITION', 'asymptomatic carotid artery stenosis')]"
"['A', 'Randomized', ',', 'Double', '-', 'blind', ',', 'Placebo', '-', 'controlled', ',', 'Parallel', '-', 'group', ',', 'Dose', '-', 'response', 'Study', 'to', 'Evaluate', 'the', 'Efficacy', 'and', 'Safety', 'of', '3', 'Fixed', 'Doses', '(', '25', 'mg', 'eq', ',', '50', 'mg', 'eq', ',', 'and', '100', 'mg', 'eq', ')', 'of', 'Paliperidone', 'Palmitate', 'in', 'Patients', 'With', 'Schizophrenia', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'the', 'efficacy', '(', 'how', 'well', 'the', 'drug', 'works', ')', ',', 'safety', ',', 'and', 'side', 'effects', 'of', 'paliperidone', 'palmitate', 'compared', 'to', 'placebo', 'in', 'the', 'treatment', 'of', 'the', 'symptoms', 'of', 'schizophrenia', 'in', 'adults', '.', 'The', 'placebo', 'used', 'in', 'this', 'study', 'was', 'a', 'nutritional', 'substance', 'known', 'as', '20', '%', 'Intralipid', 'emulsion', 'given', 'to', 'patients', 'requiring', 'intravenous', 'feedings', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'I-DRUG', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'I-CTRL', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT00101634,NCT00101634,"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia | The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.","[(28, 35, 'CONTROL', 'Placebo'), (176, 198, 'DRUG', 'Paliperidone Palmitate'), (216, 229, 'CONDITION', 'Schizophrenia'), (342, 364, 'DRUG', 'paliperidone palmitate'), (377, 384, 'CONTROL', 'placebo'), (421, 434, 'CONDITION', 'schizophrenia'), (450, 457, 'CONTROL', 'placebo'), (518, 537, 'CONTROL', 'Intralipid emulsion')]"
"['Effect', 'of', 'Technological', 'Processes', 'on', 'Nutritional', 'Quality', 'of', 'Meat', 'Proteins', '|', 'This', 'project', 'aims', 'to', 'assess', 'the', 'impact', 'of', 'technological', 'processes', 'of', 'meat', ',', 'as', 'cooking', 'conditions', ',', 'on', 'amino', 'acid', 'bioavailability', 'and', 'protein', 'metabolism', '.', 'The', 'hypothesis', 'is', 'that', ',', 'even', 'if', 'meat', 'is', 'considered', 'as', 'a', 'good', 'provider', 'of', 'fast', 'proteins', 'and', 'so', 'could', 'be', 'useful', 'to', 'prevent', 'sarcopenia', 'in', 'aged', 'people', ',', 'the', 'manner', 'it', 'is', 'cooked', 'can', 'change', 'its', 'digestion', 'rate', 'and', 'amino', 'acids', 'bioavailability', 'for', 'muscle', 'synthesis', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT02157805,NCT02157805,"Effect of Technological Processes on Nutritional Quality of Meat Proteins | This project aims to assess the impact of technological processes of meat, as cooking conditions, on amino acid bioavailability and protein metabolism. The hypothesis is that, even if meat is considered as a good provider of fast proteins and so could be useful to prevent sarcopenia in aged people, the manner it is cooked can change its digestion rate and amino acids bioavailability for muscle synthesis.","[(10, 73, 'OTHER', 'Technological Processes on Nutritional Quality of Meat Proteins'), (118, 149, 'OTHER', 'technological processes of meat'), (349, 359, 'CONDITION', 'sarcopenia')]"
"['Effect', 'of', 'Duloxetine', '30/60', 'mg', 'Once', 'Daily', 'Versus', 'Placebo', 'in', 'Adolescents', 'With', 'Juvenile', 'Primary', 'Fibromyalgia', 'Syndrome', '|', 'The', 'purpose', 'of', 'this', 'study', 'is', 'to', 'determine', 'whether', 'duloxetine', 'is', 'safe', 'and', 'effective', 'in', 'the', 'treatment', 'of', 'adolescents', 'with', 'Juvenile', 'Primary', 'Fibromyalgia', 'Syndrome', '(', 'JPFS', ')', '.', '\n\n', 'This', 'trial', 'consists', 'of', 'two', 'distinct', 'study', 'periods', '.', 'A', 'blinded', 'treatment', 'period', 'of', '13', 'weeks', 'and', 'an', 'open', 'label', 'extension', 'period', 'of', '26', 'weeks', '.']","['O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-CTRL', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01237587,NCT01237587,"Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome | The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS).

This trial consists of two distinct study periods. A blinded treatment period of 13 weeks and an open label extension period of 26 weeks.","[(10, 20, 'DRUG', 'Duloxetine'), (48, 55, 'CONTROL', 'Placebo'), (76, 114, 'CONDITION', 'Juvenile Primary Fibromyalgia Syndrome'), (167, 177, 'DRUG', 'duloxetine'), (237, 275, 'CONDITION', 'Juvenile Primary Fibromyalgia Syndrome'), (277, 281, 'CONDITION', 'JPFS')]"
"['Effect', 'of', 'Unimodal', '(', 'EEG', ')', 'and', 'Bimodal', '(', 'EEG', '-', 'fMRI', ')', 'Neurofeedback', 'on', 'Upper', 'Limb', 'Recovery', 'After', 'Stroke', '|', 'Interventional', 'study', 'with', 'minimal', 'risks', 'and', 'constraints', ',', 'prospective', ',', 'monocentric', '.']","['O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT03766113,NCT03766113,"Effect of Unimodal (EEG) and Bimodal (EEG-fMRI) Neurofeedback on Upper Limb Recovery After Stroke | Interventional study with minimal risks and constraints, prospective, monocentric.","[(10, 61, 'OTHER', 'Unimodal (EEG) and Bimodal (EEG-fMRI) Neurofeedback'), (85, 97, 'CONDITION', 'After Stroke')]"
"['Two', '-', 'phase', 'Randomized', 'Controlled', 'Trial', 'of', 'Low', 'and', 'Moderate', 'Dose', 'Methylphenidate', 'for', 'Non', '-', 'motor', 'and', 'Postural', 'Symptoms', 'in', 'Parkinson', ""'s"", 'Disease', '.', '|', 'This', 'project', 'aims', 'to', 'determine', 'if', 'methylphenidate', 'can', 'improve', 'deficits', 'in', 'attention', 'and', 'symptoms', 'of', 'orthostatic', 'hypotension', ',', 'two', 'common', 'non', '-', 'motor', 'symptoms', ',', 'in', 'patients', 'with', 'Parkinson', ""'s"", 'Disease', '.', 'This', 'project', 'also', 'seeks', 'to', 'evaluate', 'the', 'effect', 'of', 'methylphenidate', 'on', 'postural', 'control', 'in', 'these', 'patients', ',', 'a', 'debilitating', 'motor', 'symptom', 'that', 'places', 'patients', 'at', 'an', 'increased', 'risk', 'of', 'falling', '.', 'This', 'study', 'will', 'build', 'on', 'existing', 'data', 'to', 'support', 'a', 'new', 'indication', 'for', 'the', 'use', 'of', 'methylphenidate', 'in', 'Parkinson', ""'s"", 'Disease', '.', 'Using', 'standard', 'and', 'objective', 'evaluations', ',', 'this', 'study', 'will', 'quantify', 'the', 'effect', 'of', 'methylphenidate', 'at', 'two', 'doses', 'on', 'attention', 'levels', ',', 'orthostatic', 'hypotension', ',', 'and', 'measures', 'of', 'postural', 'control', '.', 'Phase', 'I', 'of', 'the', 'study', 'will', 'compare', 'methylphenidate', '10', 'mg', 'three', 'times', 'daily', 'to', 'placebo', 'and', 'Phase', 'II', 'of', 'the', 'study', ',', 'for', 'those', 'tolerating', 'the', 'lower', 'dose', 'in', 'Phase', 'I', ',', 'will', 'compare', 'methylphenidate', '20', 'mg', 'three', 'times', 'daily', 'to', 'placebo', '.', 'By', 'incorporating', 'two', 'different', 'doses', ',', 'the', 'study', 'also', 'seeks', 'to', 'determine', 'if', 'any', 'improvements', 'are', 'dose', '-', 'related', '.', 'Secondary', 'endpoints', 'will', 'include', 'safety', 'assessments', '(', 'adverse', 'event', 'monitoring', 'and', 'vital', 'signs', ')', 'performed', 'every', '30', 'minutes', 'following', 'supervised', 'drug', 'administration', '.', 'Visual', 'analog', 'scales', 'will', 'be', 'presented', 'to', 'each', 'participant', 'before', 'treatment', 'and', 'following', 'the', 'final', 'dose', 'of', 'each', 'treatment', 'to', 'assess', 'changes', 'in', 'fatigue', '.', 'A', 'secondary', 'task', 'will', 'be', 'added', 'to', 'postural', 'tests', 'to', 'assess', 'the', 'influence', 'of', 'cognitive', 'processes', '.', 'It', 'is', 'hypothesized', 'that', 'methylphenidate', 'will', 'demonstrate', 'a', 'significant', 'beneficial', 'effect', 'on', 'all', 'outcomes', '.', 'It', 'is', 'projected', 'that', 'objective', 'improvements', 'will', 'be', 'observed', 'following', 'treatment', 'with', 'methylphenidate', 'at', 'both', 'doses', '(', '10', 'and', '20', 'mg', 'three', 'time', 'daily', ')', 'when', 'compared', 'to', 'placebo', '.', 'It', 'is', 'further', 'hypothesized', 'that', 'the', 'effects', 'will', 'be', 'dose', '-', 'related', 'and', 'therefore', 'more', 'profound', 'with', 'higher', 'doses', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O']",NCT01244269,NCT01244269,"Two-phase Randomized Controlled Trial of Low and Moderate Dose Methylphenidate for Non-motor and Postural Symptoms in Parkinson's Disease. | This project aims to determine if methylphenidate can improve deficits in attention and symptoms of orthostatic hypotension, two common non-motor symptoms, in patients with Parkinson's Disease. This project also seeks to evaluate the effect of methylphenidate on postural control in these patients, a debilitating motor symptom that places patients at an increased risk of falling. This study will build on existing data to support a new indication for the use of methylphenidate in Parkinson's Disease. Using standard and objective evaluations, this study will quantify the effect of methylphenidate at two doses on attention levels, orthostatic hypotension, and measures of postural control. Phase I of the study will compare methylphenidate 10mg three times daily to placebo and Phase II of the study, for those tolerating the lower dose in Phase I, will compare methylphenidate 20mg three times daily to placebo. By incorporating two different doses, the study also seeks to determine if any improvements are dose-related. Secondary endpoints will include safety assessments (adverse event monitoring and vital signs) performed every 30 minutes following supervised drug administration. Visual analog scales will be presented to each participant before treatment and following the final dose of each treatment to assess changes in fatigue. A secondary task will be added to postural tests to assess the influence of cognitive processes. It is hypothesized that methylphenidate will demonstrate a significant beneficial effect on all outcomes. It is projected that objective improvements will be observed following treatment with methylphenidate at both doses (10 and 20mg three time daily) when compared to placebo. It is further hypothesized that the effects will be dose-related and therefore more profound with higher doses.","[(63, 78, 'DRUG', 'Methylphenidate'), (97, 114, 'CONDITION', 'Postural Symptoms'), (118, 137, 'CONDITION', ""Parkinson's Disease""), (175, 190, 'DRUG', 'methylphenidate'), (203, 224, 'CONDITION', 'deficits in attention'), (241, 264, 'CONDITION', 'orthostatic hypotension'), (314, 333, 'CONDITION', ""Parkinson's Disease""), (385, 400, 'DRUG', 'methylphenidate'), (605, 620, 'DRUG', 'methylphenidate'), (624, 643, 'CONDITION', ""Parkinson's Disease""), (726, 741, 'DRUG', 'methylphenidate'), (776, 799, 'CONDITION', 'orthostatic hypotension'), (869, 884, 'DRUG', 'methylphenidate'), (911, 918, 'OTHER', 'placebo'), (1007, 1022, 'DRUG', 'methylphenidate'), (1049, 1056, 'OTHER', 'placebo'), (1606, 1621, 'DRUG', 'methylphenidate'), (1774, 1789, 'DRUG', 'methylphenidate'), (1852, 1859, 'OTHER', 'placebo')]"
"['Drug', 'Eluting', 'Stenting', 'and', 'Aggressive', 'Medical', 'Treatment', 'for', 'Preventing', 'Recurrent', 'Stroke', 'in', 'Intracranial', 'Atherosclerotic', 'Disease', 'Trial', ':', 'a', 'Prospective', ',', 'Randomized', ',', 'Open', '-', 'labelled', ',', 'Blinded', 'End', '-', 'point', 'Trial', '(', 'DREAM', '-', 'PRIDE', ')', '|', 'The', 'aim', 'of', 'DREAM', '-', 'PRIDE', 'is', 'to', 'evaluate', 'whether', 'implantation', 'of', 'drug', '-', 'eluting', 'stent', '(', 'DES', ')', 'combined', 'with', 'aggressive', 'medical', 'treatment', 'is', 'more', 'efficacious', 'in', 'prevention', 'of', '1', '-', 'year', 'stroke', 'recurrence', 'than', 'standard', 'medical', 'treatment', 'alone', 'for', 'symptomatic', 'intracranial', 'atherosclerotic', 'disease', '.']","['B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'B-COND', 'I-COND', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'B-OTHER', 'O', 'O', 'O', 'B-OTHER', 'I-OTHER', 'I-OTHER', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'O', 'O', 'B-CTRL', 'I-CTRL', 'I-CTRL', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04948749,NCT04948749,"Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial: a Prospective, Randomized, Open-labelled, Blinded End-point Trial (DREAM-PRIDE) | The aim of DREAM-PRIDE is to evaluate whether implantation of drug-eluting stent (DES) combined with aggressive medical treatment is more efficacious in prevention of 1-year stroke recurrence than standard medical treatment alone for symptomatic intracranial atherosclerotic disease.","[(0, 21, 'OTHER', 'Drug Eluting Stenting'), (26, 54, 'OTHER', 'Aggressive Medical Treatment'), (70, 86, 'CONDITION', 'Recurrent Stroke'), (90, 126, 'CONDITION', 'Intracranial Atherosclerotic Disease'), (278, 296, 'OTHER', 'drug-eluting stent'), (298, 301, 'OTHER', 'DES'), (317, 345, 'OTHER', 'aggressive medical treatment'), (390, 407, 'CONDITION', 'stroke recurrence'), (422, 445, 'CONTROL', 'medical treatment alone'), (450, 498, 'CONDITION', 'symptomatic intracranial atherosclerotic disease')]"
"['Phase', 'I', '/', 'II', 'Trial', 'of', 'Dasatinib', '(', 'Sprycel', ')', 'With', 'Radiation', 'Therapy', 'and', 'Concomitant', 'and', 'Adjuvant', 'Temozolomide', 'in', 'Patients', 'With', 'Newly', '-', 'Diagnosed', 'Glioblastoma', '|', 'Phase', 'I', ':', '\n\n', 'Primary', 'Objectives', ':', '\n\n', '-To', 'define', 'the', 'maximum', 'tolerated', 'dose', '(', 'MTD', ')', 'of', 'dasatinib', '(', 'Sprycel', ')', 'with', 'radiotherapy', '(', 'RT', ')', 'and', '6', 'weeks', 'of', 'concomitant', 'temozolomide', '(', 'TMZ', ')', 'administered', 'at', '75', 'mg', '/', 'm^2', '/', 'day', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'glioblastoma', '(', 'GBM', ')', '.', '\n\n', 'Secondary', 'Objectives', ':', '\n\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'radiotherapy', '(', 'RT', ')', 'and', 'concomitant', 'TMZ', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'GBM', '.', '\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'adjuvant', 'TMZ', 'in', 'patients', 'with', 'glioblastoma', 'after', 'RT', '.', '\n\n', 'STUDY', 'DID', 'NOT', 'PROGRESS', 'TO', 'PHASE', 'II', 'PORTION', '.', '\n\n', 'Phase', 'II', ':', '\n\n', 'Primary', 'Objectives', ':', '\n\n', '-To', 'determine', 'the', 'effectiveness', 'of', 'dasatinib', '(', 'Sprycel', ')', 'with', 'radiotherapy', '(', 'RT', ')', 'and', '6', 'weeks', 'of', 'concomitant', 'temozolomide', '(', 'TMZ', ')', 'administered', 'at', '75', 'mg', '/', 'm^2', '/', 'day', 'followed', 'by', 'adjuvant', 'temozolomide', 'with', 'concurrent', 'dasatinib', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'glioblastoma', '(', 'GBM', ')', 'as', 'measured', 'by', 'overall', 'survival', '.', '\n\n', 'Secondary', 'Objectives', ':', '\n\n', 'To', 'determine', 'the', 'efficacy', 'of', 'this', 'treatment', 'as', 'measured', 'by', 'radiographic', 'response', '(', 'RR', ')', ',', 'progression', '-', 'free', 'survival', '(', 'PFS', ')', 'and', 'time', 'to', 'progression', '(', 'TTP', ')', '.', '\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'RT', 'and', 'concomitant', 'TMZ', 'in', 'patients', 'with', 'newly', '-', 'diagnosed', 'GBM', '.', '\n', 'To', 'characterize', 'the', 'safety', 'profile', 'of', 'dasatinib', '(', 'Sprycel', ')', 'in', 'combination', 'with', 'adjuvant', 'TMZ', 'in', 'patients', 'with', 'GBM', 'after', 'RT', '.', '\n\n', 'Exploratory', 'Objectives', ':', '\n\n', '-To', 'correlate', 'tumor', 'genotype', ',', 'tumor', 'expression', 'of', 'dasatinib', 'target', 'proteins', '(', 'e.g.', 'Src', ',', 'EphA2', ',', 'c', '-', 'kit', 'and', 'PDGFR', ')', ',', 'and', 'PTEN', 'levels', 'with', 'response', 'to', 'therapy', 'with', 'dasatinib', 'and', 'temozolomide', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-RADIO', 'I-RADIO', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'B-RADIO', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'B-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-RADIO', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'B-COND', 'O', 'B-RADIO', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'O', 'O', 'B-COND', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'B-DRUG', 'O']",NCT00895960,NCT00895960,"Phase I/II Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma | Phase I:

Primary Objectives:

-To define the maximum tolerated dose (MTD) of dasatinib (Sprycel) with radiotherapy (RT) and 6 weeks of concomitant temozolomide (TMZ) administered at 75 mg/m^2/day in patients with newly-diagnosed glioblastoma (GBM).

Secondary Objectives:

To characterize the safety profile of dasatinib (Sprycel) in combination with radiotherapy (RT) and concomitant TMZ in patients with newly-diagnosed GBM.
To characterize the safety profile of dasatinib (Sprycel) in combination with adjuvant TMZ in patients with glioblastoma after RT.

STUDY DID NOT PROGRESS TO PHASE II PORTION.

Phase II:

Primary Objectives:

-To determine the effectiveness of dasatinib (Sprycel) with radiotherapy (RT) and 6 weeks of concomitant temozolomide (TMZ) administered at 75 mg/m^2/day followed by adjuvant temozolomide with concurrent dasatinib in patients with newly-diagnosed glioblastoma (GBM) as measured by overall survival.

Secondary Objectives:

To determine the efficacy of this treatment as measured by radiographic response (RR), progression-free survival (PFS) and time to progression (TTP).
To characterize the safety profile of dasatinib (Sprycel) in combination with RT and concomitant TMZ in patients with newly-diagnosed GBM.
To characterize the safety profile of dasatinib (Sprycel) in combination with adjuvant TMZ in patients with GBM after RT.

Exploratory Objectives:

-To correlate tumor genotype, tumor expression of dasatinib target proteins (e.g. Src, EphA2, c-kit and PDGFR), and PTEN levels with response to therapy with dasatinib and temozolomide.","[(20, 29, 'DRUG', 'Dasatinib'), (31, 38, 'DRUG', 'Sprycel'), (45, 62, 'RADIOTHERAPY', 'Radiation Therapy'), (92, 104, 'DRUG', 'Temozolomide'), (122, 150, 'CONDITION', 'Newly-Diagnosed Glioblastoma'), (231, 240, 'DRUG', 'dasatinib'), (242, 249, 'DRUG', 'Sprycel'), (256, 268, 'RADIOTHERAPY', 'radiotherapy'), (270, 272, 'RADIOTHERAPY', 'RT'), (301, 313, 'DRUG', 'temozolomide'), (315, 318, 'DRUG', 'TMZ'), (367, 395, 'CONDITION', 'newly-diagnosed glioblastoma'), (397, 400, 'CONDITION', 'GBM'), (465, 474, 'DRUG', 'dasatinib'), (476, 483, 'DRUG', 'Sprycel'), (505, 517, 'RADIOTHERAPY', 'radiotherapy'), (519, 521, 'RADIOTHERAPY', 'RT'), (539, 542, 'DRUG', 'TMZ'), (560, 579, 'CONDITION', 'newly-diagnosed GBM'), (619, 628, 'DRUG', 'dasatinib'), (630, 637, 'DRUG', 'Sprycel'), (668, 671, 'DRUG', 'TMZ'), (689, 701, 'CONDITION', 'glioblastoma'), (708, 710, 'RADIOTHERAPY', 'RT'), (825, 834, 'DRUG', 'dasatinib'), (836, 843, 'DRUG', 'Sprycel'), (850, 862, 'RADIOTHERAPY', 'radiotherapy'), (864, 866, 'RADIOTHERAPY', 'RT'), (895, 907, 'DRUG', 'temozolomide'), (909, 912, 'DRUG', 'TMZ'), (965, 977, 'DRUG', 'temozolomide'), (994, 1003, 'DRUG', 'dasatinib'), (1021, 1049, 'CONDITION', 'newly-diagnosed glioblastoma'), (1051, 1054, 'CONDITION', 'GBM'), (1301, 1310, 'DRUG', 'dasatinib'), (1312, 1319, 'DRUG', 'Sprycel'), (1341, 1343, 'RADIOTHERAPY', 'RT'), (1360, 1363, 'DRUG', 'TMZ'), (1381, 1400, 'CONDITION', 'newly-diagnosed GBM'), (1440, 1449, 'DRUG', 'dasatinib'), (1451, 1458, 'DRUG', 'Sprycel'), (1489, 1492, 'DRUG', 'TMZ'), (1510, 1513, 'CONDITION', 'GBM'), (1520, 1522, 'RADIOTHERAPY', 'RT'), (1564, 1569, 'CONDITION', 'tumor'), (1580, 1585, 'CONDITION', 'tumor'), (1600, 1609, 'DRUG', 'dasatinib'), (1708, 1717, 'DRUG', 'dasatinib'), (1722, 1734, 'DRUG', 'temozolomide')]"
"['A', 'Phase', 'I', 'Clinical', 'Trial', 'of', 'BAT4406F', 'Injection', 'on', 'the', 'Safety', ',', 'Tolerability', ',', 'and', 'Pharmacokinetics', 'in', 'Patients', 'With', 'Neuromyelitis', 'Optica', 'Spectrum', 'Disorders', '|', 'This', 'study', 'is', 'a', 'phase', 'I', 'clinical', 'study', 'of', 'the', 'safety', ',', 'tolerability', ',', 'and', 'pharmacokinetics', 'of', 'BAT4406F', 'injection', 'in', 'patients', 'with', 'neuromyelitis', 'optica', 'spectrum', 'disorders', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'I-COND', 'O']",NCT04146285,NCT04146285,"A Phase I Clinical Trial of BAT4406F Injection on the Safety, Tolerability, and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders | This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.","[(28, 36, 'DRUG', 'BAT4406F'), (114, 153, 'CONDITION', 'Neuromyelitis Optica Spectrum Disorders'), (248, 256, 'DRUG', 'BAT4406F'), (284, 323, 'CONDITION', 'neuromyelitis optica spectrum disorders')]"
"['A', '12', '-', 'month', 'Open', '-', 'label', 'Extension', 'Study', 'Evaluating', 'The', 'Safety', 'And', 'Tolerability', 'Of', 'Flexible', 'Doses', 'Of', 'Pregabalin', 'In', 'Pediatric', 'Patients', 'With', 'Partial', 'Onset', 'Seizures', '|', 'The', 'study', 'will', 'evaluate', 'the', 'long', '-', 'term', 'safety', 'and', 'tolerability', 'of', 'pregabalin', 'in', 'pediatric', 'patients', ',', 'age', '1', 'month', 'through', '16', 'years', ',', 'with', 'partial', 'onset', 'seizures', '.']","['O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-DRUG', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'O', 'B-COND', 'I-COND', 'I-COND', 'O']",NCT00448916,NCT00448916,"A 12-month Open-label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Pregabalin In Pediatric Patients With Partial Onset Seizures | The study will evaluate the long-term safety and tolerability of pregabalin in pediatric patients, age 1 month through 16 years, with partial onset seizures.","[(98, 108, 'DRUG', 'Pregabalin'), (136, 158, 'CONDITION', 'Partial Onset Seizures'), (226, 236, 'DRUG', 'pregabalin'), (295, 317, 'CONDITION', 'partial onset seizures')]"
